<!DOCTYPE html>
<!-- saved from url=(0029)http://briansamson.info/nice/ -->
<html dir="ltr" lang="en-US"><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
<meta charset="UTF-8">
<title>NICE Syndication Example | Dummy blog to test out NICE Syndication platform</title>
<link rel="profile" href="http://gmpg.org/xfn/11">
<link rel="stylesheet" type="text/css" media="all" href="./NICE Syndication Example   Dummy blog to test out NICE Syndication platform_files/style.css">
<link rel="pingback" href="http://briansamson.info/nice/xmlrpc.php">
<link rel="alternate" type="application/rss+xml" title="NICE Syndication Example » Feed" href="http://briansamson.info/nice/?feed=rss2">
<link rel="alternate" type="application/rss+xml" title="NICE Syndication Example » Comments Feed" href="http://briansamson.info/nice/?feed=comments-rss2">

<!-- Highlight NICE Search Terms 1.0 -->
<script type="text/javascript">
var hnst_areas = new Array("div.hentry","#content","#main","div.content","#middle","#container","#wrapper");
</script>
<style type="text/css">
.trigger
{

	border-bottom: 3px double red;

}
</style>



<link rel="stylesheet" id="admin-bar-css" href="./NICE Syndication Example   Dummy blog to test out NICE Syndication platform_files/admin-bar.css" type="text/css" media="all">
<script type="text/javascript" src="./NICE Syndication Example   Dummy blog to test out NICE Syndication platform_files/l10n.js"></script>
<link rel="EditURI" type="application/rsd+xml" title="RSD" href="http://briansamson.info/nice/xmlrpc.php?rsd">
<link rel="wlwmanifest" type="application/wlwmanifest+xml" href="http://briansamson.info/nice/wp-includes/wlwmanifest.xml"> 
<link rel="index" title="NICE Syndication Example" href="http://briansamson.info/nice">
<meta name="generator" content="WordPress 3.2.1">
<style type="text/css" media="print">#wpadminbar { display:none; }</style>
<style type="text/css" media="screen">
	html { margin-top: 28px !important; }
	* html body { margin-top: 28px !important; }
</style>
</head><style>#A9AdsMiddleBoxTop, #A9AdsOutOfStockWidgetTop, #A9AdsServicesWidgetTop, #ADNETwallBanner1, #ADNETwallBanner2, #ADSLOT_1, #ADSLOT_2, #ADSLOT_3, #ADSLOT_4, #ADSLOT_SKYSCRAPER, #ADVERTISE_HERE_ROW, #AD_CONTROL_22, #AD_CONTROL_28, #AD_CONTROL_29, #AD_CONTROL_8, #AD_ROW, #AD_Top, #AD_newsblock, #ADgoogle_newsblock, #ADsmallWrapper { display: none !important; } #Ad160x600, #Ad300x250, #Ad3Left, #Ad3Right, #Ad3TextAd, #AdArea, #AdBanner_F1, #AdBar, #AdBar1, #AdBox2, #AdContainer, #AdContainerTop, #AdContentModule_F, #AdDetails_GoogleLinksBottom, #AdDetails_InsureWith, #AdFrame4, #AdHeader, #AdLeaderboardBottom, #AdLeaderboardTop, #AdMiddle { display: none !important; } #AdMobileLink, #AdPopUp, #AdRectangle, #AdSenseDiv, #AdSenseResults1_adSenseSponsorDiv, #AdServer, #AdShowcase_F1, #AdSky23, #AdSkyscraper, #AdSpacing, #AdSponsor_SF, #AdSubsectionShowcase_F1, #AdTargetControl1_iframe, #AdTop, #AdTopLeader, #Ad_BelowContent, #Ad_Block, #Ad_Center1, #Ad_Right1, #Ad_RightBottom { display: none !important; } #Ad_RightTop, #Ad_Top, #Adbanner, #Adrectangle, #AdsContent, #AdsRight, #AdsWrap, #Ads_BA_CAD, #Ads_BA_CAD2, #Ads_BA_CAD_box, #Ads_BA_SKY, #Ads_CAD, #Ads_OV_BS, #Ads_Special, #AdvertMPU23b, #AdvertPanel, #AdvertiseFrame, #Advertisement, #Advertisements, #Advertorial { display: none !important; } #Advertorials, #AdvertsBottom, #AdvertsBottomR, #BANNER_160x600, #BANNER_300x250, #BANNER_728x90, #BannerAd, #BannerAdvert, #BigBoxAd, #BodyAd, #BotAd, #Bottom468x60AD, #ButtonAd, #ClickPop_LayerPop_Container, #CompanyDetailsNarrowGoogleAdsPresentationControl, #CompanyDetailsWideGoogleAdsPresentationControl, #ContentAd, #ContentAd1, #ContentAd2, #ContentAdPlaceHolder1 { display: none !important; } #ContentAdPlaceHolder2, #ContentAdXXL, #ContentPolepositionAds_Result, #CornerAd, #DartAd300x250, #DivAdEggHeadCafeTopBanner, #FIN_videoplayer_300x250ad, #FooterAd, #FooterAdContainer, #GOOGLE_ADS_47, #GoogleAd1, #GoogleAd2, #GoogleAd3, #GoogleAdsPlaceHolder, #GoogleAdsPresentationControl, #GoogleAdsense, #Google_Adsense_Main, #HEADERAD, #HOME_TOP_RIGHT_BOXAD, #HeaderAD { display: none !important; } #HeaderAdsBlock, #HeaderAdsBlockFront, #HeaderBannerAdSpacer, #HeaderTextAd, #HeroAd, #HomeAd1, #HouseAd, #ID_Ad_Sky, #JobsearchResultsAds, #Journal_Ad_125, #Journal_Ad_300, #JuxtapozAds, #KH-contentAd, #LargeRectangleAd, #LeftAd, #LeftAd1, #LeftAdF1, #LeftAdF2, #LftAd, #LoungeAdsDiv { display: none !important; } #LowerContentAd, #MPUAdSpace, #MainSponsoredLinks, #Meebo\:AdElement\.Root, #Nightly_adContainer, #NormalAdModule, #OpenXAds, #OverrideAdArea, #PREFOOTER_LEFT_BOXAD, #PREFOOTER_RIGHT_BOXAD, #PageLeaderAd, #PreRollAd, #RelevantAds, #RgtAd1, #RightAd, #RightBottom300x250AD, #RightNavTopAdSpot, #RightSponsoredAd, #SectionAd300-250, #SectionSponsorAd { display: none !important; } #SideAdMpu, #SidebarAdContainer, #SkyAd, #SpecialAds, #SponsoredAd, #SponsoredLinks, #TL_footer_advertisement, #TOP_ADROW, #TOP_RIGHT_BOXAD, #Tadspacefoot, #Tadspacehead, #Tadspacemrec, #TextLinkAds, #ThreadAd, #Top468x60AD, #TopAd, #TopAdBox, #TopAdContainer, #TopAdDiv, #TopAdPos { display: none !important; } #TopBannerAd, #VM-MPU-adspace, #VM-footer-adspace, #VM-header-adspace, #VM-header-adwrap, #XEadLeaderboard, #XEadSkyscraper, #YahooAdParentContainer, #_ads, #abHeaderAdStreamer, #about_adsbottom, #abovepostads, #ad-1000x90-1, #ad-120x600-sidebar, #ad-120x60Div, #ad-160x600, #ad-160x600-sidebar, #ad-250, #ad-250x300, #ad-300 { display: none !important; } #ad-300x250, #ad-300x250-1, #ad-300x250-sidebar, #ad-300x250Div, #ad-300x60-1, #ad-376x280, #ad-728, #ad-728x90, #ad-728x90-1, #ad-728x90-leaderboard-top, #ad-728x90-top0, #ad-ads, #ad-article, #ad-banner, #ad-banner-1, #ad-bigbox, #ad-billboard-bottom, #ad-block-125, #ad-bottom, #ad-bottom-wrapper { display: none !important; } #ad-box, #ad-box-first, #ad-box-second, #ad-boxes, #ad-bs, #ad-buttons, #ad-colB-1, #ad-column, #ad-container, #ad-content, #ad-contentad, #ad-first-post, #ad-flex-first, #ad-footer, #ad-footprint-160x600, #ad-frame, #ad-front-footer, #ad-front-sponsoredlinks, #ad-fullbanner2, #ad-globalleaderboard { display: none !important; } #ad-halfpage, #ad-header, #ad-header-728x90, #ad-horizontal-header, #ad-img, #ad-inner, #ad-label, #ad-leaderboard, #ad-leaderboard-1-container, #ad-leaderboard-bottom, #ad-leaderboard-container, #ad-leaderboard-spot, #ad-leaderboard-top, #ad-left, #ad-left-sidebar-ad-1, #ad-left-sidebar-ad-2, #ad-left-sidebar-ad-3, #ad-links-content, #ad-list-row, #ad-lrec { display: none !important; } #ad-medium, #ad-medium-rectangle, #ad-medrec, #ad-middlethree, #ad-middletwo, #ad-module, #ad-mpu, #ad-mpu1-spot, #ad-mpu2, #ad-mpu2-spot, #ad-north, #ad-one, #ad-placard, #ad-placeholder, #ad-rectangle, #ad-right, #ad-right-sidebar-ad-1, #ad-right-sidebar-ad-2, #ad-righttop, #ad-row { display: none !important; } #ad-side, #ad-side-text, #ad-sidebar, #ad-sky, #ad-skyscraper, #ad-slot-right, #ad-slug-wrapper, #ad-small-banner, #ad-space, #ad-special, #ad-splash, #ad-sponsors, #ad-spot, #ad-squares, #ad-story-bottom-out, #ad-story-right, #ad-target, #ad-target-Leaderbord, #ad-teaser, #ad-text { display: none !important; } #ad-top, #ad-top-banner, #ad-top-text-low, #ad-top-wrap, #ad-tower, #ad-trailerboard-spot, #ad-two, #ad-typ1, #ad-unit, #ad-wrap, #ad-wrap-right, #ad-wrapper, #ad-wrapper1, #ad-yahoo-simple, #ad-zone-1, #ad-zone-2, #ad-zone-inline, #ad01, #ad02, #ad1006 { display: none !important; } #ad11, #ad125BL, #ad125BR, #ad125TL, #ad125TR, #ad125x125, #ad160x600, #ad160x600right, #ad1Sp, #ad2Sp, #ad300, #ad300-250, #ad300X250, #ad300_x_250, #ad300x100Middle, #ad300x150, #ad300x250, #ad300x250Module, #ad300x60, #ad300x600 { display: none !important; } #ad300x600_callout, #ad336, #ad336x280, #ad375x85, #ad468, #ad468x60, #ad468x60_top, #ad526x250, #ad600, #ad728, #ad728Mid, #ad728Top, #ad728Wrapper, #ad728top, #ad728x90, #ad728x90_1, #ad90, #adBadges, #adBanner, #adBanner10 { display: none !important; } #adBanner120x600, #adBanner160x600, #adBanner2, #adBanner3, #adBanner336x280, #adBanner4, #adBanner728, #adBanner9, #adBannerTable, #adBannerTop, #adBar, #adBelt, #adBlock125, #adBlockTop, #adBlocks, #adBottbanner, #adBox, #adBox11, #adBox16, #adBox350 { display: none !important; } #adBox390, #adCirc300X200, #adCirc_620_100, #adCol, #adColumn, #adCompanionSubstitute, #adComponentWrapper, #adContainer, #adContainer_1, #adContainer_2, #adContainer_3, #adDiv, #adDiv300, #adDiv728, #adFiller, #adFps, #adFtofrs, #adGallery, #adGoogleText, #adGroup1 { display: none !important; } #adHeader, #adHeaderTop, #adIsland, #adLB, #adLabel, #adLayer, #adLeader, #adLeaderTop, #adLeaderboard, #adMPU, #adMediumRectangle, #adMiddle0Frontpage, #adMiniPremiere, #adMonster1, #adOuter, #adPlaceHolderRight, #adPlacer, #adPosOne, #adRight, #adRight2 { display: none !important; } #adSPLITCOLUMNTOPRIGHT, #adSenseModule, #adSenseWrapper, #adServer_marginal, #adShortTower, #adSidebar, #adSidebarSq, #adSky, #adSkyscraper, #adSlider, #adSpace, #adSpace0, #adSpace1, #adSpace10, #adSpace11, #adSpace12, #adSpace13, #adSpace14, #adSpace15, #adSpace16 { display: none !important; } #adSpace17, #adSpace18, #adSpace19, #adSpace2, #adSpace20, #adSpace21, #adSpace22, #adSpace23, #adSpace24, #adSpace25, #adSpace3, #adSpace300_ifrMain, #adSpace4, #adSpace5, #adSpace6, #adSpace7, #adSpace8, #adSpace9, #adSpace_footer, #adSpace_right { display: none !important; } #adSpace_top, #adSpacer, #adSpecial, #adSplotlightEm, #adSpot-Leader, #adSpot-banner, #adSpot-island, #adSpot-mrec1, #adSpot-sponsoredlinks, #adSpot-textbox1, #adSpot-widestrip, #adSpotAdvertorial, #adSpotIsland, #adSpotSponsoredLinks, #adSquare, #adStaticA, #adStrip, #adSuperAd, #adSuperPremiere, #adSuperSkyscraper { display: none !important; } #adSuperbanner, #adTableCell, #adTag1, #adTag2, #adText, #adTextCustom, #adTextLink, #adText_container, #adTile, #adTop, #adTopContent, #adTopbanner, #adTopboxright, #adTower, #adUnit, #adWrapper, #adZoneTop, #ad_1, #ad_130x250_inhouse, #ad_160x160 { display: none !important; } #ad_160x600, #ad_190x90, #ad_2, #ad_3, #ad_300, #ad_300_250, #ad_300_250_1, #ad_300a, #ad_300b, #ad_300c, #ad_300x100_m_c, #ad_300x250, #ad_300x250_content_column, #ad_300x250_m_c, #ad_300x250m, #ad_300x90, #ad_4, #ad_468_60, #ad_468x60, #ad_5 { display: none !important; } #ad_728_foot, #ad_728x90, #ad_728x90_container, #ad_940, #ad_984, #ad_A, #ad_B, #ad_Banner, #ad_C, #ad_C2, #ad_D, #ad_E, #ad_F, #ad_G, #ad_H, #ad_I, #ad_J, #ad_K, #ad_L, #ad_M { display: none !important; } #ad_N, #ad_O, #ad_P, #ad_YieldManager-300x250, #ad_YieldManager-728x90, #ad_adsense, #ad_after_navbar, #ad_anchor, #ad_area, #ad_banner, #ad_bannerManage_1, #ad_banner_top, #ad_banners, #ad_bar, #ad_bellow_post, #ad_bigsize_wrapper, #ad_block_1, #ad_block_2, #ad_bottom, #ad_box { display: none !important; } #ad_box_colspan, #ad_box_top, #ad_branding, #ad_bs_area, #ad_buttons, #ad_center_monster, #ad_circ300x250, #ad_cna2, #ad_cont, #ad_container, #ad_container_0, #ad_container_marginal, #ad_container_side, #ad_container_sidebar, #ad_container_top, #ad_content_top, #ad_content_wrap, #ad_feature, #ad_firstpost, #ad_footer { display: none !important; } #ad_frame, #ad_front_three, #ad_fullbanner, #ad_gallery, #ad_global_header, #ad_h3, #ad_haha_1, #ad_haha_4, #ad_halfpage, #ad_head, #ad_header, #ad_holder, #ad_horizontal, #ad_horseshoe_left, #ad_horseshoe_right, #ad_horseshoe_spacer, #ad_horseshoe_top, #ad_hotpots, #ad_in_arti, #ad_island { display: none !important; } #ad_label, #ad_large_rectangular, #ad_lastpost, #ad_layer, #ad_layer2, #ad_leader, #ad_leaderBoard, #ad_leaderboard, #ad_leaderboard728x90, #ad_leaderboard_top, #ad_left, #ad_lnk, #ad_lrec, #ad_lwr_square, #ad_main, #ad_medium_rectangle, #ad_medium_rectangular, #ad_mediumrectangle, #ad_menu_header, #ad_message { display: none !important; } #ad_middle, #ad_most_pop_234x60_req_wrapper, #ad_mpu, #ad_mpu300x250, #ad_mpuav, #ad_mrcontent, #ad_newsletter, #ad_overlay, #ad_place, #ad_play_300, #ad_rect, #ad_rect_body, #ad_rect_bottom, #ad_rectangle, #ad_rectangle_medium, #ad_related_links_div, #ad_related_links_div_program, #ad_replace_div_0, #ad_replace_div_1, #ad_report_leaderboard { display: none !important; } #ad_report_rectangle, #ad_results, #ad_right, #ad_right_main, #ad_ros_tower, #ad_rr_1, #ad_script_head, #ad_sec, #ad_sec_div, #ad_sgd, #ad_sidebar, #ad_sidebar1, #ad_sidebar2, #ad_sidebar3, #ad_sky, #ad_skyscraper, #ad_skyscraper160x600, #ad_skyscraper_text, #ad_slot_leaderboard, #ad_slot_livesky { display: none !important; } #ad_slot_sky_top, #ad_space, #ad_square, #ad_ss, #ad_table, #ad_term_bottom_place, #ad_text:not(textarea), #ad_thread_first_post_content, #ad_top, #ad_top_holder, #ad_tp_banner_1, #ad_tp_banner_2, #ad_txt, #ad_unit, #ad_vertical, #ad_wide, #ad_wide_box, #ad_widget, #ad_window, #ad_wrap { display: none !important; } #ad_wrapper, #adaptvcompanion, #adbForum, #adbanner, #adbar, #adbig, #adbnr, #adboard, #adbody, #adbottom, #adbox, #adbox1, #adbox2, #adbutton, #adclear, #adcode, #adcode1, #adcode2, #adcode3, #adcode4 { display: none !important; } #adcolumnwrapper, #adcontainer, #adcontainer1, #adcontainerRight, #adcontainsm, #adcontent, #adcontent1, #adcontrolPushSite, #add_ciao2, #addbottomleft, #addiv-bottom, #addiv-top, #adfooter, #adfooter_728x90, #adframe:not(frameset), #adhead, #adhead_g, #adheader, #adhome, #adiframe1_iframe { display: none !important; } #adiframe2_iframe, #adiframe3_iframe, #adimg, #adition_content_ad, #adlabel, #adlabelFooter, #adlayer, #adlayerContainer, #adlayer_back, #adlayerad, #adleaderboard, #adleaderboard_flex, #adleaderboardb, #adleaderboardb_flex, #adleft, #adlinks, #adlinkws, #adlrec, #admanager_leaderboard, #admid { display: none !important; } #admiddle3center, #admiddle3left, #adposition, #adposition-C, #adposition-FPMM, #adposition1, #adposition2, #adposition3, #adposition4, #adrectangle, #adrectanglea, #adrectanglea_flex, #adrectangleb, #adrectangleb_flex, #adrig, #adright, #adright2, #adrighthome, #ads-250, #ads-468 { display: none !important; } #ads-area, #ads-block, #ads-bot, #ads-bottom, #ads-col, #ads-dell, #ads-footer, #ads-footer-inner, #ads-horizontal, #ads-indextext, #ads-leaderboard1, #ads-lrec, #ads-main, #ads-menu, #ads-middle, #ads-prices, #ads-rhs, #ads-right, #ads-sponsored-boxes, #ads-top { display: none !important; } #ads-vers7, #ads-wrapper, #ads120, #ads125, #ads160left, #ads300, #ads300-250, #ads300Bottom, #ads300Top, #ads315, #ads336x280, #ads728, #ads728bottom, #ads728top, #ads790, #adsBox-460_left, #adsBox-dynamic-right, #adsBoxResultsPage, #adsContent, #adsDisplay { display: none !important; } #adsDiv1, #adsDiv2, #adsDiv3, #adsDiv4, #adsDiv5, #adsDiv6, #adsDiv7, #adsHeader, #adsID, #ads_160, #ads_300, #ads_728, #ads_banner, #ads_belowforumlist, #ads_belownav, #ads_bottom, #ads_bottom_inner, #ads_bottom_outer, #ads_box, #ads_button { display: none !important; } #ads_catDiv, #ads_container, #ads_footer, #ads_fullsize, #ads_halfsize, #ads_header, #ads_html1, #ads_html2, #ads_inner, #ads_lb, #ads_medrect, #ads_notice, #ads_right, #ads_right_sidebar, #ads_sidebar_roadblock, #ads_space, #ads_text, #ads_top, #ads_topbanner, #ads_watch_top_square { display: none !important; } #ads_zone27, #adsbottom, #adsbox, #adsbox-left, #adsbox-right, #adscolumn, #adsd_contentad_r1, #adsd_contentad_r2, #adsd_contentad_r3, #adsd_topbanner, #adsd_txt_sky, #adsdiv, #adsection, #adsense, #adsense-2, #adsense-header, #adsense-new, #adsense-tag, #adsense-text, #adsense03 { display: none !important; } #adsense04, #adsense05, #adsense1, #adsenseLeft, #adsenseOne, #adsenseWrap, #adsense_article_left, #adsense_block, #adsense_box, #adsense_box_video, #adsense_inline, #adsense_leaderboard, #adsense_overlay, #adsense_placeholder_2, #adsenseheader, #adsensetopplay, #adsensewidget-3, #adserv, #adshometop, #adsimage { display: none !important; } #adskinlink, #adsky, #adskyscraper, #adslider, #adslot, #adsmiddle, #adsonar, #adspace, #adspace-1, #adspace-300x250, #adspace-leaderboard-top, #adspace300x250, #adspaceBox, #adspaceBox300, #adspace_header, #adspace_leaderboard, #adspacer, #adsponsorImg, #adspot, #adspot-1 { display: none !important; } #adspot-149x170, #adspot-1x4, #adspot-2, #adspot-295x60, #adspot-2a, #adspot-2b, #adspot-300x110-pos-1, #adspot-300x125, #adspot-300x250-pos-1, #adspot-300x250-pos-2, #adspot-468x60-pos-2, #adspot-a, #adspot300x250, #adspot_220x90, #adspot_300x250, #adspot_468x60, #adspot_728x90, #adsquare, #adsright, #adstop { display: none !important; } #adtab, #adtag_right_side, #adtagfooter, #adtagheader, #adtagrightcol, #adtaily-widget-light, #adtech_0, #adtech_1, #adtech_2, #adtech_3, #adtech_googleslot_03c, #adtech_takeover, #adtext, #adtop, #adtophp, #adtxt, #adv-300, #adv-leaderboard, #adv-left, #adv-masthead { display: none !important; } #adv-middle, #adv-mpux, #adv-x36, #adv-x37, #adv-x38, #adv-x39, #adv-x40, #adv1, #adv300bottom, #adv300top, #adv728, #adv_300, #adv_728, #adv_border, #adv_google_300, #adv_google_728, #adv_halfpage, #adv_halfpage_title, #adv_leaderboard, #adv_sky { display: none !important; } #adv_top_banner_wrapper, #adver1, #adver2, #adver3, #adver4, #adver5, #adver6, #adver7, #advert-1, #advert-120, #advert-boomer, #advert-display, #advert-header, #advert-leaderboard, #advert-links-bottom, #advert-skyscraper, #advert-top, #advert1, #advertBanner, #advertContainer { display: none !important; } #advertDB, #advertRight, #advertSection, #advert_125x125, #advert_250x250, #advert_box, #advert_home01, #advert_leaderboard, #advert_lrec_format, #advert_mid, #advert_mpu, #advert_mpu_1, #advert_right_skyscraper, #advert_sky, #advertbox, #advertbox2, #advertbox3, #advertbox4, #adverthome, #advertise { display: none !important; } #advertise-here, #advertise-here-sidebar, #advertise-now, #advertise1, #advertiseHere, #advertisement1, #advertisement160x600, #advertisement3, #advertisement728x90, #advertisementHorizontal, #advertisementLigatus, #advertisementPrio2, #advertisementRight, #advertisementRightcolumn0, #advertisementRightcolumn1, #advertisementsarticle, #advertiser-container, #advertiserLinks, #advertisers, #advertising { display: none !important; } #advertising-banner, #advertising-caption, #advertising-container, #advertising-control, #advertising-skyscraper, #advertising-top, #advertising2, #advertisingModule160x600, #advertisingModule728x90, #advertisingTopWrapper, #advertising_btm, #advertising_contentad, #advertising_horiz_cont, #advertisment, #advertismentElementInUniversalbox, #advertorial, #advertorial_red_listblock, #adverts, #adverts-top-container, #adverts-top-left { display: none !important; } #adverts-top-middle, #adverts-top-right, #advertsingle, #advertspace, #advheader, #advsingle, #advt, #advtext, #advtop, #adwhitepaperwidget, #adwin_rec, #adwith, #adwords-4-container, #adwrapper, #adxBigAd, #adxMiddle5, #adxSponLink, #adxSponLinkA, #adxtop, #adxtop2 { display: none !important; } #adzbanner, #adzerk, #adzerk1, #adzerk2, #adzone, #adzoneBANNER, #adzoneheader, #afc-container, #affinityBannerAd, #after-content-ads, #after-header-ad-left, #after-header-ad-right, #after-header-ads, #agi-ad300x250, #agi-ad300x250overlay, #agi-sponsored, #alert_ads, #anchorAd, #annoying_ad, #ap_adframe { display: none !important; } #ap_cu_overlay, #ap_cu_wrapper, #apiBackgroundAd, #apiTopAdWrap, #apmNADiv, #apolload, #araHealthSponsorAd, #area-adcenter, #area1ads, #article-ad, #article-ad-container, #article-box-ad, #articleAdReplacement, #articleLeftAdColumn, #articleSideAd, #article_ad, #article_ad_container, #article_box_ad, #articlead1, #articlead2 { display: none !important; } #asideads, #asinglead, #atlasAdDivGame, #awds-nt1-ad, #babAdTop, #banner-300x250, #banner-ad, #banner-ad-container, #banner-ads, #banner250x250, #banner300x250, #banner468x60, #banner728x90, #bannerAd, #bannerAdTop, #bannerAdWrapper, #bannerAd_ctr, #bannerAd_rdr, #banner_160x600, #banner_300_250 { display: none !important; } #banner_ad, #banner_ad_footer, #banner_ad_module, #banner_admicro, #banner_ads, #banner_advertisement, #banner_content_ad, #banner_topad, #bannerad, #bannerad2, #baseAdvertising, #basket-adContainer, #bbccom_mpu, #bbo_ad1, #bg-footer-ads, #bg-footer-ads2, #bg_YieldManager-160x600, #bg_YieldManager-300x250, #bg_YieldManager-728x90, #bigAd { display: none !important; } #bigBoxAd, #bigad300outer, #bigadbox, #bigadframe, #bigadspot, #billboard_ad, #block-ad_cube-1, #block-openads-0, #block-openads-1, #block-openads-2, #block-openads-3, #block-openads-4, #block-openads-5, #block-spti_ga-spti_ga_adwords, #block-thewrap_ads_250x300-0, #block_advert, #block_advertisement, #blog-ad, #blog_ad_content, #blog_ad_opa { display: none !important; } #blog_ad_right, #blog_ad_top, #blox-big-ad, #blox-big-ad-bottom, #blox-big-ad-top, #blox-halfpage-ad, #blox-tile-ad, #blox-tower-ad, #body_728_ad, #book-ad, #botad, #bott_ad2, #bott_ad2_300, #bottom-ad, #bottom-ad-container, #bottom-ad-tray, #bottom-ad-wrapper, #bottom-ads, #bottomAd, #bottomAdCCBucket { display: none !important; } #bottomAdContainer, #bottomAdSense, #bottomAdSenseDiv, #bottomAds, #bottomAdvBox, #bottomContentAd, #bottomRightAd, #bottomRightAdSpace, #bottom_ad, #bottom_ad_area, #bottom_ad_unit, #bottom_ads, #bottom_banner_ad, #bottom_overture, #bottom_sponsor_ads, #bottom_sponsored_links, #bottom_text_ad, #bottomad, #bottomadholder, #bottomads { display: none !important; } #bottomadsense, #bottomadwrapper, #bottomleaderboardad, #box-ad-section, #box-ads-small-1, #box-ads-small-2, #box-content-ad, #box-googleadsense-1, #box-googleadsense-r, #box1ad, #boxAd300, #boxAdContainer, #boxAdvert, #box_ad, #box_advertisment, #box_mod_googleadsense, #boxad1, #boxad2, #boxad3, #boxad4 { display: none !important; } #boxad5, #boxads, #bpAd, #bps-header-ad-container, #btnAds, #btnads, #btr_horiz_ad, #burn_header_ad, #button-ads-horizontal, #button-ads-vertical, #buttonAdWrapper1, #buttonAdWrapper2, #buttonAds, #buttonAdsContainer, #button_ad_container, #button_ad_wrap, #button_ads, #buttonad, #buy-sell-ads, #c4ad-Middle1 { display: none !important; } #c_ad_sb, #c_ad_sky, #caAdLarger, #catad, #category-ad, #cellAd, #channel_ad, #channel_ads, #ciHomeRHSAdslot, #circ_ad, #closeable-ad, #cmn_ad_box, #cmn_toolbar_ad, #cnnAboveFoldBelowAd, #cnnRR336ad, #cnnSponsoredPods, #cnnTopAd, #cnnVPAd, #col3_advertising, #colAd { display: none !important; } #colRightAd, #collapseobj_adsection, #column4-google-ads, #comments-ad-container, #commercial_ads, #common_right_ad_wrapper, #common_right_lower_ad_wrapper, #common_right_lower_adspace, #common_right_lower_player_ad_wrapper, #common_right_lower_player_adspace, #common_right_player_ad_wrapper, #common_right_player_adspace, #common_right_right_adspace, #common_top_adspace, #comp_AdsLeaderboardTop, #companion-ad, #companionAd, #companionAdDiv, #companionad, #container-righttopads { display: none !important; } #container-topleftads, #containerLocalAds, #containerLocalAdsInner, #containerMrecAd, #containerSqAd, #content-ad-header, #content-header-ad, #content-left-ad, #content-right-ad, #contentAd, #contentBoxad, #contentTopAds2, #content_ad, #content_ad_square, #content_ad_top, #content_ads_content, #content_box_300body_sponsoredoffers, #content_box_adright300_google, #content_lower_center_right_ad, #content_mpu { display: none !important; } #contentad, #contentad_imtext, #contentad_right, #contentads, #contentinlineAd, #contents_post_ad, #contextad, #contextual-ads, #contextual-ads-block, #contextualad, #coverADS, #coverads, #ctl00_Adspace_Top_Height, #ctl00_BottomAd, #ctl00_ContentMain_BanManAd468_BanManAd, #ctl00_ContentPlaceHolder1_blockAdd_divAdvert, #ctl00_ContentRightColumn_RightColumn_Ad1_BanManAd, #ctl00_ContentRightColumn_RightColumn_Ad2_BanManAd, #ctl00_ContentRightColumn_RightColumn_PremiumAd1_ucBanMan_BanManAd, #ctl00_LHTowerAd { display: none !important; } #ctl00_LeftHandAd, #ctl00_MasterHolder_IBanner_adHolder, #ctl00_TopAd, #ctl00_TowerAd, #ctl00_VBanner_adHolder, #ctl00__Content__RepeaterReplies_ctl03__AdReply, #ctl00_abot_bb, #ctl00_adFooter, #ctl00_advert_LargeMPU_div_AdPlaceHolder, #ctl00_atop_bt, #ctl00_cphMain_hlAd1, #ctl00_cphMain_hlAd2, #ctl00_cphMain_hlAd3, #ctl00_ctl00_MainPlaceHolder_itvAdSkyscraper, #ctl00_ctl00_ctl00_Main_Main_PlaceHolderGoogleTopBanner_MPTopBannerAd, #ctl00_ctl00_ctl00_Main_Main_SideBar_MPSideAd, #ctl00_dlTilesAds, #ctl00_m_skinTracker_m_adLBL, #ctl00_phCrackerMain_ucAffiliateAdvertDisplayMiddle_pnlAffiliateAdvert, #ctl00_phCrackerMain_ucAffiliateAdvertDisplayRight_pnlAffiliateAdvert { display: none !important; } #ctl00_topAd, #ctrlsponsored, #cubeAd, #cube_ads, #cube_ads_inner, #cubead, #cubead-2, #currencies-sponsored-by, #custom-advert-leadboard-spacer, #dAdverts, #dItemBox_ads, #dart_160x600, #dc-display-right-ad-1, #dcadSpot-Leader, #dcadSpot-LeaderFooter, #dcol-sponsored, #defer-adright, #detail_page_vid_topads, #div-gpt-ad-1, #div-gpt-ad-2 { display: none !important; } #div-gpt-ad-3, #div-gpt-ad-4, #divAd, #divAdBox, #divAdWrapper, #divAdvertisement, #divBottomad1, #divBottomad2, #divDoubleAd, #divLeftAd12, #divLeftRecAd, #divMenuAds, #divWNAdHeader, #divWrapper_Ad, #div_ad_leaderboard, #div_video_ads, #dlads, #dni-header-ad, #dnn_adLeaderBoard2008, #dnn_ad_banner { display: none !important; } #download_ads, #dp_ads1, #ds-mpu, #ds_ad_north_leaderboard, #editorsmpu, #em_ad_superbanner, #embedded-ad, #evotopTen_advert, #ex-ligatus, #exads, #extra-search-ads, #fb_adbox, #fb_rightadpanel, #featAds, #featuread, #featured-advertisements, #featuredAdContainer2, #featuredAds, #featured_ad_links, #feed_links_ad_container { display: none !important; } #file_sponsored_link, #first-300-ad, #first-adlayer, #first_ad_unit, #firstad, #flAdData6, #fl_hdrAd, #flash_ads_1, #flexiad, #floatingAd, #floating_ad_container, #foot-ad-1, #footad, #footer-ad, #footer-ads, #footer-advert, #footer-adverts, #footer-sponsored, #footerAd, #footerAdDiv { display: none !important; } #footerAds, #footerAdvertisement, #footerAdverts, #footer_ad, #footer_ad_01, #footer_ad_block, #footer_ad_container, #footer_ad_modules, #footer_ads, #footer_adspace, #footer_text_ad, #footerad, #footerads, #footeradsbox, #forum_top_ad, #four_ads, #fpad1, #fpad2, #fpv_companionad, #fr_ad_center { display: none !important; } #frame_admain, #frnAdSky, #frnBannerAd, #frnContentAd, #front_ad728, #front_advert, #front_mpu, #ft-ad, #ft-ad-1, #ft-ad-container, #ft_mpu, #fullsizebanner_468x60, #fusionad, #fw-advertisement, #g_ad, #g_adsense, #ga_300x250, #galleries-tower-ad, #gallery-ad, #gallery-ad-m0 { display: none !important; } #gallery-random-ad, #gallery_ads, #game-info-ad, #gamead, #gameads, #gasense, #gglads, #global_header_ad_area, #gm-ad-lrec, #gmi-ResourcePageAd, #gmi-ResourcePageLowerAd, #goad1, #goads, #gooadtop, #google-ad, #google-ad-art, #google-ad-table-right, #google-ad-tower, #google-ads, #google-ads-bottom { display: none !important; } #google-ads-header, #google-ads-left-side, #google-adsense-mpusize, #googleAd, #googleAdArea, #googleAds, #googleAdsSml, #googleAdsense, #googleAdsenseBanner, #googleAdsenseBannerBlog, #googleAdwordsModule, #googleAfcContainer, #googleSearchAds, #googleShoppingAdsRight, #googleShoppingAdsTop, #googleSubAds, #google_ad, #google_ad_container, #google_ad_inline, #google_ad_test { display: none !important; } #google_ads, #google_ads_aCol, #google_ads_frame1, #google_ads_frame1_anchor, #google_ads_frame2, #google_ads_frame2_anchor, #google_ads_frame3, #google_ads_frame3_anchor, #google_ads_test, #google_ads_top, #google_adsense_home_468x60_1, #googlead, #googlead-sidebar-middle, #googlead-sidebar-top, #googlead2, #googleadbox, #googleads, #googleads_mpu_injection, #googleadsense, #googlesponsor { display: none !important; } #gpt-ad-halfpage, #gpt-ad-rectangle1, #gpt-ad-rectangle2, #gpt-ad-skyscraper, #gpt-ad-story_rectangle3, #grid_ad, #gsyadrectangleload, #gsyadrightload, #gsyadtop, #gsyadtopload, #gtopadvts, #half-page-ad, #halfPageAd, #halfe-page-ad-box, #hd-ads, #hd-banner-ad, #hdtv_ad_ss, #head-ad, #head-ad-1, #head-banner468 { display: none !important; } #headAd, #head_ad, #head_advert, #headad, #header-ad, #header-ad-left, #header-ad-rectangle-container, #header-ad-right, #header-ad2010, #header-ads, #header-adspace, #header-advert, #header-advertisement, #header-advertising, #header-adverts, #header-banner-ad, #headerAd, #headerAdBackground, #headerAdContainer, #headerAdWrap { display: none !important; } #headerAds, #headerAdsWrapper, #headerTopAd, #header_ad, #header_ad_728_90, #header_ad_container, #header_adcode, #header_ads, #header_advertisement_top, #header_flag_ad, #header_leaderboard_ad_container, #header_publicidad, #headerad, #headeradbox, #headerads, #headeradsbox, #headeradvertholder, #headeradwrap, #headline_ad, #headlinesAdBlock { display: none !important; } #hiddenadAC, #hideads, #hl-sponsored-results, #hly_ad_side_bar_tower_left, #hly_inner_page_google_ad, #home-advert-module, #home-rectangle-ad, #home-top-ads, #homeMPU, #homeTopRightAd, #home_ad, #home_bottom_ad, #home_contentad, #home_feature_ad, #home_lower_center_right_ad, #home_mpu, #home_spensoredlinks, #homead, #homepage-ad, #homepageAdsTop { display: none !important; } #homepageFooterAd, #homepage_right_ad, #homepage_right_ad_container, #homepage_top_ads, #hometop_234x60ad, #hor_ad, #horizad, #horizontal-banner-ad, #horizontal_ad, #horizontal_ad_top, #horizontalads, #hot-deals-ad, #houseAd, #hp-header-ad, #hp-mpu, #hp-right-ad, #hp-store-ad, #hpV2_300x250Ad, #hpV2_googAds, #hp_ad300x250 { display: none !important; } #ibt_local_ad728, #icePage_SearchLinks_AdRightDiv, #icePage_SearchLinks_DownloadToolbarAdRightDiv, #icePage_SearchResults_ads0_SponsoredLink, #icePage_SearchResults_ads1_SponsoredLink, #icePage_SearchResults_ads2_SponsoredLink, #icePage_SearchResults_ads3_SponsoredLink, #icePage_SearchResults_ads4_SponsoredLink, #idSponsoredresultend, #idSponsoredresultstart, #iframeRightAd, #iframeTopAd, #imu_ad_module, #in_serp_ad, #inadspace, #indexad, #inline-story-ad, #inlineAd, #inlinead, #inlinegoogleads { display: none !important; } #inlist-ad-block, #inner-advert-row, #inner-top-ads, #innerpage-ad, #inside-page-ad, #insider_ad_wrapper, #instoryad, #instoryadtext, #instoryadwrap, #int-ad, #interstitial_ad_wrapper, #iqadtile8, #islandAd, #j_ad, #ji_medShowAdBox, #jmp-ad-buttons, #joead, #joead2, #js_adsense, #ka_adRightSkyscraperWide { display: none !important; } #ka_samplead, #kaufDA-widget, #kdz_ad1, #kdz_ad2, #keyadvertcontainer, #landing-adserver, #lapho-top-ad-1, #largead, #lateAd, #layerAds_layerDiv, #layerTLDADSERV, #layer_ad_content, #layer_ad_main, #layerad, #leader-board-ad, #leaderAd, #leaderAdContainer, #leader_ad, #leader_board_ad, #leaderad { display: none !important; } #leaderad_section, #leaderboard-ad, #leaderboard-bottom-ad, #leaderboardAd, #leaderboard_ad, #leaderboard_ad_gam, #left-ad-1, #left-ad-2, #left-ad-col, #left-ad-skin, #left-bottom-ad, #left-lower-adverts, #left-lower-adverts-container, #leftAdContainer, #leftAd_rdr, #leftAdvert, #leftSectionAd300-100, #left_ad, #left_adspace, #leftad { display: none !important; } #leftads, #leftcolAd, #lg-banner-ad, #ligatus, #linkAds, #linkads, #live-ad, #localAds, #logoAd, #longAdSpace, #long_advertisement, #lowerAdvertisementImg, #lower_ad, #lowerads, #lowerthirdad, #lowertop-adverts, #lowertop-adverts-container, #lpAdPanel, #lrecad, #lsadvert-left_menu_1 { display: none !important; } #lsadvert-left_menu_2, #lsadvert-top, #mBannerAd, #main-ad, #main-ad160x600, #main-ad160x600-img, #main-ad728x90, #main-advert1, #main-advert2, #main-advert3, #main-bottom-ad, #main-tj-ad, #mainAd, #mainAdUnit, #mainAdvert, #mainAdvertismentP, #mainHeaderAdvertisment, #main_ad, #main_rec_ad, #main_top_ad_container { display: none !important; } #marketing-promo, #mastAd, #mastAdvert, #mastad, #mastercardAd, #masthead_ad, #masthead_topad, #medRecAd, #media_ad, #mediaplayer_adburner, #mediumAdvertisement, #medrectad, #menuAds, #menubanner-ad-content, #mi_story_assets_ad, #mid-ad300x250, #mid-table-ad, #midRightTextAds, #mid_ad_div, #mid_ad_title { display: none !important; } #mid_mpu, #midadd, #midadspace, #middle-ad, #middle_ad, #middle_body_advertising, #middlead, #middleads, #midrect_ad, #midstrip_ad, #mini-ad, #mochila-column-right-ad-300x250, #mochila-column-right-ad-300x250-1, #module-google_ads, #module_ad, #module_box_ad, #module_sky_scraper, #monsterAd, #moogleAd, #moreads { display: none !important; } #most_popular_ad, #motionAd, #mpu-advert, #mpu-cont, #mpu300250, #mpuAd, #mpuDiv, #mpuSlot, #mpuWrapper, #mpuWrapperAd, #mpu_banner, #mpu_firstpost, #mpu_holder, #mpu_text_ad, #mpuad, #mpubox, #mr_banner_topad, #mrecAdContainer, #msAds, #ms_ad { display: none !important; } #msad, #multiLinkAdContainer, #multi_ad, #my-ads, #myads_HeaderButton, #n_sponsor_ads, #namecom_ad_hosting_main, #narrow-ad, #narrow_ad_unit, #natadad300x250, #national_microlink_ads, #nationalad, #navi_banner_ad_780, #nba160PromoAd, #nba300Ad, #nbaGI300ad, #nbaHouseAnd600Ad, #nbaLeft600Ad, #nbaMidAds, #nbaVid300Ad { display: none !important; } #nbcAd300x250, #new_topad, #newads, #news_advertorial_content, #news_advertorial_top, #ng_rtcol_ad, #noresults_ad_container, #noresultsads, #northad, #northbanner-advert, #northbanner-advert-container, #ns_ad1, #ns_ad2, #ns_ad3, #oanda_ads, #onespot-ads, #online_ad, #ovadsense, #p-googleadsense, #page-header-ad { display: none !important; } #page-top-ad, #pageAds, #pageAdsDiv, #pageBannerAd, #page_ad, #page_content_top_ad, #pagelet_adbox, #pagelet_netego_ads, #pagelet_search_ads2, #panelAd, #pb_report_ad, #pcworldAdBottom, #pcworldAdTop, #pinball_ad, #player-below-advert, #player_ad, #player_ads, #pmad-in1, #pod-ad-video-page, #populate_ad_bottom { display: none !important; } #populate_ad_left, #popup_domination_lightbox_wrapper, #portlet-advertisement-left, #portlet-advertisement-right, #post-promo-ad, #post5_adbox, #post_ad, #premium_ad, #priceGrabberAd, #prime-ad-space, #print-header-ad, #print_ads, #printads, #product-adsense, #promo-ad, #promoAds, #ps-vertical-ads, #pub468x60, #publicidad, #pushdown_ad { display: none !important; } #qm-ad-big-box, #qm-ad-sky, #qm-dvdad, #quigo_ad, #r1SoftAd, #rail_ad1, #rail_ad2, #realEstateAds, #rectAd, #rect_ad, #rectangle-ad, #rectangleAd, #rectangle_ad, #refine-300-ad, #region-node-advert, #region-top-ad, #relocation_ad_container, #rh-ad-container, #rh_tower_ad, #rhapsodyAd { display: none !important; } #rhs_ads, #rhsadvert, #right-ad, #right-ad-col, #right-ad-skin, #right-ad-title, #right-ad1, #right-ads-3, #right-advert, #right-bar-ad, #right-box-ad, #right-featured-ad, #right-mpu-1-ad-container, #right-uppder-adverts, #right-uppder-adverts-container, #rightAd, #rightAd300x250, #rightAd300x250Lower, #rightAdBar, #rightAdColumn { display: none !important; } #rightAd_rdr, #rightAdsDiv, #rightColAd, #rightColumnMpuAd, #rightColumnSkyAd, #right_ad, #right_ad_wrapper, #right_ads, #right_advert, #right_advertisement, #right_advertising, #right_column_ad_container, #right_column_ads, #right_column_adverts, #right_column_internal_ad_container, #right_column_top_ad_unit, #rightad, #rightadContainer, #rightads, #rightadvertbar-doubleclickads { display: none !important; } #rightbar-ad, #rightcolhouseads, #rightcolumn_300x250ad, #rightgoogleads, #rightinfoad, #rightside-ads, #rightside_ad, #righttop-adverts, #righttop-adverts-container, #rm_ad_text, #ros_ad, #rotatingads, #row2AdContainer, #rprightHeaderAd, #rr_MSads, #rt-ad, #rt-ad-top, #rt-ad468, #rtMod_ad, #rtmod_ad { display: none !important; } #sAdsBox, #sb-ad-sq, #sb_ad_links, #sb_advert, #search-google-ads, #search-sponsored-links, #search-sponsored-links-top, #searchAdSenseBox, #searchAdSenseBoxAd, #searchAdSkyscraperBox, #search_ads, #search_result_ad, #sec_adspace, #second-adlayer, #secondBoxAdContainer, #secondrowads, #sect-ad-300x100, #sect-ad-300x250-2, #section-ad-1-728, #section-ad-300-250 { display: none !important; } #section-ad-4-160, #section-blog-ad, #section-container-ddc_ads, #section_advertisements, #section_advertorial_feature, #servfail-ads, #sew-ad1, #shoppingads, #shortads, #show-ad, #showAd, #showad, #side-ad, #side-ad-container, #side-ads, #sideAd, #sideAd1, #sideAd2, #sideAdSub, #sideAds { display: none !important; } #sideBarAd, #side_ad, #side_ad_wrapper, #side_ads_by_google, #side_sky_ad, #sidead, #sideads, #sideadtop-to, #sidebar-125x125-ads, #sidebar-125x125-ads-below-index, #sidebar-ad, #sidebar-ad-boxes, #sidebar-ad-space, #sidebar-ad-wrap, #sidebar-ad3, #sidebar-ads, #sidebar-adv, #sidebar-sponsor-link, #sidebar2ads, #sidebar_ad { display: none !important; } #sidebar_ad_widget, #sidebar_ads, #sidebar_ads_180, #sidebar_sponsoredresult_body, #sidebar_txt_ad_links, #sidebarad, #sidebaradpane, #sidebarads, #sidebaradver_advertistxt, #sideline-ad, #single-mpu, #singlead, #site-ad-container, #site-leaderboard-ads, #site_top_ad, #sitead, #sky-ad, #skyAd, #skyAdContainer, #skyScrapperAd { display: none !important; } #skyWrapperAds, #sky_ad, #sky_advert, #skyads, #skyadwrap, #skyline_ad, #skyscrapeAd, #skyscraper-ad, #skyscraperAd, #skyscraperAdContainer, #skyscraper_ad, #skyscraper_advert, #skyscraperad, #slide_ad, #sliderAdHolder, #slideshow_ad_300x250, #sm-banner-ad, #small_ad, #small_ad_banners_vertical, #small_ads { display: none !important; } #smallerAd, #some-ads, #some-more-ads, #specialAd_one, #specialAd_two, #specialadvertisingreport_container, #specials_ads, #speeds_ads, #speeds_ads_fstitem, #speedtest_mrec_ad, #sphereAd, #spnAds, #sponlink, #sponlinks, #sponsAds, #sponsLinks, #sponseredlinks, #sponsorAd1, #sponsorAd2, #sponsorAdDiv { display: none !important; } #sponsorLinks, #sponsorTextLink, #sponsor_banderole, #sponsor_deals, #sponsored, #sponsored-ads, #sponsored-features, #sponsored-links, #sponsored-listings, #sponsored-resources, #sponsored1, #sponsoredBox1, #sponsoredBox2, #sponsoredLinks, #sponsoredLinks_Top, #sponsoredList, #sponsoredResults, #sponsoredResultsWide, #sponsoredSiteMainline, #sponsoredSiteSidebar { display: none !important; } #sponsored_ads_v4, #sponsored_container, #sponsored_content, #sponsored_game_row_listing, #sponsored_head, #sponsored_link, #sponsored_link_bottom, #sponsored_links, #sponsored_v12, #sponsoredads, #sponsoredlinks, #sponsoredlinks_cntr, #sponsoredlinkslabel, #sponsoredresults_top, #sponsoredwellcontainerbottom, #sponsoredwellcontainertop, #sponsorlink, #spotlightAds, #spotlightad, #sqAd { display: none !important; } #squareAd, #squareAdSpace, #squareAds, #square_ad, #srp_adsense-top, #start_middle_container_advertisment, #sticky-ad, #stickyBottomAd, #story-90-728-area, #story-ad-a, #story-ad-b, #story-leaderboard-ad, #story-sponsoredlinks, #storyAd, #storyAdWrap, #storyad2, #submenu-ads, #subpage-ad-right, #subpage-ad-top, #swads { display: none !important; } #synch-ad, #systemad_background, #tabAdvertising, #takeoverad, #tblAd, #tbl_googlead, #tcwAd, #td-GblHdrAds, #template_ad_leaderboard, #tertiary_advertising, #test_adunit_160_article, #text-ad, #text-ads, #text-link-ads, #textAd, #textAds, #text_ad, #text_ads, #text_advert, #textad { display: none !important; } #textad3, #textad_block, #the-last-ad-standing, #thefooterad, #themis-ads, #tile-ad, #tmglBannerAd, #tmp2_promo_ad, #toolbarSlideUpAd, #top-ad, #top-ad-container, #top-ad-menu, #top-ads, #top-ads-tabs, #top-advertisement, #top-banner-ad, #top-search-ad-wrapper, #topAd, #topAd728x90, #topAdBanner { display: none !important; } #topAdBox, #topAdContainer, #topAdSenseDiv, #topAdcontainer, #topAds, #topAdsContainer, #topAdvBox, #topAdvert, #topAdvert-09, #topBannerAd, #topBannerAdContainer, #topContentAdTeaser, #topNavLeaderboardAdHolder, #topOverallAdArea, #topRightBlockAdSense, #topSponsoredLinks, #top_ad, #top_ad-sense, #top_ad_area, #top_ad_banner { display: none !important; } #top_ad_game, #top_ad_unit, #top_ad_wrapper, #top_ad_zone, #top_ads, #top_ads_wrap, #top_advertise, #top_advertising, #top_rectangle_ad, #top_right_ad, #top_wide_ad, #topad, #topad1, #topad2, #topad_left, #topad_right, #topadbar, #topadblock, #topaddwide, #topads { display: none !important; } #topadsense, #topadspace, #topadwrap, #topadzone, #topbanner_ad, #topbannerad, #topbar-ad, #topcustomad, #topleaderboardad, #topnav-ad-shell, #topnavad, #toprightAdvert, #toprightad, #topsponsored, #toptextad, #tour300Ad, #tour728Ad, #tourSponsoredLinksContainer, #towerad, #ts-ad_module { display: none !important; } #ttp_ad_slot1, #ttp_ad_slot2, #twogamesAd, #txfPageMediaAdvertVideo, #txt_link_ads, #txtads, #undergameAd, #upper-ads, #upperAdvertisementImg, #upperMpu, #upper_small_ad, #upperad, #urban_contentad_1, #urban_contentad_2, #urban_contentad_article, #v_ad, #vap_adsense-top, #vert-ads, #vert_ad, #vert_ad_placeholder { display: none !important; } #vertical_ad, #vertical_ads, #videoAd, #videoAdvert, #video_ads_overdiv, #video_advert2, #video_advert3, #video_cnv_ad, #video_overlay_ad, #videoadlogo, #view_ads, #view_ads_advertisements, #viewads, #viewportAds, #viewvid_ad300x250, #wXcds12-ad, #wall_advert, #wallpaper-ad-link, #wallpaperAd_left, #wallpaperAd_right { display: none !important; } #walltopad, #weblink_ads_container, #welcomeAdsContainer, #welcome_ad_mrec, #welcome_advertisement, #wf_ContentAd, #wf_FrontSingleAd, #wf_SingleAd, #wf_bottomContentAd, #wgtAd, #whatsnews_top_ad, #whitepaper-ad, #whoisRightAdContainer, #wide_ad_unit_top, #wideskyscraper_160x600_left, #wideskyscraper_160x600_right, #widget_Adverts, #widget_advertisement, #widgetwidget_adserve2, #wrapAdRight { display: none !important; } #wrapAdTop, #wrapperAdsTopLeft, #wrapperAdsTopRight, #xColAds, #y-ad-units, #y708-ad-expedia, #y708-ad-lrec, #y708-ad-partners, #y708-ad-ysm, #y708-advertorial-marketplace, #yahoo-ads, #yahoo-sponsors, #yahooSponsored, #yahoo_ads, #yahoo_ads_2010, #yahoo_text_ad, #yahooad-tbl, #yan-sponsored, #yatadsky, #ybf-ads { display: none !important; } #yfi_fp_ad_mort, #yfi_fp_ad_nns, #yfi_pf_ad_mort, #ygrp-sponsored-links, #ymap_adbanner, #yn-gmy-ad-lrec, #yreSponsoredLinks, #ysm_ad_iframe, #zoneAdserverMrec, #zoneAdserverSuper, .ADBAR, .ADPod, .AD_ALBUM_ITEMLIST, .AD_MOVIE_ITEM, .AD_MOVIE_ITEMLIST, .AD_MOVIE_ITEMROW, .ADbox, .Ad-300x100, .Ad-Container-976x166, .Ad-Header { display: none !important; } .Ad-MPU, .Ad-Wrapper-300x100, .Ad120x600, .Ad160x600, .Ad160x600left, .Ad160x600right, .Ad247x90, .Ad300x, .Ad300x250, .Ad300x250L, .Ad728x90, .AdBorder, .AdBox, .AdBox7, .AdContainerBox308, .AdContainerModule, .AdHeader, .AdHere, .AdInfo, .AdInline { display: none !important; } .AdMedium, .AdPlaceHolder, .AdProS728x90Container, .AdProduct, .AdRingtone, .AdSense, .AdSenseLeft, .AdSlot, .AdSpace, .AdTextSmallFont, .AdTitle, .AdUnit, .AdUnit300, .Ad_C, .Ad_D_Wrapper, .Ad_E_Wrapper, .Ad_Right, .AdsBottom, .AdsBoxBottom, .AdsBoxSection { display: none !important; } .AdsBoxTop, .AdsLinks1, .AdsLinks2, .AdsRec, .AdvBoxSidebar, .Advert, .Advert300x250, .AdvertMidPage, .AdvertiseWithUs, .Advertisement, .AdvertisementTextTag, .Advman_Widget, .ArticleAd, .ArticleInlineAd, .BCA_Advertisement, .Banner300x250, .BannerAd, .BigBoxAd, .BlockAd, .BlueTxtAdvert { display: none !important; } .BottomAdContainer, .BottomAffiliate, .BoxAd, .CG_adkit_leaderboard, .CG_details_ad_dropzone, .CWReviewsProdInfoAd, .ComAread, .CommentAd, .ContentAd, .ContentAds, .DAWRadvertisement, .DeptAd, .DisplayAd, .FT_Ad, .FeaturedAdIndexAd, .FlatAds, .FooterAds, .GOOGLE_AD, .GoogleAd, .GoogleAdSenseBottomModule { display: none !important; } .GoogleAdSenseRightModule, .HPG_Ad_B, .HPNewAdsBannerDiv, .HPRoundedAd, .HeaderAds, .HomeContentAd, .IABAdSpace, .InArticleAd, .IndexRightAd, .LazyLoadAd, .LeftAd, .LeftButtonAdSlot, .LeftTowerAd, .M2Advertisement, .MD_adZone, .MOS-ad-hack, .MPUHolder, .MPUTitleWrapperClass, .MREC_ads, .MiddleAd { display: none !important; } .MiddleAdContainer, .MiddleAdvert, .NewsAds, .OpaqueAdBanner, .OpenXad, .PU_DoubleClickAdsContent, .Post5ad, .Post8ad, .Post9ad, .RBboxAd, .RW_ad300, .RectangleAd, .RelatedAds, .Right300x250AD, .RightAd1, .RightAdvertiseArea, .RightAdvertisement, .RightGoogleAFC, .RightRailAd, .RightRailTop300x250Ad { display: none !important; } .RightSponsoredAdTitle, .RightTowerAd, .STR_AdBlock, .SectionSponsor, .SideAdCol, .SidebarAd, .SidebarAdvert, .SitesGoogleAdsModule, .SkyAdContainer, .SponsoredAdTitle, .SponsoredContent, .SponsoredLinkItemTD, .SponsoredLinks, .SponsoredLinksGrayBox, .SponsoredLinksModule, .SponsoredLinksPadding, .SponsoredLinksPanel, .Sponsored_link, .SquareAd, .StandardAdLeft { display: none !important; } .StandardAdRight, .TRU-onsite-ads-leaderboard, .TextAd, .TheEagleGoogleAdSense300x250, .TopAd, .TopAdContainer, .TopAdL, .TopAdR, .TopBannerAd, .UIWashFrame_SidebarAds, .UnderAd, .VerticalAd, .Video-Ad, .VideoAd, .WidgetAdvertiser, .a160x600, .a728x90, .ad-120x60, .ad-120x600, .ad-160 { display: none !important; } .ad-160x600, .ad-160x600x1, .ad-160x600x2, .ad-160x600x3, .ad-250, .ad-300, .ad-300-block, .ad-300-blog, .ad-300x100, .ad-300x250, .ad-300x250-first, .ad-300x250-right0, .ad-300x600, .ad-350, .ad-355x75, .ad-600, .ad-635x40, .ad-728, .ad-728x90, .ad-728x90-1 { display: none !important; } .ad-728x90-top0, .ad-728x90_forum, .ad-90x600, .ad-above-header, .ad-adlink-bottom, .ad-adlink-side, .ad-area, .ad-background, .ad-banner, .ad-banner-smaller, .ad-bigsize, .ad-block, .ad-block-square, .ad-blog2biz, .ad-body, .ad-bottom, .ad-box, .ad-break, .ad-btn, .ad-btn-heading { display: none !important; } .ad-button, .ad-cell, .ad-column, .ad-container, .ad-container-300x250, .ad-container-728x90, .ad-container-994x282, .ad-context, .ad-disclaimer, .ad-display, .ad-div, .ad-enabled, .ad-feedback, .ad-filler, .ad-flex, .ad-footer, .ad-footer-leaderboard, .ad-forum, .ad-google, .ad-graphic-large { display: none !important; } .ad-gray, .ad-grey, .ad-hdr, .ad-head, .ad-header, .ad-heading, .ad-holder, .ad-homeleaderboard, .ad-img, .ad-in-post, .ad-index-main, .ad-inline, .ad-island, .ad-item, .ad-label, .ad-leaderboard, .ad-left, .ad-link, .ad-links, .ad-lrec { display: none !important; } .ad-medium, .ad-medium-two, .ad-mpl, .ad-mpu, .ad-msn, .ad-note, .ad-notice, .ad-other, .ad-permalink, .ad-place-active, .ad-placeholder, .ad-postText, .ad-poster, .ad-priority, .ad-rect, .ad-rectangle, .ad-rectangle-text, .ad-related, .ad-rh, .ad-ri { display: none !important; } .ad-right, .ad-right-header, .ad-right-txt, .ad-row, .ad-section, .ad-show-label, .ad-side, .ad-sidebar, .ad-sidebar-outer, .ad-sidebar300, .ad-sky, .ad-skyscr, .ad-skyscraper, .ad-slot, .ad-slot-234-60, .ad-slot-300-250, .ad-slot-728-90, .ad-source, .ad-space, .ad-space-mpu-box { display: none !important; } .ad-space-topbanner, .ad-spot, .ad-square, .ad-square300, .ad-squares, .ad-statement, .ad-story-inject, .ad-tabs, .ad-text, .ad-text-links, .ad-tile, .ad-title, .ad-top, .ad-top-left, .ad-unit, .ad-unit-300, .ad-unit-300-wrapper, .ad-unit-anchor, .ad-unit-top, .ad-vert { display: none !important; } .ad-vertical-container, .ad-vtu, .ad-widget-list, .ad-with-us, .ad-wrap, .ad-wrapper, .ad-zone, .ad-zone-s-q-l, .ad.super, .ad08sky, .ad100, .ad120, .ad120x240backgroundGray, .ad120x600, .ad125, .ad140, .ad160, .ad160600, .ad160x600, .ad160x600GrayBorder { display: none !important; } .ad200x60, .ad230, .ad250, .ad250c, .ad300, .ad300250, .ad300_250, .ad300x100, .ad300x250, .ad300x250-hp-features, .ad300x250Module, .ad300x250Top, .ad300x250_container, .ad300x250box, .ad300x50-right, .ad300x600, .ad310, .ad315, .ad336x280, .ad343x290 { display: none !important; } .ad400right, .ad450, .ad468, .ad468_60, .ad468x60, .ad540x90, .ad600, .ad620x70, .ad626X35, .ad644, .ad728, .ad728_90, .ad728x90, .ad728x90_container, .ad90x780, .adAgate, .adArea674x60, .adBanner, .adBanner300x250, .adBanner728x90 { display: none !important; } .adBannerTyp1, .adBannerTypSortableList, .adBannerTypW300, .adBar, .adBgBottom, .adBgMId, .adBgTop, .adBlock, .adBottomLink, .adBottomboxright, .adBox, .adBox1, .adBox230X96, .adBox728X90, .adBoxBody, .adBoxBorder, .adBoxContainer, .adBoxContent, .adBoxInBignews, .adBoxSidebar { display: none !important; } .adBoxSingle, .adBwrap, .adCMRight, .adCell, .adColumn, .adCont, .adContTop, .adContainer, .adContentAd, .adContour, .adCreative, .adCube, .adDiv, .adElement, .adFender3, .adFrame, .adFtr, .adFullWidthMiddle, .adGoogle, .adHeader { display: none !important; } .adHeadline, .adHolder, .adHome300x250, .adHorisontal, .adInNews, .adIsland, .adLabel, .adLeader, .adLeaderForum, .adLeaderboard, .adLeft, .adLoaded, .adLocal, .adMPU, .adMarker, .adMastheadLeft, .adMastheadRight, .adMegaBoard, .adMinisLR, .adMkt2Colw { display: none !important; } .adModule, .adModuleAd, .adMpu, .adNewsChannel, .adNoOutline, .adNotice, .adNoticeOut, .adObj, .adPageBorderL, .adPageBorderR, .adPanel, .adPod, .adRect, .adResult, .adRight, .adSKY, .adSelfServiceAdvertiseLink, .adServer, .adSky, .adSky600 { display: none !important; } .adSkyscaper, .adSkyscraperHolder, .adSlot, .adSpBelow, .adSpace, .adSpacer, .adSplash, .adSponsor, .adSpot, .adSpot-brought, .adSpot-searchAd, .adSpot-textBox, .adSpot-twin, .adSpotIsland, .adSquare, .adSubColPod, .adSummary, .adSuperboard, .adSupertower, .adTD { display: none !important; } .adTab, .adTag, .adText, .adTileWrap, .adTiler, .adTitle, .adTopLink, .adTopboxright, .adTout, .adTxt, .adUnit, .adUnitHorz, .adUnitVert, .adUnitVert_noImage, .adWebBoard, .adWidget, .adWithTab, .adWord, .adWrap, .adWrapper { display: none !important; } .ad_0, .ad_1, .ad_120x90, .ad_125, .ad_130x90, .ad_160, .ad_160x600, .ad_2, .ad_200, .ad_200x200, .ad_250x250, .ad_250x250_w, .ad_3, .ad_300, .ad_300_250, .ad_300x250, .ad_300x250_box_right, .ad_336, .ad_336x280, .ad_350x100 { display: none !important; } .ad_350x250, .ad_400x200, .ad_468, .ad_468x60, .ad_600, .ad_680x15, .ad_728, .ad_728_90b, .ad_728x90, .ad_925x90, .ad_Left, .ad_Right, .ad_ad_300, .ad_amazon, .ad_banner, .ad_banner_border, .ad_bar, .ad_bg, .ad_bigbox, .ad_biz { display: none !important; } .ad_block, .ad_block_338, .ad_body, .ad_border, .ad_botbanner, .ad_bottom, .ad_bottom_leaderboard, .ad_bottom_left, .ad_box, .ad_box2, .ad_box_ad, .ad_box_div, .ad_callout, .ad_caption, .ad_column, .ad_column_box, .ad_column_hl, .ad_contain, .ad_container, .ad_content { display: none !important; } .ad_content_wide, .ad_contents, .ad_descriptor, .ad_disclaimer, .ad_eyebrow, .ad_footer, .ad_frame, .ad_framed, .ad_front_promo, .ad_gutter_top, .ad_head, .ad_header, .ad_heading, .ad_headline, .ad_holder, .ad_hpm, .ad_image, .ad_info_block, .ad_inline, .ad_island { display: none !important; } .ad_jnaught, .ad_label, .ad_launchpad, .ad_leader, .ad_leaderboard, .ad_left, .ad_line, .ad_link, .ad_links, .ad_linkunit, .ad_loc, .ad_lrec, .ad_main, .ad_medrec, .ad_medrect, .ad_middle, .ad_mod, .ad_mp, .ad_mpu, .ad_mr { display: none !important; } .ad_mrec, .ad_mrec_title_article, .ad_mrect, .ad_news, .ad_note, .ad_notice, .ad_one, .ad_p360, .ad_partner, .ad_partners, .ad_plus, .ad_post, .ad_power, .ad_primary, .ad_promo, .ad_rec, .ad_rectangle, .ad_right, .ad_right_col, .ad_row { display: none !important; } .ad_row_bottom_item, .ad_side, .ad_sidebar, .ad_skyscraper, .ad_slug, .ad_slug_table, .ad_space, .ad_space_300_250, .ad_spacer, .ad_sponsor, .ad_sponsoredsection, .ad_spot_b, .ad_spot_c, .ad_square_r, .ad_square_top, .ad_sub, .ad_tag_middle, .ad_text, .ad_text_w, .ad_title { display: none !important; } .ad_top, .ad_top_leaderboard, .ad_top_left, .ad_topright, .ad_tower, .ad_unit, .ad_unit_rail, .ad_url, .ad_warning, .ad_wid300, .ad_wide, .ad_wrap, .ad_wrapper, .ad_wrapper_fixed, .ad_wrapper_top, .ad_wrp, .ad_zone, .adarea, .adarea-long, .adbanner { display: none !important; } .adbannerbox, .adbannerright, .adbar, .adboard, .adborder, .adbot, .adbottom, .adbottomright, .adbox-outer, .adbox-wrapper, .adbox_300x600, .adbox_366x280, .adbox_468X60, .adbox_bottom, .adbox_br, .adbox_left, .adboxclass, .adboxesrow, .adbreak, .adbug { display: none !important; } .adbutton, .adbuttons, .adcode, .adcol1, .adcol2, .adcolumn, .adcolumn_wrapper, .adcont, .adcopy, .add_300x250, .addiv, .adenquire, .adfieldbg, .adfoot, .adfootbox, .adframe, .adhead, .adhead_h, .adhead_h_wide, .adheader { display: none !important; } .adheader100, .adheader416, .adhi, .adhint, .adholder, .adhoriz, .adiframe, .adinfo, .adinside, .adintro, .adits, .adjlink, .adkicker, .adkit, .adkit-advert, .adkit-lb-footer, .adlabel-horz, .adlabel-vert, .adlabelleft, .adlayer { display: none !important; } .adleader, .adleaderboard, .adleft1, .adline, .adlink, .adlinks, .adlist, .adlnklst, .admarker, .admediumred, .admedrec, .admessage, .admodule, .admpu, .admpu-small, .adnation-banner, .adnotice, .adops, .adp-AdPrefix, .adpadding { display: none !important; } .adpane, .adpic, .adprice, .adproxy, .adrec, .adright, .adroot, .adrotate_widget, .adrow, .adrow-post, .adrow1box1, .adrow1box3, .adrow1box4, .adrule, .ads-125, .ads-300, .ads-300x250, .ads-728x90-wrap, .ads-ads-top, .ads-banner { display: none !important; } .ads-below-content, .ads-categories-bsa, .ads-custom, .ads-favicon, .ads-item, .ads-links-general, .ads-mpu, .ads-outer, .ads-profile, .ads-right, .ads-section, .ads-sidebar, .ads-sky, .ads-small, .ads-sponsors, .ads-stripe, .ads-text, .ads-top, .ads-wide, .ads-widget { display: none !important; } .ads-widget-partner-gallery, .ads03, .ads160, .ads1_250, .ads24Block, .ads300, .ads460, .ads460_home, .ads468, .ads728, .ads728x90, .adsArea, .adsBelowHeadingNormal, .adsBlock, .adsBottom, .adsBox, .adsCell, .adsCont, .adsDiv, .adsFull { display: none !important; } .adsImages, .adsInsideResults_v3, .adsMPU, .adsMiddle, .adsRight, .adsRow, .adsTextHouse, .adsTop, .adsTower2, .adsTowerWrap, .adsWithUs, .ads_125_square, .ads_180, .ads_300, .ads_300x100, .ads_300x250, .ads_320, .ads_337x280, .ads_728x90, .ads_big { display: none !important; } .ads_big-half, .ads_box, .ads_box_headline, .ads_brace, .ads_catDiv, .ads_container, .ads_disc_anchor, .ads_disc_leader, .ads_disc_lwr_square, .ads_disc_skyscraper, .ads_disc_square, .ads_div, .ads_footer, .ads_header, .ads_holder, .ads_horizontal, .ads_leaderboard, .ads_lr_wrapper, .ads_medrect, .ads_mpu { display: none !important; } .ads_outer, .ads_post_end, .ads_post_end_code, .ads_post_start, .ads_post_start_code, .ads_rectangle, .ads_remove, .ads_right, .ads_rightbar_top, .ads_sc_bl_i, .ads_sc_tb, .ads_sc_tl_i, .ads_show_if, .ads_side, .ads_sidebar, .ads_singlepost, .ads_spacer, .ads_takeover, .ads_title, .ads_top { display: none !important; } .ads_top_promo, .ads_tr, .ads_verticalSpace, .ads_vtlLink, .ads_widesky, .ads_wrapperads_top, .adsafp, .adsbg300, .adsblockvert, .adsborder, .adsbottom, .adsbox, .adsboxitem, .adsbttmpg, .adsbyyahoo, .adscaleAdvert, .adscaleP6_canvas, .adsclick, .adscontainer, .adscreen { display: none !important; } .adsd_shift100, .adsection_a2, .adsection_c2, .adsense-468, .adsense-ad, .adsense-category, .adsense-category-bottom, .adsense-googleAds, .adsense-heading, .adsense-overlay, .adsense-post, .adsense-right, .adsense-title, .adsense3, .adsense300, .adsenseAds, .adsenseBlock, .adsenseContainer, .adsenseGreenBox, .adsenseInPost { display: none !important; } .adsenseList, .adsense_bdc_v2, .adsense_mpu, .adsensebig, .adsenseblock, .adsenseblock_bottom, .adsenseblock_top, .adsenselr, .adsensem_widget, .adsensesq, .adsenvelope, .adserver_zone, .adset, .adsforums, .adsghori, .adsgvert, .adshome, .adside, .adsidebox, .adsider { display: none !important; } .adsingle, .adsleft, .adsleftblock, .adslink, .adslogan, .adslotleft, .adslotright, .adsmalltext, .adsmessage, .adsnippet_widget, .adspace, .adspace-MR, .adspace-widget, .adspace180, .adspace_bottom, .adspace_buysell, .adspace_rotate, .adspace_skyscraper, .adspacer, .adspot { display: none !important; } .adspot728x90, .adstext, .adstextpad, .adstitle, .adstop, .adstory, .adstrip, .adtab, .adtable, .adtag, .adtech, .adtext, .adtext_gray, .adtext_horizontal, .adtext_onwhite, .adtext_vertical, .adtile, .adtips, .adtips1, .adtitle { display: none !important; } .adtop, .adtravel, .adtxt, .adtxtlinks, .adunit, .adv-mpu, .adv-p, .adv-sidebar, .adv300, .advBox, .advSquare, .advVideobox, .adv_120x600, .adv_300x250, .adv_728x90, .adv_banner_hor, .adv_medium_rectangle, .adver, .adverTag, .adverTxt { display: none !important; } .adver_cont_below, .advert-300-side, .advert-300x100-side, .advert-728x90, .advert-article-bottom, .advert-bannerad, .advert-bg-250, .advert-bloggrey, .advert-box, .advert-btm, .advert-head, .advert-horizontal, .advert-iab-300-250, .advert-iab-468-60, .advert-mpu, .advert-skyscraper, .advert-text, .advert-title, .advert-txt, .advert120 { display: none !important; } .advert300, .advert300x250, .advert300x300, .advert300x440, .advert350ih, .advert4, .advert5, .advert728x90, .advert8, .advertColumn, .advertCont, .advertContainer, .advertContent, .advertHeadline, .advertIslandWrapper, .advertRight, .advertSuperBanner, .advertText, .advertTitleSky, .advert_336 { display: none !important; } .advert_468x60, .advert_box, .advert_cont, .advert_container, .advert_djad, .advert_google_content, .advert_google_title, .advert_home_300, .advert_label, .advert_leaderboard, .advert_list, .advert_note, .advert_surr, .advert_top, .advertheader-red, .advertise, .advertise-here, .advertise-homestrip, .advertise-horz, .advertise-inquiry { display: none !important; } .advertise-leaderboard, .advertise-list, .advertise-top, .advertise-vert, .advertiseContainer, .advertiseText, .advertise_ads, .advertise_here, .advertise_link, .advertise_link_sidebar, .advertisement, .advertisement-728x90, .advertisement-block, .advertisement-sidebar, .advertisement-space, .advertisement-sponsor, .advertisement-swimlane, .advertisement-text, .advertisement-top, .advertisement300x250 { display: none !important; } .advertisement468, .advertisementBox, .advertisementColumnGroup, .advertisementContainer, .advertisementHeader, .advertisementLabel, .advertisementPanel, .advertisementText, .advertisement_300x250, .advertisement_btm, .advertisement_caption, .advertisement_g, .advertisement_header, .advertisement_horizontal, .advertisement_top, .advertisementsOutterDiv, .advertiser, .advertiser-links, .advertisespace_div, .advertising-banner { display: none !important; } .advertising-header, .advertising-leaderboard, .advertising-local-links, .advertising2, .advertisingTable, .advertising_block, .advertising_images, .advertisment, .advertisment_bar, .advertisment_caption, .advertisment_two, .advertize, .advertize_here, .advertorial, .advertorial-2, .advertorial-promo-box, .advertorial_red, .advertorialtitle, .adverts, .adverts-125 { display: none !important; } .adverts_RHS, .advt, .advt-banner-3, .advt-block, .advt-sec, .advt300, .advt720, .advtitle, .adwhitespace, .adwordListings, .adwords, .adwordsHeader, .adwrap, .adwrapper-lrec, .adwrapper948, .adzone-footer, .adzone-sidebar, .affiliate-link, .affiliate-sidebar, .affiliateAdvertText { display: none !important; } .affiliates-sidebar, .affinityAdHeader, .afsAdvertising, .after_ad, .agi-adsaleslinks, .alb-content-ad, .alignads, .alt_ad, .anchorAd, .another_text_ad, .answer_ad_content, .aolSponsoredLinks, .aopsadvert, .apiAdMarkerAbove, .apiAds, .app_advertising_skyscraper, .archive-ads, .art_ads, .article-ad-box, .article-ads { display: none !important; } .article-content-adwrap, .articleAd, .articleAd300x250, .articleAds, .articleAdsL, .articleEmbeddedAdBox, .article_ad, .article_adbox, .article_mpu_box, .article_page_ads_bottom, .articleads, .aseadn, .aux-ad-widget-1, .aux-ad-widget-2, .b-astro-sponsored-links_horizontal, .b-astro-sponsored-links_vertical, .b_ads_cont, .b_ads_top, .banmanad, .banner-468-60 { display: none !important; } .banner-468x60, .banner-ad, .banner-ads, .banner-adv, .banner-advert, .banner-adverts, .banner-buysellads, .banner160x600, .banner300by250, .banner300x100, .banner300x250, .banner468, .banner468by60, .banner728x90, .bannerADV, .bannerAd, .bannerAdWrapper300x250, .bannerAdWrapper730x86, .bannerAds, .bannerAdvert { display: none !important; } .bannerRightAd, .banner_160x600, .banner_300x250, .banner_728x90, .banner_ad, .banner_ad_footer, .banner_ad_leaderboard, .bannerad, .bannerad-125tower, .bannerad-468x60, .barkerAd, .base-ad-mpu, .base_ad, .base_printer_widgets_AdBreak, .bg-ad-link, .bgnavad, .big-ads, .bigAd, .big_ad, .big_ads { display: none !important; } .bigad, .bigad2, .bigbox_ad, .bigboxad, .billboard300x250, .billboard_ad, .biz-ad, .biz-ads, .biz-adtext, .blk_advert, .block-ad, .block-ad300, .block-admanager, .block-ads-bottom, .block-ads-top, .block-adsense, .block-adsense-managed, .block-adspace-full, .block-bg-advertisement-region-1, .block-deca_advertising { display: none !important; } .block-google-admanager, .block-google_admanager, .block-openads, .block-openadstream, .block-openx, .block-thirdage-ads, .block-wtg_adtech, .blockAd, .blockAds, .block_ad, .block_ad_floating_bar, .block_ad_sb_text, .block_ad_sb_text2, .block_ad_sponsored_links, .block_ad_sponsored_links-wrapper, .block_ad_sponsored_links_localized, .blockad, .blocked-ads, .blog-ad-leader-inner, .blog-ads-container { display: none !important; } .blogAd, .blogAdvertisement, .blogArtAd, .blogBigAd, .blog_ad, .blogads, .blox3featuredAd, .bn_textads, .body_ad, .body_sponsoredresults_bottom, .body_sponsoredresults_middle, .body_sponsoredresults_top, .bodyads, .bodyads2, .bookseller-header-advt, .bottom-ad, .bottom-ad-fr, .bottom-ads, .bottomAd, .bottomAds { display: none !important; } .bottom_ad, .bottom_ad_block, .bottom_ads, .bottom_adsense, .bottom_right_ad, .bottomad, .bottomads, .bottomadvert, .bottombarad, .bottomrightrailAd, .bottomvidad, .box-ad, .box-ad-grey, .box-ads, .box-ads-small, .box-adsense, .box-adverts, .boxAd, .boxAds, .boxAdsInclude { display: none !important; } .box_ad, .box_ad_container, .box_ad_content, .box_ad_spacer, .box_ad_wrap, .box_ads, .box_adv, .box_adv_new, .box_advertising, .box_advertisment_62_border, .box_content_ad, .box_content_ads, .box_textads, .boxad, .boxads, .boxyads, .bps-ad-wrapper, .bps-advertisement, .bps-advertisement-inline-ads, .br-ad { display: none !important; } .breakad_container, .brokerad, .bsa_ads, .btm_ad, .btm_ad_container, .btn-ad, .bullet-sponsored-links, .bullet-sponsored-links-gray, .burstContentAdIndex, .busrep_poll_and_ad_container, .buttonAd, .buttonAds, .button_ads, .button_advert, .buttonadbox, .buttonads, .bx_ad, .bx_ad_right, .cA-adStrap, .cColumn-TextAdsBox { display: none !important; } .cLeftTextAdUnit, .c_ligatus_nxn, .calendarAd, .calloutAd, .carbonad, .carbonad-tag, .care2_adspace, .catalog_ads, .category-ad, .categorySponsorAd, .category__big_game_container_body_games_advertising, .cb-ad-banner, .cb-ad-container, .cb_ads, .cb_navigation_ad, .cbstv_ad_label, .cbzadvert, .cbzadvert_block, .cdAdTitle, .cdmainlineSearchAdParent { display: none !important; } .cdo-ad-section, .cdsidebarSearchAdParent, .centerAd, .center_ad, .centerad, .centered-ad, .chitikaAdCopy, .cinemabotad, .classifiedAdThree, .clearerad, .cmAdContainer, .cmAdFind, .cmAdSponsoredLinksBox, .cm_ads, .cms-Advert, .cnbc_badge_banner_ad_area, .cnbc_banner_ad_area, .cnbc_leaderboard_ad, .cnn160AdFooter, .cnnAd { display: none !important; } .cnnMosaic160Container, .cnnStoreAd, .cnnStoryElementBoxAd, .cnnWCAdBox, .cnnWireAdLtgBox, .cnn_728adbin, .cnn_adcntr300x100, .cnn_adcntr728x90, .cnn_adspc336cntr, .cnn_adtitle, .cntrad, .column2-ad, .columnBoxAd, .columnRightAdvert, .com-ad-server, .comment-ad, .comment-ad-wrap, .comment-advertisement, .comment_ad_box, .common_advertisement_title { display: none !important; } .communityAd, .conTSponsored, .conductor_ad, .confirm_ad_left, .confirm_ad_right, .confirm_leader_ad, .consoleAd, .container-adwords, .containerSqAd, .container_serendipity_plugin_google_adsense, .content-ad, .content-ads, .content-advert, .contentAd, .contentAdContainer, .contentAdFoot, .contentAdsWrapper, .content_ad, .content_ad_728, .content_adsense { display: none !important; } .content_adsq, .content_tagsAdTech, .contentad, .contentad-home, .contentad300x250, .contentad_right_col, .contentadcontainer, .contentadfloatl, .contentadleft, .contentads, .contentadstartpage, .contents-ads-bottom-left, .contenttextad, .contest_ad, .cp_ad, .cpmstarHeadline, .cpmstarText, .create_ad, .cs-mpu, .cscTextAd { display: none !important; } .cse_ads, .cspAd, .ct_ad, .ctnAdSkyscraper, .ctnAdSquare300, .cube-ad, .cubeAd, .cube_ads, .currency_ad, .custom_ads, .cwAdvert, .cxAdvertisement, .darla_ad, .dart-ad, .dartAdImage, .dart_ad, .dart_tag, .dartadvert, .dartiframe, .dc-ad { display: none !important; } .dcAdvertHeader, .deckAd, .deckads, .detail-ads, .detailMpu, .detail_ad, .detail_top_advert, .dfrads, .displayAdSlot, .divAd, .divAdright, .div_adv300, .div_advstrip, .divad1, .divad2, .divad3, .divads, .divider_ad, .dlSponsoredLinks, .dmco_advert_iabrighttitle { display: none !important; } .downloadAds, .download_ad, .downloadad, .dsq_ad, .dualAds, .dynamic-ads, .dynamic_ad, .e-ad, .ec-ads, .ec-ads-remove-if-empty, .em-ad, .em_ads_box_dynamic_remove, .embed-ad, .embeddedAd, .entry-body-ad, .entry-injected-ad, .entry_sidebar_ads, .entryad, .ez-clientAd, .f_Ads { display: none !important; } .feature_ad, .featuredAds, .featured_ad, .featuredadvertising, .fireplaceadleft, .fireplaceadright, .fireplaceadtop, .firstpost_advert_container, .flagads, .flash-advertisement, .flash_ad, .flash_advert, .flashad, .flexbanneritemad, .flexiad, .flipbook_v2_sponsor_ad, .floatad, .floated_right_ad, .floatingAds, .fm-badge-ad { display: none !important; } .fns_td_wrap, .fold-ads, .footad, .footer-ad, .footer-advert, .footerAd, .footerAdModule, .footerAds, .footerAdslot, .footerAdverts, .footerTextAd, .footer_ad, .footer_ad336, .footer_ads, .footer_block_ad, .footer_bottomad, .footer_line_ad, .footer_text_ad, .footerad, .forumtopad { display: none !important; } .freedownload_ads, .frn_adbox, .frn_cont_adbox, .frontads, .frontpage-google-ad, .ft-ad, .ftdAdBar, .ftdContentAd, .full_ad_box, .full_width_ad, .fullbannerad, .g3rtn-ad-site, .gAdRows, .gAdSky, .gAdvertising, .g_ggl_ad, .ga-ads, .ga-textads-bottom, .ga-textads-top, .gaTeaserAds { display: none !important; } .gaTeaserAdsBox, .gads_cb, .gads_container, .gallery_ad, .gam_ad_slot, .gameAd, .gamesPage_ad_content, .gbl_advertisement, .gen_side_ad, .gglAds, .global_banner_ad, .googad, .googads, .google-ad, .google-ad-container, .google-ads, .google-ads-boxout, .google-ads-slim, .google-adsense, .google-right-ad { display: none !important; } .google-sponsored-ads, .google-sponsored-link, .google468, .google468_60, .googleAd, .googleAd-content, .googleAd-list, .googleAd300x250_wrapper, .googleAdBox, .googleAdSense, .googleAdSenseModule, .googleAd_body, .googleAds, .googleAds_article_page_above_comments, .googleAdsense, .googleContentAds, .googleProfileAd, .googleSearchAd_content, .googleSearchAd_sidebar, .google_ad { display: none !important; } .google_ad_wide, .google_add_container, .google_ads, .google_ads_bom_title, .google_ads_content, .google_adsense_footer, .googlead, .googleaddiv, .googleaddiv2, .googleads, .googleads_300x250, .googleads_title, .googleadsense, .googleafc, .googley_ads, .gpAdBox, .gpAds, .gradientAd, .grey-ad-line, .group_ad { display: none !important; } .gsAd, .gsfAd, .gt_ad, .gt_ad_300x250, .gt_ad_728x90, .gt_adlabel, .gutter-ad-left, .gutter-ad-right, .gx_ad, .h-ad-728x90-bottom, .h_Ads, .h_ad, .half-ad, .half_ad_box, .hcf-ad, .hcf-ad-rectangle, .hcf-cms-ad, .hd_advert, .hdr-ads, .head_ad { display: none !important; } .header-ad, .header-advert, .header-google-ads, .header-taxonomy-image-sponsor, .headerAd, .headerAdCode, .headerAds, .headerAdvert, .headerTextAd, .header_ad, .header_ad_center, .header_ad_div, .header_ads, .header_advertisement, .header_advertisment, .headerad, .headerad-720, .hi5-ad, .highlightsAd, .hm_advertisment { display: none !important; } .hn-ads, .home-ad-links, .homeAd, .homeAd1, .homeAd2, .homeAdBoxA, .homeAdBoxBetweenBlocks, .homeAdBoxInBignews, .homeAdSection, .homeMediumAdGroup, .home_ad_bottom, .home_advertisement, .home_advertorial, .home_mrec_ad, .homead, .homepage-ad, .homepage300ad, .homepageFlexAdOuter, .homepageMPU, .homepage_middle_right_ad { display: none !important; } .homepageinline_adverts, .hor_ad, .horiz_adspace, .horizontalAd, .horizontal_ad, .horizontal_ads, .horizontaltextadbox, .horizsponsoredlinks, .hortad, .houseAd1, .houseAdsStyle, .housead, .hoverad, .hp-col4-ads, .hp2-adtag, .hp_ad_cont, .hp_ad_text, .hp_t_ad, .hp_w_ad, .hpa-ad1 { display: none !important; } .html-advertisement, .ic-ads, .ico-adv, .idMultiAd, .iframe-ad, .image-advertisement, .imageAd, .imageads, .imgad, .in-page-ad, .in-story-ads, .in-story-text-ad, .inStoryAd-news2, .indEntrySquareAd, .indie-sidead, .indy_googleads, .infoBoxThreadPageRankAds, .inhousead, .inline-ad, .inline-mpu { display: none !important; } .inline-mpu-left, .inlineSideAd, .inline_ad, .inline_ad_title, .inlinead, .inlineadsense, .inlineadtitle, .inlist-ad, .inlistAd, .inner-advt-banner-3, .innerAds, .innerad, .inpostad, .insert_advertisement, .insertad, .insideStoryAd, .inteliusAd_image, .interest-based-ad, .internalAdsContainer, .iprom-ad { display: none !important; } .is24-adplace, .isAd, .islandAd, .islandAdvert, .islandad, .itemAdvertise, .jimdoAdDisclaimer, .jp-advertisment-promotional, .js-advert, .kdads-empty, .kdads-link, .kw_advert, .kw_advert_pair, .l_ad_sub, .label-ad, .labelads, .largeRecAdNewsContainerRight, .largeRectangleAd, .largeUnitAd, .large_ad { display: none !important; } .lastRowAd, .lazyload_ad, .lcontentbox_ad, .leadAd, .leaderAdSlot, .leaderAdTop, .leaderAdvert, .leaderBoardAdHolder, .leaderOverallAdArea, .leader_ad, .leaderboardAd, .leaderboardAdContainer, .leaderboardAdContainerInner, .leaderboard_ad, .leaderboardad, .leaderboardadtop, .left-ad, .left-advert, .leftAd, .leftAdColumn { display: none !important; } .leftAds, .left_ad, .left_ad_box, .left_adlink, .left_ads, .left_adsense, .leftad, .leftadtag, .leftbar_ad_160_600, .leftbarads, .leftbottomads, .leftnavad, .lgRecAd, .lg_ad, .ligatus, .linead, .link_adslider, .link_advertise, .live-search-list-ad-container, .livingsocial-ad { display: none !important; } .ljad, .local-ads, .log_ads, .logoAds, .logoad, .logoutAd, .longAd, .longAdBox, .lowerAds, .lr-ad, .m-ad-tvguide-box, .m4-adsbygoogle, .m_banner_ads, .macAd, .macad, .main-ad, .main-advert, .main-tabs-ad-block, .mainAd, .mainLeftAd { display: none !important; } .mainLinkAd, .mainRightAd, .main_ad, .main_ad_bg_div, .main_adbox, .main_ads, .main_intro_ad, .map_media_banner_ad, .marginadsthin, .marketing-ad, .masthead_topad, .matador_sidebar_ad_600, .mdl-ad, .media-advert, .mediaAd, .mediaAdContainer, .mediaResult_sponsoredSearch, .medium-rectangle-ad, .mediumRectangleAdvert, .medium_ad { display: none !important; } .medrect_ad, .member-ads, .menuItemBannerAd, .menueadimg, .messageBoardAd, .mf-ad300-container, .micro_ad, .mid_ad, .mid_page_ad, .midad, .middle-ad, .middleAds, .middlead, .middleads, .min_navi_ad, .mini-ad, .miniad, .miscAd, .mmc-ad, .mmcAd_Iframe { display: none !important; } .mobile_featuredad, .mod-ad-lrec, .mod-ad-n, .mod-adopenx, .mod-vertical-ad, .mod_admodule, .module-ad, .module-ad-small, .module-ads, .module-advertisement, .module-sponsored-ads, .moduleAd, .moduleAdvertContent, .module_ad, .module_box_ad, .modulegad, .moduletable-advert, .moduletable-googleads, .moduletablesquaread, .mos-ad { display: none !important; } .mpu-ad, .mpu-ad-con, .mpu-advert, .mpu-footer, .mpu-fp, .mpu-title, .mpu-top-left, .mpu-top-left-banner, .mpu-top-right, .mpu01, .mpuAd, .mpuAdSlot, .mpuAdvert, .mpuArea, .mpuBox, .mpuContainer, .mpuHolder, .mpuTextAd, .mpu_ad, .mpu_advert { display: none !important; } .mpu_container, .mpu_gold, .mpu_holder, .mpu_platinum, .mpu_side, .mpu_text_ad, .mpuad, .mpuholderportalpage, .mrec_advert, .ms-ads-link, .msfg-shopping-mpu, .mvw_onPageAd1, .mwaads, .my-ad250x300, .nSponsoredLcContent, .nSponsoredLcTopic, .nadvt300, .narrow_ad_unit, .narrow_ads, .navAdsBanner { display: none !important; } .navBads, .nav_ad, .navadbox, .navcommercial, .navi_ad300, .naviad, .nba300Ad, .nbaT3Ad160, .nbaTVPodAd, .nbaTwo130Ads, .nbc_ad_carousel_wrp, .newPex_forumads, .newTopAdContainer, .newad, .newsAd, .news_article_ad_google, .newsviewAdBoxInNews, .newsvinemsn_adtype, .nexusad, .nf-adbox { display: none !important; } .nn-mpu, .noAdForLead, .normalAds, .nrAds, .nsAdRow, .nu2ad, .oas-ad, .oas-bottom-ads, .oas_ad, .oas_advertisement, .offer_sponsoredlinks, .oio-banner-zone, .oio-link-sidebar, .oio-zone-position, .on_single_ad_box, .onethirdadholder, .openads, .openadstext_after, .openx, .openx-ad { display: none !important; } .openx_ad, .osan-ads, .other_adv2, .outermainadtd1, .ovAdPromo, .ovAdSky, .ovAdartikel, .ov_spns, .ovadsenselabel, .pageAds, .pageBottomGoogleAd, .pageGoogleAd, .pageGoogleAdFlat, .pageGoogleAdSubcontent, .pageGoogleAds, .pageGoogleAdsContainer, .pageLeaderAd, .page_content_right_ad, .pagead, .pageads { display: none !important; } .pagenavindexcontentad, .paneladvert, .partner-ad, .partner-ads-container, .partnerAd, .partnersTextLinks, .pencil_ad, .player_ad_box, .player_hover_ad, .player_page_ad_box, .plista_inimg_box, .pm-ad, .pmad-in2, .pnp_ad, .pod-ad-300, .podRelatedAdLinksWidget, .podSponsoredLink, .portalCenterContentAdBottom, .portalCenterContentAdMiddle, .portalCenterContentAdTop { display: none !important; } .portal_searchresultssponsoredlist, .portalcontentad, .post-ad, .postAd, .post_ad, .post_ads, .post_sponsor_unit, .postbit_adbit_register, .postbit_adcode, .postgroup-ads, .postgroup-ads-middle, .prebodyads, .premium_ad_container, .promoAd, .promoAds, .promo_ad, .promoboxAd, .promotionTextAd, .ps-ligatus_placeholder, .pub_300x250 { display: none !important; } .pub_300x250m, .pub_728x90, .publication-ad, .publicidad, .puff-advertorials, .qa_ad_left, .qm-ad-content, .qm-ad-content-news, .quigo-ad, .qzvAdDiv, .r_ad_1, .r_ad_box, .r_ads, .rad_container, .rect_ad_module, .rectad, .rectangle-ad, .rectangleAd, .rectanglead, .redads_cont { display: none !important; } .referrerDetailAd, .regular_728_ad, .regularad, .relatedAds, .related_post_google_ad, .relatesearchad, .remads, .resourceImagetAd, .result_ad, .reviewMidAdvertAlign, .rght300x250, .rhads, .rhs-ad, .rhs-ads-panel, .rhs-advert-container, .rhs-advert-link, .rhs-advert-title, .right-ad, .right-ad-holder, .right-ad2 { display: none !important; } .right-ads, .right-ads2, .right-sidebar-box-ad, .rightAd, .rightAdBox, .rightAdverts, .rightColAd, .rightColumnRectAd, .rightRailAd, .right_ad, .right_ad_160, .right_ad_box, .right_ad_common_block, .right_ad_text, .right_ad_top, .right_ads, .right_ads_column, .right_box_ad_rotating_container, .right_col_ad, .right_hand_advert_column { display: none !important; } .right_side-partyad, .rightad, .rightad_1, .rightad_2, .rightadbox1, .rightads, .rightadunit, .rightbigcolumn_ads, .rightbigcolumn_ads_nobackground, .rightcol_boxad, .rightcoladvert, .rightcoltowerad, .rightmenu_ad, .rnav_ad, .rngtAd, .rot_ads, .round_box_advert, .roundedCornersAd, .roundingrayboxads, .rt_ad1_300x90 { display: none !important; } .rt_ad_300x250, .rt_ad_call, .s2k_ad, .savvyad_unit, .sb-ad-sq-bg, .sbAd, .sbAdUnitContainer, .sb_ad_holder, .sb_adsN, .sb_adsNv2, .sb_adsW, .sb_adsWv2, .scanAd, .scc_advert, .sci-ad-main, .sci-ad-sub, .search-ad, .search-results-ad, .search-sponsor, .search-sponsored { display: none !important; } .searchAd, .searchAdTop, .searchAds, .searchSponsoredResultsBox, .searchSponsoredResultsList, .search_column_results_sponsored, .search_results_sponsored_top, .section-ad2, .section_mpu_wrapper, .section_mpu_wrapper_wrapper, .selfServeAds, .sepContentAd, .serp_sponsored, .servsponserLinks, .shoppingGoogleAdSense, .showAd_No, .showAd_Yes, .showcaseAd, .sidbaread, .side-ad { display: none !important; } .side-ads, .side-sky-banner-160, .sideAd, .sideBoxAd, .side_ad, .side_ad2, .side_ad_1, .side_ad_2, .side_ad_3, .sidead, .sideads, .sideadsbox, .sideadvert, .sidebar-ad, .sidebar-ads, .sidebar-content-ad, .sidebar-text-ad, .sidebarAd, .sidebarAdUnit, .sidebarAdvert { display: none !important; } .sidebar_ad, .sidebar_ad_300_250, .sidebar_ads, .sidebar_ads_336, .sidebar_adsense, .sidebar_box_ad, .sidebarad, .sidebarad_bottom, .sidebaradbox, .sidebarads, .sidebarboxad, .sideheadnarrowad, .sideheadsponsorsad, .simple_ads_manager_widget, .single-google-ad, .singleAd, .singleAdsContainer, .single_ad, .singlead, .singleadstopcstm2 { display: none !important; } .site_ad_120_600, .site_ad_300x250, .sitesponsor, .skinAd, .skin_ad_638, .sky-ad, .skyAd, .skyAdd, .skyAdvert, .skyAdvert2, .sky_ad, .sky_scraper_ad, .skyad, .skyjobsadtext, .skyscraper-ad, .skyscraper_ad, .skyscraper_bannerAdHome, .sleekadbubble, .slideshow-ad, .slpBigSlimAdUnit { display: none !important; } .slpSquareAdUnit, .sm_ad, .smallSkyAd1, .smallSkyAd2, .small_ad, .small_ads, .smallad-left, .smallads, .smallsponsorad, .smart_ads_bom_title, .spLinks, .specialAd175x90, .speedyads, .sphereAdContainer, .spl-ads, .spl_ad, .spl_ad2, .spl_ad_plus, .splitAd, .splitAdResultsPane { display: none !important; } .sponlinkbox, .spons-link, .spons_links, .sponslink, .sponsor-ad, .sponsor-link, .sponsor-links, .sponsor-services, .sponsorPanel, .sponsorPost, .sponsorPostWrap, .sponsorStrip, .sponsor_ad_area, .sponsor_area, .sponsor_bar, .sponsor_columns, .sponsor_footer, .sponsor_line, .sponsor_links, .sponsor_logo { display: none !important; } .sponsoradtitle, .sponsored-ads, .sponsored-chunk, .sponsored-editorial, .sponsored-features, .sponsored-links, .sponsored-links-alt-b, .sponsored-links-holder, .sponsored-links-right, .sponsored-post, .sponsored-post_ad, .sponsored-results, .sponsored-right-border, .sponsored-text, .sponsoredBox, .sponsoredInfo, .sponsoredInner, .sponsoredLabel, .sponsoredLink, .sponsoredLinks { display: none !important; } .sponsoredLinks2, .sponsoredLinksHeader, .sponsoredProduct, .sponsoredResults, .sponsoredSideInner, .sponsored_ads, .sponsored_box, .sponsored_box_search, .sponsored_by, .sponsored_link, .sponsored_links, .sponsored_links_title_container, .sponsored_links_title_container_top, .sponsored_links_top, .sponsored_result, .sponsored_results, .sponsored_ss, .sponsored_well, .sponsoredibbox, .sponsoredlink { display: none !important; } .sponsoredlinks, .sponsoredlinkscontainer, .sponsoredresults, .sponsoredtextlink_container_ovt, .sponsoring_link, .sponsorlink, .sponsorlink2, .sponsormsg, .sport-mpu-box, .spotlightAd, .squareAd, .square_ad, .square_banner_ad, .squared_ad, .ss-ad-banner, .ss-ad-mpu, .standard-ad, .start__newest__big_game_container_body_games_advertising, .staticAd, .stickyAdLink { display: none !important; } .stock-ticker-ad-tag, .stocks-ad-tag, .store-ads, .story_AD, .story_ad_div, .story_right_adv, .storyad, .subad, .subadimg, .subcontent-ad, .subtitle-ad-container, .sugarad, .super-ad, .supercommentad_left, .supercommentad_right, .supp-ads, .supportAdItem, .surveyad, .t10ad, .tab_ad { display: none !important; } .tab_ad_area, .tablebordersponsor, .tadsanzeige, .tadsbanner, .tadselement, .tallad, .tblTopAds, .tbl_ad, .tbox_ad, .td-Adholder, .td-TrafficWeatherWidgetAdGreyBrd, .teaser-sponsor, .teaserAdContainer, .teaser_adtiles, .teaser_advert_content, .text-ad, .text-ad-links, .text-ads, .text-advertisement, .text-g-advertisement { display: none !important; } .text-g-group-short-rec-ad, .text-g-net-grp-google-ads-article-page, .textAd, .textAdBox, .textAds, .text_ad, .text_ads, .textad, .textadContainer, .textad_headline, .textadbox, .textadheadline, .textadlink, .textads, .textads_left, .textads_right, .textadsds, .textadsfoot, .textadtext, .textadtxt { display: none !important; } .textadtxt2, .textlink-ads, .textlinkads, .tf_page_ad_search, .thirdage_ads_300x250, .thirdage_ads_728x90, .thisIsAd, .thisIsAnAd, .ticket-ad, .tileAds, .tips_advertisement, .title-ad, .title_adbig, .tncms-region-ads, .toolad, .toolbar-ad, .top-ad, .top-ad-space, .top-ads, .top-banner-ad { display: none !important; } .top-left-nav-ad, .top-menu-ads, .topAd, .topAdWrap, .topAds, .topAdvertisement, .topAdverts, .topBannerAd, .topLeaderboardAd, .top_Ad, .top_ad, .top_ad1, .top_ad_728, .top_ad_728_90, .top_ad_disclaimer, .top_ad_div, .top_ad_post, .top_ad_wrapper, .top_ads, .top_advert { display: none !important; } .top_advertisement, .top_advertising_lb, .top_bar_ad, .top_container_ad, .topad, .topad-bar, .topadbox, .topads, .topadspot, .topadvertisementsegment, .topboardads, .topcontentadvertisement, .topic_inad, .topstoriesad, .toptenAdBoxA, .tourFeatureAd, .tower-ad, .towerAd, .towerAdLeft, .towerAds { display: none !important; } .tower_ad, .tower_ad_disclaimer, .towerad, .tr-ad-adtech-placement, .tribal-ad, .ts-ad_unit_bigbox, .ts-banner_ad, .ttlAdsensel, .tto-sponsored-element, .tucadtext, .tvs-mpu, .twoColumnAd, .twoadcoll, .twoadcolr, .tx_smartadserver_pi1, .txt-ads, .txtAd, .txtAds, .txt_ad, .txt_ads { display: none !important; } .txtadvertise, .type_adscontainer, .type_miniad, .type_promoads, .ukAds, .ukn-banner-ads, .under_ads, .undertimyads, .unit-ad, .universalboxADVBOX01, .universalboxADVBOX03, .universalboxADVBOX04a, .usenext, .v5rc_336x280ad, .vert-ads, .vert-adsBlock, .vertad, .vertical-adsense, .vidadtext, .videoAd { display: none !important; } .videoBoxAd, .video_ad, .view-promo-mpu-right, .view_rig_ad, .virgin-mpu, .wa_adsbottom, .wantads, .weather_ad, .webads336x280, .wide-ad, .wide-advert, .wide-skyscraper-ad, .wideAd, .wideAdTable, .wide_ad, .wide_ad_unit_top, .wide_ads, .wide_google_ads, .widget-ad, .widget-ad-codes { display: none !important; } .widget-ad300x250, .widget-entry-ads-160, .widgetYahooAds, .widget_ad, .widget_ad_boxes_widget, .widget_ad_rotator, .widget_adrotate_widgets, .widget_advert_widget, .widget_econaabachoadswidget, .widget_island_ad, .widget_maxbannerads, .widget_sdac_bottom_ad_widget, .widget_sdac_footer_ads_widget, .widget_sdac_skyscraper_ad_widget, .wikia-ad, .wikia_ad_placeholder, .wingadblock, .withAds, .wl-ad, .wnMultiAd { display: none !important; } .wp125_write_ads_widget, .wp125ad, .wp125ad_2, .wpn_ad_content, .wrap-ads, .wrapper-ad, .wrapper-ad-sidecol, .wsSponsoredLinksRight, .wsTopSposoredLinks, .x03-adunit, .x04-adunit, .x81_ad_detail, .xads-blk-top-hld, .xads-blk2, .xads-ojedn, .y-ads, .y-ads-wide, .y7-advertisement, .yahoo-sponsored, .yahoo-sponsored-links { display: none !important; } .yahooAd, .yahooAds, .yahoo_ads, .yahooad, .yahooad-image, .yahooad-urlline, .yan-sponsored, .ygrp-ad, .yom-ad, .youradhere, .yrail_ad_wrap, .yrail_ads, .ysmsponsor, .ysponsor, .yw-ad, .zRightAdNote, a[href*="/adrotate/adrotate-out.php?"], a[href^="http://ad-apac.doubleclick.net/"], a[href^="http://ad-emea.doubleclick.net/"], a[href^="http://ad.doubleclick.net/"] { display: none !important; } a[href^="http://ads.pheedo.com/"], a[href^="http://adserving.liveuniversenetwork.com/"], a[href^="http://api.ringtonematcher.com/"], a[href^="http://galleries.pinballpublishernetwork.com/"], a[href^="http://galleries.securewebsiteaccess.com/"], a[href^="http://install.securewebsiteaccess.com/"], a[href^="http://latestdownloads.net/download.php?"], a[href^="http://secure.signup-page.com/"], a[href^="http://secure.signup-way.com/"], a[href^="http://www.FriendlyDuck.com/AF_"], a[href^="http://www.adbrite.com/mb/commerce/purchase_form.php?"], a[href^="http://www.firstload.de/affiliate/"], a[href^="http://www.friendlyduck.com/AF_"], a[href^="http://www.google.com/aclk?"], a[href^="http://www.liutilities.com/aff"], a[href^="http://www.liutilities.com/products/campaigns/adv/"], a[href^="http://www.my-dirty-hobby.com/?sub="], a[href^="http://www.ringtonematcher.com/"], #center_col > div[style="background:#fbf0fa;margin:0 0 14px;min-height:0;padding-top:2px;padding-bottom:1px;padding-right:8px;padding-left:7px"], #mbEnd[cellspacing="0"][cellpadding="0"] { display: none !important; } #mclip_container:last-child, #ssmiwdiv[jsdisplay], #tads.c, #tadsb.c, #tadsto.c, .ch[onclick="ga(this,event)"], .ra[align="left"][width="30%"], .ra[align="right"][width="30%"], iframe[name^="AdbriteFrame"] { display: none !important; }</style>

<body class="home blog logged-in admin-bar">
<div id="wrapper" class="hfeed">
	<div id="header">
		<div id="masthead">
			<div id="branding" role="banner">
								<h1 id="site-title">
					<span>
						<a href="./NICE Syndication Example   Dummy blog to test out NICE Syndication platform_files/NICE Syndication Example   Dummy blog to test out NICE Syndication platform.html" title="NICE Syndication Example" rel="home">NICE Syndication Example</a>
					</span>
				</h1>
				<div id="site-description">Dummy blog to test out NICE Syndication platform</div>

										<img src="./NICE Syndication Example   Dummy blog to test out NICE Syndication platform_files/path.jpg" width="940" height="198" alt="">
								</div><!-- #branding -->

			<div id="access" role="navigation">
			  				<div class="skip-link screen-reader-text"><a href="http://briansamson.info/nice/#content" title="Skip to content">Skip to content</a></div>
								<div class="menu"><ul><li class="current_page_item"><a href="./NICE Syndication Example   Dummy blog to test out NICE Syndication platform_files/NICE Syndication Example   Dummy blog to test out NICE Syndication platform.html" title="Home">Home</a></li><li class="page_item page-item-2"><a href="http://briansamson.info/nice/?page_id=2" title="Sample Page">Sample Page</a></li></ul></div>
			</div><!-- #access -->
		</div><!-- #masthead -->
	</div><!-- #header -->

	<div id="main">

		<div id="container">
			<div id="content" role="main">

			




			<div id="post-4" class="post-4 post type-post status-publish format-standard hentry category-uncategorized">
			<h2 class="entry-title"><a href="http://briansamson.info/nice/?p=4" title="Permalink to Infection control: Prevention of healthcare-associated infection in primary and community care" rel="bookmark"><span class="trigger">Infection</span> control: Prevention of healthcare-associated <span class="trigger">infection</span> in primary and community care</a></h2>

			<div class="entry-meta">
				<span class="meta-prep meta-prep-author">Posted on</span> <a href="http://briansamson.info/nice/?p=4" title="10:31 am" rel="bookmark"><span class="entry-date">November 30, 2011</span></a> <span class="meta-sep">by</span> <span class="author vcard"><a class="url fn n" href="http://briansamson.info/nice/?author=1" title="View all posts by Brian Samson">Brian Samson</a></span>			</div><!-- .entry-meta -->

				<div class="entry-content">
	    <div id="page" class="container_16">

				<div id="simple-header-wrap"><div id="header">

  <a href="http://www.nice.org.uk/" title="Link to main NICE site">

	  <img src="/media/2/Viewer-2.6/images/nice-logo-normal.png" alt="NICE logo"/>

  </a>

	<div id="site-menu">

		<ul id="utilityLinks">

			<li>

				<a href="http://www.nice.org.uk/" title="Link to main NICE site">Home</a>

			</li>

			<li class="last">

				<a href="http://www.nice.org.uk/guidance" title="Find guidance">Find guidance</a>

			</li>

		</ul>

		<a class="return" href="http://www.nice.org.uk/CG87">Return to main guidance site</a>

	</div>

	

</div>

				</div>

            <div id="contentWrap" class="clearfix">

                <a id="startContent"></a>

                <div id="content" class="grid_12 push_2">



  <div id="guidanceContent">

		

	<div class="title-wrapper">

		<div class="nice-short-code">CG87</div>

		<div class="nice-title">

      <h1>

        Type 2 diabetes: The management of type 2 diabetes

      </h1>

		</div>

	</div>

		<div id="information-bar">

			<p class="issued">

				Issued: May 2009

			</p>

			<p>

				<a class="view-summary" title="View summary" href="http://www.nice.org.uk/CG87" target="_blank">View implementation support and guidance summary</a>

			</p>

		</div>

		

		<div id="guidance-sidebar">

			



				<div id="chapter-chooser-background">

					<a href="/type-2-diabetes-cg87/contents" rel="rels/chapter-chooser" class="chapter-chooser">Select chapters to save or share</a>

				</div>



			



  <div id="guidanceChapters">

    

    <h3>Table of contents</h3>



        <a href="/type-2-diabetes-cg87/important-information-about-this-guideline" title="Important information about this guideline">				

            Important information about this guideline

        </a>

      



        <a href="/type-2-diabetes-cg87/introduction" title="Introduction ">				

            Introduction 

        </a>

      



        <a href="/type-2-diabetes-cg87/patient-centred-care" title="Patient-centred care  ">				

            Patient-centred care  

        </a>

      



        <a href="/type-2-diabetes-cg87/key-priorities-for-implementation" title="Key priorities for implementation">				

            Key priorities for implementation

        </a>

      



        <a href="/type-2-diabetes-cg87/guidance" title="1 Guidance" class="current-item">							

            1 Guidance

        </a>

      



        <a href="/type-2-diabetes-cg87/notes-on-the-scope-of-the-guidance" title="2 Notes on the scope of the guidance">				

            2 Notes on the scope of the guidance

        </a>

      



        <a href="/type-2-diabetes-cg87/implementation" title="3 Implementation ">				

            3 Implementation 

        </a>

      



        <a href="/type-2-diabetes-cg87/research-recommendations" title="4 Research recommendations">				

            4 Research recommendations

        </a>

      



        <a href="/type-2-diabetes-cg87/other-versions-of-this-guideline" title="5 Other versions of this guideline">				

            5 Other versions of this guideline

        </a>

      



        <a href="/type-2-diabetes-cg87/related-nice-guidance" title="6 Related NICE guidance ">				

            6 Related NICE guidance 

        </a>

      



        <a href="/type-2-diabetes-cg87/updating-the-guideline" title="7 Updating the guideline">				

            7 Updating the guideline

        </a>

      



        <a href="/type-2-diabetes-cg87/appendix-b-the-guideline-development-groups" title="Appendix B: The Guideline Development Groups">				

            Appendix B: The Guideline Development Groups

        </a>

      



        <a href="/type-2-diabetes-cg87/appendix-b-the-guideline-review-panel" title="Appendix B: The Guideline Review Panel ">				

            Appendix B: The Guideline Review Panel 

        </a>

      



        <a href="/type-2-diabetes-cg87/appendix-c-the-algorithms" title="Appendix C: The algorithms ">				

            Appendix C: The algorithms 

        </a>

      

    

  </div>

    



			<div id="guidanceToolbar" class="clearfix">

				<div class="guidanceToolbarInner">

		

	<ul>

			<li>

				<a href="http://www.nice.org.uk/guidance/CG87/NICEGuidance/pdf/English" title="Download document as PDF">

					Download PDF <img src='/media/2/Viewer-2.6/images/pdf_icon.gif' alt="PDF icon"/>

				</a>

			</li>

			<li>

				<a href="http://www.nice.org.uk/guidance/CG87/NICEGuidance/doc/English" title="Download document as Microsoft Word document">			

					Download word document<img src='/media/2/Viewer-2.6/images/word_icon.gif' alt="Microsoft Word document icon"/>				

				</a>

			</li>

		<li class="last">

			<a href="/type-2-diabetes-cg87/help" title="Link to help">Help</a>

		</li>

	</ul>



				</div>

			</div>





		</div>



		<div id="guidanceContentBody">













  <div id="guidanceFragment">

		

	

	<div class="chapter-controls">

		

            <div>

				<a href="/type-2-diabetes-cg87/key-priorities-for-implementation" title="Go to previous chapter" class="previous-img">

					<img src='/media/2/Viewer-2.6/images/previous-chapter-button.png' alt="Navigate to Previous chapter icon"/>

                </a>

                <a href="/type-2-diabetes-cg87/key-priorities-for-implementation" title="Go to previous chapter" class="previous">   

                    Previous

			    </a>

            </div>

            <div>

			    <a href="/type-2-diabetes-cg87/notes-on-the-scope-of-the-guidance" title="Go to next chapter" class="next">

				    Next

			    </a>

                <a href="/type-2-diabetes-cg87/notes-on-the-scope-of-the-guidance" title="Go to next chapter" class="next-img">

                    <img src='/media/2/Viewer-2.6/images/next-chapter-button.png' alt="Navigate to Next chapter icon"/>

                </a>

            </div>

        

	</div>





  <p id="extractDisclaimer">

    This is an extract from the guidance and may be misleading if read alone. The complete guidance is available at www.nice.org.uk/cg87

  </p>



    <h2 id="fragmentTitle">

      
                1 Guidance

    </h2>



    <ul id="chapterToc">

      <li>

        <a href='#patient-education-the-recommendations-in-this-section-replace-guidance-on-the-use-of' title="Jump to 1.1 Patient education The recommendations in this section replace &#39;Guidance on the use of patient-education models for diabetes&#39; (NICE technology appraisal guidance 60).">1.1 Patient education The recommendations in this section replace &#39;Guidance on the use of patient-education models for diabetes&#39; (NICE technology appraisal guidance 60).</a>

      </li>

      <li>

        <a href='#lifestyle-managementnon-pharmacological-management' title="Jump to 1.2 Lifestyle management/non-pharmacological management">1.2 Lifestyle management/non-pharmacological management</a>

      </li>

      <li>

        <a href='#glucose-control-levels' title="Jump to 1.3 Glucose control levels">1.3 Glucose control levels</a>

      </li>

      <li>

        <a href='#self-monitoring-of-plasma-glucose' title="Jump to 1.4 Self-monitoring of plasma glucose">1.4 Self-monitoring of plasma glucose</a>

      </li>

      <li>

        <a href='#oral-glucose-control-therapies-1-metformin-insulin-secretagogues-and-acarbose' title="Jump to 1.5 Oral glucose control therapies (1): metformin, insulin secretagogues and acarbose ">1.5 Oral glucose control therapies (1): metformin, insulin secretagogues and acarbose </a>

      </li>

      <li>

        <a href='#oral-glucose-control-therapies-2-other-oral-agents-and-exenatide' title="Jump to 1.6 Oral glucose control therapies (2): other oral agents and exenatide">1.6 Oral glucose control therapies (2): other oral agents and exenatide</a>

      </li>

      <li>

        <a href='#glucose-control-insulin-therapy' title="Jump to 1.7 Glucose control: insulin therapy">1.7 Glucose control: insulin therapy</a>

      </li>

      <li>

        <a href='#blood-pressure-therapy' title="Jump to 1.8 Blood pressure therapy">1.8 Blood pressure therapy</a>

      </li>

      <li>

        <a href='#cardiovascular-risk-estimation' title="Jump to 1.9 Cardiovascular risk estimation">1.9 Cardiovascular risk estimation</a>

      </li>

      <li>

        <a href='#management-of-blood-lipid-levels' title="Jump to 1.10 Management of blood lipid levels">1.10 Management of blood lipid levels</a>

      </li>

      <li>

        <a href='#anti-thrombotic-therapy' title="Jump to 1.11 Anti-thrombotic therapy">1.11 Anti-thrombotic therapy</a>

      </li>

      <li>

        <a href='#eye-damage' title="Jump to 1.13 Eye damage">1.13 Eye damage</a>

      </li>

      <li>

        <a href='#nerve-damage' title="Jump to 1.14 Nerve damage">1.14 Nerve damage</a>

      </li>

    </ul>



		<div class="chapter" title="1 Guidance" xmlns="http://www.w3.org/1999/xhtml">

        

        <p>The following guidance is based on the best available evidence. The full guidelines (<a class="link" href="http://www.nice.org.uk/CG87" target="_top">www.nice.org.uk/CG87</a>) give details of the methods and the evidence used to develop the guidance.</p>

        <div class="section" title="1.1 Patient education">

          <h3 class="title">

                  <a id="patient-education-the-recommendations-in-this-section-replace-guidance-on-the-use-of"></a>1.1 Patient education<sup>[<a id="footnote_2" href="#ftn.footnote_2" class="footnote" name="footnote_2">2</a>]</sup></h3>

          <p>1.1.1 Offer structured education to every person and/or their carer at and around the time of diagnosis, with annual reinforcement and review. Inform people and their carers that structured education is an integral part of diabetes care.</p>

          <p>1.1.2 Select a patient-education programme that meets the criteria laid down by the Department of Health and Diabetes UK Patient Education Working Group<sup>[<a id="footnote_3" href="#ftn.footnote_3" class="footnote" name="footnote_3">3</a>]</sup>.</p>

          <div class="itemizedlist">

            <ul class="itemizedlist">

              <li class="listitem">

                <p>Any programme should be evidence-based and suit the needs of the individual. The programme should have specific aims and learning objectives, and should support development of self-management attitudes, beliefs, knowledge and skills for the learner, their family and carers.</p>

              </li>

              <li class="listitem">

                <p>The programme should have a structured curriculum that is theory driven and evidence-based, resource-effective, has supporting materials, and is written down.</p>

              </li>

              <li class="listitem">

                <p>The programme should be delivered by trained educators who have an understanding of education theory appropriate to the age and needs of the programme learners, and are trained and competent in delivery of the principles and content of the programme they are offering.</p>

              </li>

              <li class="listitem">

                <p>The programme itself should be quality assured, and be reviewed by trained, competent, independent assessors who assess it against key criteria to ensure sustained consistency.</p>

              </li>

              <li class="listitem">

                <p>The outcomes from the programme should be regularly audited.</p>

              </li>

            </ul>

          </div>

          <p>1.1.3 Ensure the patient-education programme provides the necessary resources to support the educators, and that educators are properly trained and given time to develop and maintain their skills.</p>

          <p>1.1.4 Offer group education programmes as the preferred option. Provide an alternative of equal standard for a person unable or unwilling to participate in group education.</p>

          <p>1.1.5 Ensure the patient-education programmes available meet the cultural, linguistic, cognitive and literacy needs in the locality.</p>

          <p>1.1.6 Ensure all members of the diabetes healthcare team are familiar with the programmes of patient education available locally, that these programmes are integrated with the rest of the care pathway, and that people with diabetes and their carers have the opportunity to contribute to the design and provision of local programmes. </p>

        </div>

        <div class="section" title="1.2 Lifestyle management/non-pharmacological management">

          <h3 class="title">

                  <a id="lifestyle-managementnon-pharmacological-management"></a>1.2 Lifestyle management/non-pharmacological management</h3>

          <p>Neither the management of obesity nor smoking cessation is specifically addressed in this guideline. Follow other NICE guidance in these areas (see section 6 for further details). </p>

          <div class="section" title="1.2.1 Dietary advice">

            <h4 class="title">

                    <a id="dietary-advice"></a>1.2.1 Dietary advice</h4>

            <p>1.2.1.1 Provide individualised and ongoing nutritional advice from a healthcare professional with specific expertise and competencies in nutrition. </p>

            <p>1.2.1.2 Provide dietary advice in a form sensitive to the individual's needs, culture and beliefs, being sensitive to their willingness to change and the effects on their quality of life.  </p>

            <p>1.2.1.3 Emphasise advice on healthy balanced eating that is applicable to the general population when providing advice to people with type 2 diabetes. Encourage high-fibre, low-glycaemic-index sources of carbohydrate in the diet, such as fruit, vegetables, wholegrains and pulses; include low-fat dairy products and oily fish; and control the intake of foods containing saturated and trans fatty acids). </p>

            <p>1.2.1.4 Integrate dietary advice with a personalised diabetes management plan, including other aspects of lifestyle modification, such as increasing physical activity and losing weight.</p>

            <p>1.2.1.5 Target, for people who are overweight, an initial body weight loss of 5–10%, while remembering that lesser degrees of weight loss may still be of benefit and that larger degrees of weight loss in the longer term will have advantageous metabolic impact.</p>

            <p>1.2.1.6 Individualise recommendations for carbohydrate and alcohol intake, and meal patterns. Reducing the risk of hypoglycaemia should be a particular aim for a person using insulin or an insulin secretagogue.</p>

            <p>1.2.1.7 Advise individuals that limited substitution of sucrose-containing foods for other carbohydrate in the meal plan is allowable, but that care should be taken to avoid excess energy intake.</p>

            <p>1.2.1.8 Discourage the use of foods marketed specifically for people with diabetes.</p>

            <p>1.2.1.9 When patients are admitted to hospital as inpatients or to any other institutions, implement a meal-planning system that provides consistency in the carbohydrate content of meals and snacks. </p>

          </div>

          <div class="section" title="1.2.2 Management of depression">

            <h4 class="title">

                    <a id="management-of-depression"></a>1.2.2 Management of depression</h4>

            <p>1.2.2.1 Follow the recommendations in 'Depression: management of depression in primary and secondary care clinical guideline' (NICE clinical guideline 23).</p>

          </div>

        </div>

        <div class="section" title="1.3 Glucose control levels">

          <h3 class="title">

                  <a id="glucose-control-levels"></a>1.3 Glucose control levels</h3>

          <p>1.3.1 When setting a target glycated haemoglobin (HbA<sub>1c</sub>):</p>

          <div class="itemizedlist">

            <ul class="itemizedlist">

              <li class="listitem">

                <p>involve the person in decisions about their individual HbA<sub>1c</sub> target level, which may be above that of 6.5% set for people with type 2 diabetes in general</p>

              </li>

              <li class="listitem">

                <p>encourage the person to maintain their individual target unless the resulting side effects (including hypoglycaemia) or their efforts to achieve this impair their quality of life</p>

              </li>

              <li class="listitem">

                <p>offer therapy (lifestyle and medication) to help achieve and maintain the HbA<sub>1c</sub> target level</p>

              </li>

              <li class="listitem">

                <p>inform a person with a higher HbA<sub>1c</sub> that any reduction in HbA<sub>1c</sub> towards the agreed target is advantageous to future health</p>

              </li>

              <li class="listitem">

                <p>avoid pursuing highly intensive management to levels of less than 6.5%.  </p>

              </li>

            </ul>

          </div>

          <p>1.3.2 Measure the individual's HbA<sub>1c</sub> levels at: </p>

          <div class="itemizedlist">

            <ul class="itemizedlist">

              <li class="listitem">

                <p>2–6-monthly intervals (tailored to individual needs) until the blood glucose level is stable on unchanging therapy; use a measurement made at an interval of less than 3 months as a indicator of direction of change, rather than as a new steady state</p>

              </li>

              <li class="listitem">

                <p>6-monthly intervals once the blood glucose level and blood glucose-lowering therapy are stable.</p>

              </li>

            </ul>

          </div>

          <p>1.3.3 If HbA<sub>1c</sub> levels remain above target levels, but pre-meal self-monitoring levels remain well controlled (&lt; 7.0 mmol/litre), consider self-monitoring to detect postprandial hyperglycaemia (&gt; 8.5 mmol/litre) and manage to below this level if detected (see sections 1.5–1.7). </p>

          <p>1.3.4 Measure HbA<sub>1c</sub> using high-precision methods and report results in units aligned with those used in the DCCT trial<sup>[<a id="footnote_4" href="#ftn.footnote_4" class="footnote" name="footnote_4">4</a>]</sup> (or as recommended by national agreement after publication of this guideline).</p>

          <p>1.3.5 When HbA<sub>1c</sub> monitoring is invalid (because of disturbed erythrocyte turnover or abnormal haemoglobin type), estimate trends in blood glucose control using one of the following: </p>

          <div class="itemizedlist">

            <ul class="itemizedlist">

              <li class="listitem">

                <p>fructosamine estimation </p>

              </li>

              <li class="listitem">

                <p>quality-controlled plasma glucose profiles </p>

              </li>

              <li class="listitem">

                <p>total glycated haemoglobin estimation (if abnormal haemoglobins). </p>

              </li>

            </ul>

          </div>

          <p>1.3.6 Investigate unexplained discrepancies between HbA<sub>1c</sub> and other glucose measurements. Seek advice from a team with specialist expertise in diabetes or clinical biochemistry.</p>

        </div>

        <div class="section" title="1.4 Self-monitoring of plasma glucose">

          <h3 class="title">

                  <a id="self-monitoring-of-plasma-glucose"></a>1.4 Self-monitoring of plasma glucose</h3>

          <p>1.4.1 Offer self-monitoring of plasma glucose to a person newly diagnosed with type 2 diabetes only as an integral part of his or her self-management education. Discuss its purpose and agree how it should be interpreted and acted upon.</p>

          <p>1.4.2 Self-monitoring of plasma glucose should be available: </p>

          <div class="itemizedlist">

            <ul class="itemizedlist">

              <li class="listitem">

                <p>to those on insulin treatment </p>

              </li>

              <li class="listitem">

                <p>to those on oral glucose-lowering medications to provide information on hypoglycaemia </p>

              </li>

              <li class="listitem">

                <p>to assess changes in glucose control resulting from medications and lifestyle changes </p>

              </li>

              <li class="listitem">

                <p>to monitor changes during intercurrent illness </p>

              </li>

              <li class="listitem">

                <p>to ensure safety during activities, including driving. </p>

              </li>

            </ul>

          </div>

          <p>1.4.3 Assess at least annually and in a structured way:</p>

          <div class="itemizedlist">

            <ul class="itemizedlist">

              <li class="listitem">

                <p>self-monitoring skills</p>

              </li>

              <li class="listitem">

                <p>the quality and appropriate frequency of testing</p>

              </li>

              <li class="listitem">

                <p>the use made of the results obtained</p>

              </li>

              <li class="listitem">

                <p>the impact on quality of life</p>

              </li>

              <li class="listitem">

                <p>the continued benefit</p>

              </li>

              <li class="listitem">

                <p>the equipment used.</p>

              </li>

            </ul>

          </div>

          <p>1.4.4 If self-monitoring is appropriate but blood glucose monitoring is unacceptable to the individual, discuss the use of urine glucose monitoring.</p>

        </div>

        <div class="section" title="1.5 Oral glucose control therapies (1): metformin, insulin secretagogues and acarbose">

          <h3 class="title">

                  <a id="oral-glucose-control-therapies-1-metformin-insulin-secretagogues-and-acarbose"></a>1.5 Oral glucose control therapies (1): metformin, insulin secretagogues and acarbose </h3>

          <div class="section" title="1.5.1 Metformin">

            <h4 class="title">

                    <a id="metformin"></a>1.5.1 Metformin</h4>

            <p>1.5.1.1 Start metformin treatment in a person who is overweight or obese (tailoring the assessment of body-weight-associated risk according to ethnic group<sup>[<a id="footnote_5" href="#ftn.footnote_5" class="footnote" name="footnote_5">5</a>]</sup>) and whose blood glucose is inadequately controlled (see 1.3.1) by lifestyle interventions (nutrition and exercise) alone.</p>

            <p>1.5.1.2 Consider metformin as an option for first-line glucose-lowering therapy for a person who is not overweight.  </p>

            <p>1.5.1.3 Continue with metformin if blood glucose control remains or becomes inadequate (see 1.3.1) and another oral glucose-lowering medication (usually a sulfonylurea) is added.</p>

            <p>1.5.1.4 Step up metformin therapy gradually over weeks to minimise risk of gastro-intestinal (GI) side effects. Consider a trial of extended-absorption metformin tablets where GI tolerability prevents continuation of metformin therapy.</p>

            <p>1.5.1.5 Review the dose of metformin if the serum creatinine exceeds 130 micromol/litre or the estimated glomerular filtration rate (eGFR) is below 45 ml/minute/1.73-m<sup>2</sup>.</p>

            <div class="itemizedlist">

              <ul class="itemizedlist">

                <li class="listitem">

                  <p>Stop the metformin if the serum creatinine exceeds 150 micromol/litre or the eGFR is below 30 ml/minute/1.73-m<sup>2</sup>. </p>

                </li>

                <li class="listitem">

                  <p>Prescribe metformin with caution for those at risk of a sudden deterioration in kidney function and those at risk of eGFR falling below 45 ml/minute/1.73-m<sup>2</sup>. </p>

                </li>

              </ul>

            </div>

            <p>1.5.1.6 The benefits of metformin therapy should be discussed with a person with mild to moderate liver dysfunction or cardiac impairment so that:</p>

            <div class="itemizedlist">

              <ul class="itemizedlist">

                <li class="listitem">

                  <p>due consideration can be given to the cardiovascular-protective effects of the drug</p>

                </li>

                <li class="listitem">

                  <p>an informed decision can be made on whether to continue or stop the metformin.</p>

                </li>

              </ul>

            </div>

          </div>

          <div class="section" title="1.5.2 Insulin secretagogues">

            <h4 class="title">

                    <a id="insulin-secretagogues"></a>1.5.2 Insulin secretagogues </h4>

            <p>1.5.2.1 Consider a sulfonylurea as an option for first-line glucose-lowering therapy if: </p>

            <div class="itemizedlist">

              <ul class="itemizedlist">

                <li class="listitem">

                  <p>the person is not overweight</p>

                </li>

                <li class="listitem">

                  <p>the person does not tolerate metformin (or it is contraindicated) <strong>or</strong></p>

                </li>

                <li class="listitem">

                  <p>a rapid response to therapy is required because of hyperglycaemic symptoms. </p>

                </li>

              </ul>

            </div>

            <p>1.5.2.2 Add a sulfonylurea as second-line therapy when blood glucose control remains or becomes inadequate (see 1.3.1) with metformin. </p>

            <p>1.5.2.3 Continue with a sulfonylurea if blood glucose control remains or becomes inadequate (see 1.3.1) and another oral glucose-lowering medication is added.</p>

            <p>1.5.2.4 Prescribe a sulfonylurea with a low acquisition cost (but not glibenclamide) when an insulin secretagogue is indicated (see 1.5.2.1 and 1.5.2.2).</p>

            <p>1.5.2.5 When drug concordance is a problem, offer a once-daily, long-acting sulfonylurea.</p>

            <p>1.5.2.6 Educate a person being treated with an insulin secretagogue, particularly if renally impaired, about the risk of hypoglycaemia. </p>

          </div>

          <div class="section" title="1.5.3 Rapid-acting insulin secretagogues">

            <h4 class="title">

                    <a id="rapid-acting-insulin-secretagogues"></a>1.5.3 Rapid-acting insulin secretagogues</h4>

            <p>1.5.3.1 Consider offering a rapid-acting insulin secretagogue to a person with an erratic lifestyle.  </p>

          </div>

          <div class="section" title="1.5.4 Acarbose">

            <h4 class="title">

                    <a id="acarbose"></a>1.5.4 Acarbose</h4>

            <p>1.5.4.1 Consider acarbose for a person unable to use other oral glucose-lowering medications.</p>

          </div>

        </div>

        <div class="section" title="1.6 Oral glucose control therapies (2): other oral agents and exenatide">

          <h3 class="title">

                  <a id="oral-glucose-control-therapies-2-other-oral-agents-and-exenatide"></a>1.6 Oral glucose control therapies (2): other oral agents and exenatide</h3>

          <p>The recommendations in this section were updated by the short clinical guideline 'Type 2 diabetes: newer agents for blood glucose control in type 2 diabetes' (<a class="link" href="http://www.nice.org.uk/CG87shortguideline" target="_top">www.nice.org.uk/CG87shortguideline</a>). The guideline gives details of the methods and the evidence used to develop the recommendations.</p>

          <div class="section" title="1.6.1 DPP-4 inhibitors (sitagliptin, vildagliptin)">

            <h4 class="title">

                    <a id="dpp-4-inhibitors-sitagliptin-vildagliptin"></a>1.6.1 DPP-4 inhibitors (sitagliptin, vildagliptin)</h4>

            <p>1.6.1.1 Consider adding a DPP-4 inhibitor (sitagliptin, vildagliptin) instead of a sulfonylurea as second-line therapy to first-line metformin when control of blood glucose remains or becomes inadequate (HbA<sub>1c </sub>≥ 6.5%, or other higher level agreed with the individual) if:</p>

            <div class="itemizedlist">

              <ul class="itemizedlist">

                <li class="listitem">

                  <p>the person is at significant risk of hypoglycaemia or its consequences (for example, older people and people in certain jobs [for example, those working at heights or with heavy machinery] or people in certain social circumstances [for example, those living alone]), or</p>

                </li>

                <li class="listitem">

                  <p>the person does not tolerate a sulfonylurea or a sulfonylurea is contraindicated. <strong>[new 2009]</strong></p>

                </li>

              </ul>

            </div>

            <p>1.6.1.2 Consider adding a DPP-4 inhibitor (sitagliptin, vildagliptin) as second-line therapy to first-line sulfonylurea monotherapy when control of blood glucose remains or becomes inadequate (HbA<sub>1c</sub> ≥ 6.5%, or other higher level agreed with the individual) if:</p>

            <div class="itemizedlist">

              <ul class="itemizedlist">

                <li class="listitem">

                  <p>the person does not tolerate metformin, or metformin is contraindicated. <strong>[new 2009]</strong></p>

                </li>

              </ul>

            </div>

            <p>1.6.1.3 Consider adding sitagliptin<sup>[<a id="footnote_6" href="#ftn.footnote_6" class="footnote" name="footnote_6">6</a>]</sup> as third-line therapy to first-line metformin and a second-line sulfonylurea when control of blood glucose remains or becomes inadequate (HbA<sub>1c</sub> ≥ 7.5% or other higher level agreed with the individual) and insulin is unacceptable or inappropriate<sup>[<a id="footnote_7" href="#ftn.footnote_7" class="footnote" name="footnote_7">7</a>]</sup>. <strong>[new 2009]</strong></p>

            <p>1.6.1.4 Only continue DPP-4 inhibitor therapy (sitagliptin, vildagliptin) if the person has had a beneficial metabolic response (a reduction of at least 0.5 percentage points in HbA<sub>1c</sub> in 6 months). <strong>[new 2009]</strong></p>

            <p>1.6.1.5 Discuss the potential benefits and risks of treatment with a DPP-4 inhibitor (sitagliptin, vildagliptin) with the person to enable them to make an informed decision.</p>

            <p>A DPP-4 inhibitor (sitagliptin, vildagliptin) may be preferable to a thiazolidinedione (pioglitazone) if:</p>

            <div class="itemizedlist">

              <ul class="itemizedlist">

                <li class="listitem">

                  <p>further weight gain would cause or exacerbate significant problems associated with a high body weight, or</p>

                </li>

                <li class="listitem">

                  <p>a thiazolidinedione (pioglitazone) is contraindicated, or</p>

                </li>

                <li class="listitem">

                  <p>the person has previously had a poor response to, or did not tolerate, a thiazolidinedione (pioglitazone). </p>

                </li>

              </ul>

            </div>

            <p>There may be some people for whom either a DPP-4 inhibitor (sitagliptin, vildagliptin) or a thiazolidinedione (pioglitazone) may be suitable and, in this case, the choice of treatment should be based on patient preference. <strong>[</strong><strong>new</strong><strong> 2009]</strong></p>

          </div>

          <div class="section" title="1.6.2 Thiazolidinediones (pioglitazone)">

            <h4 class="title">

                    <a id="thiazolidinediones-pioglitazone-the-recommendations-in-this-section-replace-guidance-on-the-use"></a>1.6.2 Thiazolidinediones (pioglitazone)<sup>[<a id="footnote_8" href="#ftn.footnote_8" class="footnote" name="footnote_8">8</a>]</sup></h4>

            <p>1.6.2.1 Consider adding a thiazolidinedione (pioglitazone) instead of a sulfonylurea as second-line therapy to first-line metformin when control of blood glucose remains or becomes inadequate (HbA<sub>1c</sub> ≥ 6.5%, or other higher level agreed with the individual) if:</p>

            <div class="itemizedlist">

              <ul class="itemizedlist">

                <li class="listitem">

                  <p>the person is at significant risk of hypoglycaemia or its consequences (for example, older people and people in certain jobs [for example, those working at heights or with heavy machinery] or people in certain social circumstances [for example, those living alone]), or</p>

                </li>

                <li class="listitem">

                  <p>a person does not tolerate a sulfonylurea or a sulfonylurea is contraindicated. <strong>[new 2009]</strong></p>

                </li>

              </ul>

            </div>

            <p>1.6.2.2 Consider adding a thiazolidinedione (pioglitazone) as second-line therapy to first-line sulfonylurea monotherapy when control of blood glucose remains or becomes inadequate (HbA<sub>1c </sub>≥ 6.5%, or other higher level agreed with the individual) if:</p>

            <div class="itemizedlist">

              <ul class="itemizedlist">

                <li class="listitem">

                  <p>the person does not tolerate metformin or metformin is contraindicated. <strong>[new 2009]</strong></p>

                </li>

              </ul>

            </div>

            <p>1.6.2.3 Consider adding a thiazolidinedione (pioglitazone) as third-line therapy to first-line metformin and a second-line sulfonylurea when control of blood glucose remains or becomes inadequate (HbA<sub>1c</sub> ≥ 7.5%, or other higher level agreed with the individual) and insulin is unacceptable or inappropriate<sup>[<a id="footnote_9" href="#ftn.footnote_9" class="footnote" name="footnote_9">9</a>]</sup>. <strong>[new 2009]</strong></p>

            <p>1.6.2.4 Do not commence or continue a thiazolidinedione (pioglitazone) in people who have heart failure, or who are at higher risk of fracture. <strong>[new 2009]</strong></p>

            <p>1.6.2.5 When selecting a thiazolidinedione (pioglitazone), take into account up-to-date advice from the relevant regulatory bodies (the European Medicines Agency and the Medicines and Healthcare products Regulatory Agency), cost, safety and prescribing issues (see 1.6.2.8). <strong>[new 2009]</strong></p>

            <p>1.6.2.6 Only continue thiazolidinedione therapy (pioglitazone) if the person has had a beneficial metabolic response (a reduction of at least 0.5 percentage points in HbA<sub>1c</sub> in 6 months). <strong>[new 2009]</strong></p>

            <p>1.6.2.7 Consider combining pioglitazone with insulin therapy<sup>[<a id="footnote_10" href="#ftn.footnote_10" class="footnote" name="footnote_10">10</a>]</sup> for a person:</p>

            <div class="itemizedlist">

              <ul class="itemizedlist">

                <li class="listitem">

                  <p>who has previously had a marked glucose-lowering response to thiazolidinedione therapy (pioglitazone), or </p>

                </li>

                <li class="listitem">

                  <p>who is on high-dose insulin therapy and whose blood glucose is inadequately controlled. <strong>[new 2009]</strong></p>

                </li>

              </ul>

            </div>

            <p>1.6.2.8 Discuss the potential benefits and risks of treatment with a thiazolidinedione (pioglitazone) with the person to enable them to make an informed decision. </p>

            <p>A thiazolidinedione (pioglitazone) may be preferable to a DPP-4 inhibitor (sitagliptin, vildagliptin) if:</p>

            <div class="itemizedlist">

              <ul class="itemizedlist">

                <li class="listitem">

                  <p>the person has marked insulin insensitivity, or </p>

                </li>

                <li class="listitem">

                  <p>a DPP-4 inhibitor (sitagliptin, vildagliptin) is contraindicated, or</p>

                </li>

                <li class="listitem">

                  <p>the person has previously had a poor response to, or did not tolerate, a DPP-4 inhibitor (sitagliptin, vildagliptin).</p>

                </li>

              </ul>

            </div>

            <p>There may be some people for whom either a thiazolidinedione (pioglitazone) or a DPP-4 inhibitor (sitagliptin, vildagliptin) may be suitable and, in this case, the choice of treatment should be based on patient preference. <strong>[</strong><strong>new</strong><strong> 2009]</strong></p>

          </div>

          <div class="section" title="1.6.3 GLP-1 mimetic (exenatide)">

            <h4 class="title">

                    <a id="glp-1-mimetic-exenatide"></a>1.6.3 GLP-1 mimetic (exenatide)</h4>

            <p>1.6.3.1 Consider adding a GLP-1 mimetic (exenatide) as third-line therapy to first-line metformin and a second-line sulfonylurea when control of blood glucose remains or becomes inadequate (HbA<sub>1c</sub> ≥ 7.5%, or other higher level agreed with the individual), and the person has:</p>

            <div class="itemizedlist">

              <ul class="itemizedlist">

                <li class="listitem">

                  <p>a body mass index (BMI) ≥ 35.0 kg/m<sup>2</sup> in those of European descent (with appropriate adjustment for other ethnic groups) and specific psychological or medical problems associated with high body weight, or</p>

                </li>

                <li class="listitem">

                  <p>a BMI &lt; 35.0 kg/m<sup>2</sup>, and therapy with insulin would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities. <strong>[new 2009]</strong></p>

                </li>

              </ul>

            </div>

            <p>1.6.3.2 Only continue GLP-1 mimetic (exenatide) therapy if the person has had a beneficial metabolic response (a reduction of at least 1.0 percentage point in HbA<sub>1c</sub> and a weight loss of at least 3% of initial body weight at 6 months). <strong>[new 2009]</strong></p>

            <p>1.6.3.3 Discuss the potential benefits and risks of treatment with a GLP-1 mimetic (exenatide) with the person to enable them to make an informed decision. <strong>[new 2009]</strong></p>

          </div>

        </div>

        <div class="section" title="1.7 Glucose control: insulin therapy">

          <h3 class="title">

                  <a id="glucose-control-insulin-therapy"></a>1.7 Glucose control: insulin therapy</h3>

          <div class="section" title="1.7.1 Oral agent combination therapy with insulin">

            <h4 class="title">

                    <a id="oral-agent-combination-therapy-with-insulin"></a>1.7.1 Oral agent combination therapy with insulin</h4>

            <p>1.7.1.1 When starting basal insulin therapy: </p>

            <div class="itemizedlist">

              <ul class="itemizedlist">

                <li class="listitem">

                  <p>continue with metformin and the sulfonylurea (and acarbose, if used)</p>

                </li>

                <li class="listitem">

                  <p>review the use of the sulfonylurea if hypoglycaemia occurs. </p>

                </li>

              </ul>

            </div>

            <p>1.7.1.2 When starting pre-mixed insulin therapy (or mealtime plus basal insulin regimens): </p>

            <div class="itemizedlist">

              <ul class="itemizedlist">

                <li class="listitem">

                  <p>continue with metformin </p>

                </li>

                <li class="listitem">

                  <p>continue the sulfonylurea initially, but review and discontinue if hypoglycaemia occurs.</p>

                </li>

              </ul>

            </div>

          </div>

          <div class="section" title="1.7.2 Insulin therapy">

            <h4 class="title">

                    <a id="insulin-therapy"></a>1.7.2 Insulin therapy</h4>

            <p>The recommendations in this section were updated by the short clinical guideline 'Type 2 diabetes newer agents for blood glucose control in type 2 diabetes' (<a class="link" href="http://www.nice.org.uk/CG87shortguideline" target="_top">www.nice.org.uk/CG87shortguideline</a>). The guideline gives details of the methods and the evidence used to develop the recommendations.</p>

            <p>1.7.2.1 Discuss the benefits and risks of insulin therapy when control of blood glucose remains or becomes inadequate (HbA<sub>1c</sub> ≥ 7.5% or other higher level agreed with the individual) with other measures. Start insulin therapy if the person agrees. <strong>[new 2009]</strong></p>

            <p>1.7.2.2 For a person on dual therapy who is markedly hyperglycaemic, consider starting insulin therapy in preference to adding other drugs to control blood glucose unless there is strong justification<sup>[<a id="footnote_11" href="#ftn.footnote_11" class="footnote" name="footnote_11">11</a>]</sup> not to. <strong>[new 2009]</strong></p>

            <p>1.7.2.3 When starting insulin therapy, use a structured programme employing active insulin dose titration that encompasses: </p>

            <div class="itemizedlist">

              <ul class="itemizedlist">

                <li class="listitem">

                  <p>structured education </p>

                </li>

                <li class="listitem">

                  <p>continuing telephone support </p>

                </li>

                <li class="listitem">

                  <p>frequent self-monitoring </p>

                </li>

                <li class="listitem">

                  <p>dose titration to target </p>

                </li>

                <li class="listitem">

                  <p>dietary understanding</p>

                </li>

                <li class="listitem">

                  <p>management of hypoglycaemia </p>

                </li>

                <li class="listitem">

                  <p>management of acute changes in plasma glucose control</p>

                </li>

                <li class="listitem">

                  <p>support from an appropriately trained and experienced healthcare professional.</p>

                </li>

              </ul>

            </div>

            <p>1.7.2.4 Initiate insulin therapy from a choice of a number of insulin types and regimens.</p>

            <div class="itemizedlist">

              <ul class="itemizedlist">

                <li class="listitem">

                  <p>Begin with human NPH insulin injected at bed-time or twice daily according to need.</p>

                </li>

                <li class="listitem">

                  <p>Consider, as an alternative, using a long-acting insulin analogue (insulin detemir, insulin glargine) if:</p>

                  <p>

                    <div class="itemizedlist">

                      <ul class="itemizedlist">

                        <li class="listitem">

                          <p>the person needs assistance from a carer or healthcare professional to inject insulin, and use of a long-acting insulin analogue (insulin detemir, insulin glargine) would reduce the frequency of injections from twice to once daily, or</p>

                        </li>

                        <li class="listitem">

                          <p>the person's lifestyle is restricted by recurrent symptomatic hypoglycaemic episodes, or</p>

                        </li>

                        <li class="listitem">

                          <p>the person would otherwise need twice-daily NPH insulin injections in combination with oral glucose-lowering drugs, or</p>

                        </li>

                        <li class="listitem">

                          <p>the person cannot use the device to inject NPH insulin.</p>

                        </li>

                      </ul>

                    </div>

                  </p>

                </li>

                <li class="listitem">

                  <p>Consider twice-daily pre-mixed (biphasic) human insulin (particularly if HbA<sub>1c</sub> ≥ 9.0%). A once-daily regimen may be an option.</p>

                </li>

                <li class="listitem">

                  <p>Consider pre-mixed preparations that include short-acting insulin analogues, rather than pre-mixed preparations that include short-acting human insulin preparations, if: </p>

                  <p>

                    <div class="itemizedlist">

                      <ul class="itemizedlist">

                        <li class="listitem">

                          <p>a person prefers injecting insulin immediately before a meal, or </p>

                        </li>

                        <li class="listitem">

                          <p>hypoglycaemia is a problem, or</p>

                        </li>

                        <li class="listitem">

                          <p>blood glucose levels rise markedly after meals. <strong>[new 2009]</strong></p>

                        </li>

                      </ul>

                    </div>

                  </p>

                </li>

              </ul>

            </div>

            <p>1.7.2.5 Consider switching to a long-acting insulin analogue (insulin detemir, insulin glargine) from NPH insulin in people:</p>

            <div class="itemizedlist">

              <ul class="itemizedlist">

                <li class="listitem">

                  <p>who do not reach their target HbA<sub>1c</sub> because of significant hypoglycaemia, or </p>

                </li>

                <li class="listitem">

                  <p>who experience significant hypoglycaemia on NPH insulin irrespective of the level of HbA<sub>1c</sub> reached, or</p>

                </li>

                <li class="listitem">

                  <p>who cannot use the device needed to inject NPH insulin but who could administer their own insulin safely and accurately if a switch to a long-acting insulin analogue were made, or </p>

                </li>

                <li class="listitem">

                  <p>who need help from a carer or healthcare professional to administer insulin injections and for whom switching to a long-acting insulin analogue would reduce the number of daily injections. <strong>[new 2009]</strong></p>

                </li>

              </ul>

            </div>

            <p>1.7.2.6 Monitor a person on a basal insulin regimen (NPH insulin or a long-acting insulin analogue [insulin detemir, insulin glargine]) for the need for short-acting insulin before meals (or a pre-mixed insulin preparation). <strong>[new 2009]</strong></p>

            <p>1.7.2.7 Monitor a person who is using pre-mixed insulin once or twice daily for the need for a further injection of short-acting insulin before meals or for a change to a regimen of mealtime plus basal insulin, based on NPH insulin or long-acting insulin analogues (insulin detemir, insulin glargine), if blood glucose control remains inadequate. <strong>[new 2009]</strong></p>

          </div>

          <div class="section" title="1.7.3 Insulin delivery devices">

            <h4 class="title">

                    <a id="insulin-delivery-devices"></a>1.7.3 Insulin delivery devices</h4>

            <p>1.7.3.1 Offer education to a person who requires insulin about using an injection device (usually a pen injector and cartridge or a disposable pen) that they and/or their carer find easy to use.</p>

            <p>1.7.3.2 Appropriate local arrangements should be in place for the disposal of sharps.</p>

            <p>1.7.3.3 If a person has a manual or visual disability and requires insulin, offer a device or adaptation that: </p>

            <div class="itemizedlist">

              <ul class="itemizedlist">

                <li class="listitem">

                  <p>takes into account his or her individual needs</p>

                </li>

                <li class="listitem">

                  <p>he or she can use successfully.</p>

                </li>

              </ul>

            </div>

          </div>

        </div>

        <div class="section" title="1.8 Blood pressure therapy">

          <h3 class="title">

                  <a id="blood-pressure-therapy"></a>1.8 Blood pressure therapy</h3>

          <p>1.8.1 Measure blood pressure at least annually in a person without previously diagnosed hypertension or renal disease. Offer and reinforce preventive lifestyle advice.</p>

          <p>1.8.2 For a person on antihypertensive therapy at diagnosis of diabetes, review control of blood pressure and medications used, and make changes only where there is poor control or where current medications are not appropriate because of microvascular complications or metabolic problems.</p>

          <p>1.8.3 Repeat blood pressure (BP) measurements within:</p>

          <div class="itemizedlist">

            <ul class="itemizedlist">

              <li class="listitem">

                <p>1 month if BP is higher than 150/90 mmHg</p>

              </li>

              <li class="listitem">

                <p>2 months if BP is higher than 140/80 mmHg</p>

              </li>

              <li class="listitem">

                <p>2 months if BP is higher than 130/80 mmHg and there is kidney, eye or cerebrovascular damage.</p>

              </li>

            </ul>

          </div>

          <p>Offer lifestyle advice (diet and exercise) at the same time.</p>

          <p>1.8.4 Offer lifestyle advice (see dietary recommendations in section 1.2.1 of this guideline and the lifestyle recommendations in section 1.2 of 'Hypertension: management of hypertension in adults in primary care' [NICE clinical guideline 34]) if blood pressure is confirmed as being consistently above 140/80 mmHg (or above 130/80 mmHg if there is kidney, eye or cerebrovascular damage).</p>

          <p>1.8.5 Add medications if lifestyle advice does not reduce blood pressure to below 140/80 mmHg (below 130/80 mmHg if there is kidney, eye or cerebrovascular damage).</p>

          <p>1.8.6 Monitor blood pressure 1–2-monthly, and intensify therapy if on medications until blood pressure is consistently below 140/80 mmHg (below 130/80 mmHg if there is kidney, eye or cerebrovascular disease).</p>

          <p>1.8.7 First-line blood-pressure-lowering therapy should be a once-daily, generic angiotensin-converting enzyme (ACE) inhibitor. Exceptions to this are people of African-Caribbean descent or women for whom there is a possibility of becoming pregnant (see 1.8.8 and 1.8.9).</p>

          <p>1.8.8 First-line blood-pressure-lowering therapy for a person of AfricanCaribbean descent should be an ACE inhibitor plus either a diuretic or a generic calcium-channel antagonist (calcium-channel blocker).</p>

          <p>1.8.9 A calcium-channel blocker should be the first-line blood-pressure-lowering therapy for a woman for whom, after an informed discussion, it is agreed there is a possibility of her becoming pregnant.</p>

          <p>1.8.10 For a person with continuing intolerance to an ACE inhibitor (other than renal deterioration or hyperkalaemia), substitute an angiotensin II-receptor antagonist for the ACE inhibitor.</p>

          <p>1.8.11 If the person's blood pressure is not reduced to the individually agreed target with first-line therapy, add a calcium-channel blocker or a diuretic (usually bendroflumethiazide, 2.5 mg daily). Add the other drug (that is, the calcium-channel blocker or diuretic) if the target is not reached with dual therapy.</p>

          <p>1.8.12 If the person's blood pressure is not reduced to the individually agreed target with triple therapy (see 1.8.11), add an alpha-blocker, a beta-blocker or a potassium-sparing diuretic (the last with caution if the individual is already taking an ACE inhibitor or an angiotensin II-receptor antagonist).</p>

          <p>1.8.13 Monitor the blood pressure of a person who has attained and consistently remained at his or her blood pressure target every 4–6 months, and check for possible adverse effects of antihypertensive therapy – including the risks from unnecessarily low blood pressure. </p>

        </div>

        <div class="section" title="1.9 Cardiovascular risk estimation">

          <h3 class="title">

                  <a id="cardiovascular-risk-estimation"></a>1.9 Cardiovascular risk estimation</h3>

          <p>1.9.1 Consider a person to be at high premature cardiovascular risk for his or her age unless he or she: </p>

          <div class="itemizedlist">

            <ul class="itemizedlist">

              <li class="listitem">

                <p>is not overweight, tailoring this with an assessment of body-weight-associated risk according to ethnic group<sup>[<a id="footnote_12" href="#ftn.footnote_12" class="footnote" name="footnote_12">12</a>]</sup></p>

              </li>

              <li class="listitem">

                <p>is normotensive (&lt; 140/80 mmHg in the absence of antihypertensive therapy) </p>

              </li>

              <li class="listitem">

                <p>does not have microalbuminuria</p>

              </li>

              <li class="listitem">

                <p>does not smoke</p>

              </li>

              <li class="listitem">

                <p>does not have a high-risk lipid profile </p>

              </li>

              <li class="listitem">

                <p>has no history of cardiovascular disease <strong>and</strong></p>

              </li>

              <li class="listitem">

                <p>has no family history of cardiovascular disease.</p>

              </li>

            </ul>

          </div>

          <p>1.9.2 If the person is considered not to be at high cardiovascular risk, estimate cardiovascular risk annually using the UK Prospective Diabetes Study (UKPDS) risk engine (see <a class="link" href="http://www.dtu.ox.ac.uk/index.php?maindoc=/riskengine/" target="_top">www.dtu.ox.ac.uk/index.php?maindoc=/riskengine/</a>). </p>

          <p>1.9.3 Consider using cardiovascular risk estimates from the UKPDS risk engine (see 1.9.2) for educational purposes when discussing cardiovascular complications with the individual. </p>

          <p>1.9.4 Perform a full lipid profile (including high-density lipoprotein [HDL] cholesterol and triglyceride estimations) when assessing cardiovascular risk after diagnosis and annually, and before starting lipid-modifying therapy. </p>

        </div>

        <div class="section" title="1.10 Management of blood lipid levels">

          <h3 class="title">

                  <a id="management-of-blood-lipid-levels"></a>1.10 Management of blood lipid levels</h3>

          <div class="section" title="1.10.1 Statins and ezetimibe">

            <h4 class="title">

                    <a id="statins-and-ezetimibe"></a>1.10.1 Statins and ezetimibe</h4>

            <p>1.10.1.1 Review cardiovascular risk status annually by assessment of cardiovascular risk factors, including features of the metabolic syndrome and waist circumference, and change in personal or family cardiovascular history.</p>

            <p>1.10.1.2 For a person who is 40 years old or over:</p>

            <div class="itemizedlist">

              <ul class="itemizedlist">

                <li class="listitem">

                  <p>initiate therapy with generic simvastatin (to 40 mg) or a statin of similar efficacy and cost unless the cardiovascular risk from non-hyperglycaemia-related factors is low (see 1.9.1 )</p>

                </li>

                <li class="listitem">

                  <p>if the cardiovascular risk from non-hyperglycaemia-related factors is low, assess cardiovascular risk using the UKPDS risk engine (see 1.9.2) and initiate simvastatin therapy (to 40 mg), or a statin of similar efficacy and cost, if the cardiovascular risk exceeds 20% over 10 years.</p>

                </li>

              </ul>

            </div>

            <p>1.10.1.3 For a person who is under 40 years old, consider initiating generic simvastatin therapy (to 40 mg), or a statin of similar efficacy and cost, where the cardiovascular risk factor profile appears particularly poor (multiple features of the metabolic syndrome, presence of conventional risk factors, microalbuminuria, at-risk ethnic group, or strong family history of premature cardiovascular disease). </p>

            <p>1.10.1.4 Once a person has been started on cholesterol-lowering therapy, assess his or her lipid profile (together with other modifiable risk factors and any new diagnosis of cardiovascular disease) 1–3 months after starting treatment, and annually thereafter. In those not on cholesterol-lowering therapy, reassess cardiovascular risk annually and consider initiating a statin (see 1.10.1.2 and 1.10.1.3).</p>

            <p>1.10.1.5 Increase the dose of simvastatin, in anyone initiated on simvastatin in line with the above recommendations, to 80 mg daily unless total cholesterol level is below 4.0 mmol/litre or low-density lipoprotein [LDL] cholesterol level is below 2.0 mmol/litre.</p>

            <p>1.10.1.6 Consider intensifying cholesterol-lowering therapy (with a more effective statin or ezetimibe in line with NICE guidance)<sup>[<a id="footnote_13" href="#ftn.footnote_13" class="footnote" name="footnote_13">13</a>]</sup> if there is existing or newly diagnosed cardiovascular disease, or if there is an increased albumin excretion rate, to achieve a total cholesterol level below 4.0 mmol/litre (and HDL cholesterol not exceeding 1.4 mmol/litre) or an LDL cholesterol level below 2.0 mmol/litre.</p>

            <p>1.10.1.7 If there is a possibility of a woman becoming pregnant, do not use statins unless the issues have been discussed with the woman and agreement has been reached. </p>

          </div>

          <div class="section" title="1.10.2 Fibrates">

            <h4 class="title">

                    <a id="fibrates"></a>1.10.2 Fibrates</h4>

            <p>1.10.2.1 If there is a history of elevated serum triglycerides, perform a full fasting lipid profile (including HDL cholesterol and triglyceride estimations) when assessing cardiovascular risk annually.</p>

            <p>1.10.2.2 Assess possible secondary causes of high serum triglyceride levels, including poor blood glucose control (others include hypothyroidism, renal impairment and liver inflammation, particularly from alcohol). If a secondary cause is identified, manage according to need.</p>

            <p>1.10.2.3 Prescribe a fibrate (fenofibrate as first-line) if triglyceride levels remain above 4.5 mmol/litre despite attention to other causes. In some circumstances, this will be before a statin has been started because of acute need (that is, risk of pancreatitis) and because of the undesirability of initiating two drugs at the same time.</p>

            <p>1.10.2.4 If cardiovascular risk is high (as is usual in people with type 2 diabetes), consider adding a fibrate to statin therapy if triglyceride levels remain in the range 2.3–4.5 mmol/litre despite statin therapy. </p>

          </div>

          <div class="section" title="1.10.3 Nicotinic acid">

            <h4 class="title">

                    <a id="nicotinic-acid"></a>1.10.3 Nicotinic acid</h4>

            <p>1.10.3.1 Do not use nicotinic acid preparations and derivatives routinely for people with type 2 diabetes. They may have a role in a few people who are intolerant of other therapies and have more extreme disorders of blood lipid metabolism, when managed by those with specialist expertise in this area. </p>

          </div>

          <div class="section" title="1.10.4 Omega-3 fish oils">

            <h4 class="title">

                    <a id="omega-3-fish-oils"></a>1.10.4 Omega-3 fish oils</h4>

            <p>1.10.4.1 Do not prescribe fish oil preparations for the primary prevention of cardiovascular disease in people with type 2 diabetes. This recommendation does not apply to people with hypertriglyceridaemia receiving advice from a healthcare professional with special expertise in blood lipid management.</p>

            <p>1.10.4.2 Consider a trial of highly concentrated, licensed omega-3 fish oils for refractory hypertriglyceridaemia if lifestyle measures and fibrate therapy have failed.</p>

          </div>

        </div>

        <div class="section" title="1.11 Anti-thrombotic therapy">

          <h3 class="title">

                  <a id="anti-thrombotic-therapy"></a>1.11 Anti-thrombotic therapy</h3>

          <p>1.11.1 Offer low-dose aspirin, 75 mg daily, to a person who is 50 years old or over, if blood pressure is below 145/90 mmHg.</p>

          <p>1.11.2 Offer low-dose aspirin, 75 mg daily, to a person who is under 50 years old and has significant other cardiovascular risk factors (features of the metabolic syndrome, strong early family history of cardiovascular disease, smoking, hypertension, extant cardiovascular disease, microalbuminuria).</p>

          <p>1.11.3 Clopidogrel should be used instead of aspirin only in those with clear aspirin intolerance (except in the context of acute cardiovascular events and procedures). Follow the recommendations in 'Clopidogrel and modified-release dipyridamole in the prevention of occlusive vascular events' (NICE technology appraisal guidance 90).</p>

          <div class="section" title="1.12 Kidney damage">

            <h4 class="title">

                    <a id="kidney-damage"></a>1.12 Kidney damage</h4>

            <p>1.12.1 Ask all people with or without detected nephropathy to bring in a first-pass morning urine specimen once a year. In the absence of proteinuria/urinary tract infection (UTI), send this for laboratory estimation of albumin:creatinine ratio. Request a specimen on a subsequent visit if UTI prevents analysis.</p>

            <p>1.12.2 Make the measurement on a spot sample if a first-pass sample is not provided (and repeat on a first-pass specimen if abnormal) or make a formal arrangement for a first-pass specimen to be provided.</p>

            <p>1.12.3 Measure serum creatinine and estimate the glomerular filtration rate (using the method-abbreviated modification of diet in renal disease [MDRD] four-variable equation) annually at the time of albumin:creatinine ratio estimation.</p>

            <p>1.12.4 Repeat the test if an abnormal albumin:creatinine ratio is obtained (in the absence of proteinuria/UTI) at each of the next two clinic visits but within a maximum of 3–4 months. Take the result to be confirming microalbuminuria if a further specimen (out of two more) is also abnormal (&gt; 2.5 mg/mmol for men, &gt; 3.5 mg/mmol for women).</p>

            <p>1.12.5 Suspect renal disease other than diabetic nephropathy and consider further investigation or referral when the albumin:creatinine ratio (ACR) is raised and <strong>any</strong> of the following apply: </p>

            <div class="itemizedlist">

              <ul class="itemizedlist">

                <li class="listitem">

                  <p>there is no significant or progressive retinopathy </p>

                </li>

                <li class="listitem">

                  <p>blood pressure is particularly high or resistant to treatment </p>

                </li>

                <li class="listitem">

                  <p>the person previously had a documented normal ACR and develops heavy proteinuria (ACR &gt; 100 mg/mmol)</p>

                </li>

                <li class="listitem">

                  <p>significant haematuria is present </p>

                </li>

                <li class="listitem">

                  <p>the glomerular filtration rate has worsened rapidly</p>

                </li>

                <li class="listitem">

                  <p>the person is systemically ill. </p>

                </li>

              </ul>

            </div>

            <p>1.12.6 Discuss the significance of a finding of abnormal albumin excretion rate, and its trend over time, with the individual concerned.</p>

            <p>1.12.7 Start ACE inhibitors with the usual precautions and titrate to full dose in all individuals with confirmed raised albumin excretion rate (&gt; 2.5 mg/mmol for men, &gt; 3.5 mg/mmol for women).</p>

            <p>1.12.8 Have an informed discussion before starting an ACE inhibitor in a woman for whom there is a possibility of pregnancy, assessing the relative risks and benefits of the use of the ACE inhibitor.</p>

            <p>1.12.9 Substitute an angiotensin II-receptor antagonist for an ACE inhibitor for a person with an abnormal albumin:creatinine ratio if an ACE inhibitor is poorly tolerated.</p>

            <p>1.12.10 For a person with an abnormal albumin:creatinine ratio, maintain blood pressure below 130/80 mmHg.</p>

            <p>1.12.11 Agree referral criteria for specialist renal care between local diabetes specialists and nephrologists.</p>

          </div>

        </div>

        <div class="section" title="1.13 Eye damage">

          <h3 class="title">

                  <a id="eye-damage"></a>1.13 Eye damage</h3>

          <p>1.13.1 Arrange or perform eye screening at or around the time of diagnosis. Arrange repeat of structured eye surveillance annually.</p>

          <p>1.13.2 Explain the reasons for, and success of, eye surveillance systems to the individual and ensure attendance is not reduced by ignorance of need or fear of outcome.</p>

          <p>1.13.3 Use mydriasis with tropicamide when photographing the retina, after prior informed agreement following discussion of the advantages and disadvantages. Discussions should include precautions for driving.</p>

          <p>1.13.4 Use a quality-assured digital retinal photography programme using appropriately trained staff.</p>

          <p>1.13.5 Perform visual acuity testing as a routine part of eye surveillance programmes.</p>

          <p>1.13.6 Repeat structured eye surveillance according to the findings by:</p>

          <div class="itemizedlist">

            <ul class="itemizedlist">

              <li class="listitem">

                <p>routine review in 1 year, or</p>

              </li>

              <li class="listitem">

                <p>earlier review, or</p>

              </li>

              <li class="listitem">

                <p>referral to an ophthalmologist.</p>

              </li>

            </ul>

          </div>

          <p>1.13.7 Arrange emergency review by an ophthalmologist for: </p>

          <div class="itemizedlist">

            <ul class="itemizedlist">

              <li class="listitem">

                <p>sudden loss of vision</p>

              </li>

              <li class="listitem">

                <p>rubeosis iridis</p>

              </li>

              <li class="listitem">

                <p>pre-retinal or vitreous haemorrhage</p>

              </li>

              <li class="listitem">

                <p>retinal detachment.</p>

              </li>

            </ul>

          </div>

          <p>1.13.8 Arrange rapid review by an ophthalmologist for new vessel formation. </p>

          <p>1.13.9 Refer to an ophthalmologist in accordance with the National Screening Committee criteria and timelines if any of these features is present: </p>

          <div class="itemizedlist">

            <ul class="itemizedlist">

              <li class="listitem">

                <p>referable maculopathy:</p>

                <p>

                  <div class="itemizedlist">

                    <ul class="itemizedlist">

                      <li class="listitem">

                        <p>exudate or retinal thickening within one disc diameter of the centre of the fovea</p>

                      </li>

                      <li class="listitem">

                        <p>circinate or group of exudates within the macula (the macula is defined here as a circle centred on the fovea, with a diameter the distance between the temporal border of the optic disc and the fovea)</p>

                      </li>

                      <li class="listitem">

                        <p>any microaneurysm or haemorrhage within one disc diameter of the centre of the fovea, only if associated with deterioration of best visual acuity to 6/12 or worse</p>

                      </li>

                    </ul>

                  </div>

                </p>

              </li>

              <li class="listitem">

                <p>referable pre-proliferative retinopathy (if cotton wool spots are present, look carefully for the following features, but cotton wool spots themselves do not define pre-proliferative retinopathy):</p>

                <p>

                  <div class="itemizedlist">

                    <ul class="itemizedlist">

                      <li class="listitem">

                        <p>any venous beading</p>

                      </li>

                      <li class="listitem">

                        <p>any venous loop or reduplication</p>

                      </li>

                      <li class="listitem">

                        <p>any intraretinal microvascular abnormalities</p>

                      </li>

                      <li class="listitem">

                        <p>multiple deep, round or blot haemorrhages</p>

                      </li>

                    </ul>

                  </div>

                </p>

              </li>

              <li class="listitem">

                <p>any unexplained drop in visual acuity.</p>

              </li>

            </ul>

          </div>

        </div>

        <div class="section" title="1.14 Nerve damage">

          <h3 class="title">

                  <a id="nerve-damage"></a>1.14 Nerve damage</h3>

          <p>1.14.1 For the management of foot problems relating to type 2 diabetes, follow recommendations in 'Type 2 diabetes: prevention and management of foot problems' (NICE clinical guideline 10).</p>

          <div class="section" title="1.14.2 Diabetic neuropathic pain management">

            <h4 class="title">

                    <a id="diabetic-neuropathic-pain-management"></a>1.14.2 Diabetic neuropathic pain management</h4>

            <p>1.14.2.1 Make a formal enquiry annually about the development of neuropathic symptoms causing distress.</p>

            <div class="itemizedlist">

              <ul class="itemizedlist">

                <li class="listitem">

                  <p>Discuss the cause and prognosis (including possible medium-term remission) of troublesome neuropathic symptoms, if present (bearing in mind alternative diagnoses).</p>

                </li>

                <li class="listitem">

                  <p>Agree appropriate therapeutic options and review understanding at each clinical contact.</p>

                </li>

              </ul>

            </div>

            <p>1.14.2.2 Be alert to the psychological consequences of chronic, painful diabetic neuropathy and offer psychological support according to the needs of the individual.</p>

            <p>1.14.2.3 <strong>This recommendation has been replaced by 'neuropathic pain' (NICE clinical guideline 96).</strong></p>

            <p>1.14.2.4 <strong>This recommendation has been replaced by 'neuropathic pain' (NICE clinical guideline 96).</strong></p>

            <p>1.14.2.5 <strong>This recommendation has been replaced by 'neuropathic pain' (NICE clinical guideline 96).</strong></p>

            <p>1.14.2.6 <strong>This recommendation has been replaced by 'neuropathic pain' (NICE clinical guideline 96).</strong></p>

            <p>1.14.2.7 If neuropathic symptoms cannot be controlled adequately, it may be helpful to further discuss:</p>

            <div class="itemizedlist">

              <ul class="itemizedlist">

                <li class="listitem">

                  <p>the reasons for the problem</p>

                </li>

                <li class="listitem">

                  <p>the likelihood of remission in the medium term</p>

                </li>

                <li class="listitem">

                  <p>the role of improved blood glucose control.</p>

                </li>

              </ul>

            </div>

          </div>

          <div class="section" title="1.14.3 Gastroparesis">

            <h4 class="title">

                    <a id="gastroparesis"></a>1.14.3 Gastroparesis</h4>

            <p>1.14.3.1 Consider the diagnosis of gastroparesis in an adult with erratic blood glucose control or unexplained gastric bloating or vomiting, taking into consideration possible alternative diagnoses.</p>

            <p>1.14.3.2 Consider a trial of metoclopramide, domperidone or erythromycin for an adult with gastroparesis.</p>

            <p>1.14.3.3 If gastroparesis is suspected, consider referral to specialist services if: </p>

            <div class="itemizedlist">

              <ul class="itemizedlist">

                <li class="listitem">

                  <p>the differential diagnosis is in doubt, or </p>

                </li>

                <li class="listitem">

                  <p>persistent or severe vomiting occurs.</p>

                </li>

              </ul>

            </div>

          </div>

          <div class="section" title="1.14.4 Erectile dysfunction">

            <h4 class="title">

                    <a id="erectile-dysfunction"></a>1.14.4 Erectile dysfunction</h4>

            <p>1.14.4.1 Review the issue of erectile dysfunction with men annually.</p>

            <p>1.14.4.2 Provide assessment and education for men with erectile dysfunction to address contributory factors and treatment options. </p>

            <p>1.14.4.3 Offer a phosphodiesterase-5 inhibitor (choosing the drug with the lowest acquisition cost), in the absence of contraindications, if erectile dysfunction is a problem.</p>

            <p>1.14.4.4 Following discussion, refer to a service offering other medical, surgical, or psychological management of erectile dysfunction if phosphodiesterase-5 inhibitors have been unsuccessful.</p>

          </div>

          <div class="section" title="1.14.5 Other aspects of autonomic neuropathy">

            <h4 class="title">

                    <a id="other-aspects-of-autonomic-neuropathy"></a>1.14.5 Other aspects of autonomic neuropathy</h4>

            <p>1.14.5.1 Consider the possibility of contributory sympathetic nervous system damage for a person who loses the warning signs of hypoglycaemia.</p>

            <p>1.14.5.2 Consider the possibility of autonomic neuropathy affecting the gut in an adult with unexplained diarrhoea, particularly at night.</p>

            <p>1.14.5.3 When using tricyclic drugs and antihypertensive medications in people with autonomic neuropathy, be aware of the increased likelihood of side effects such as orthostatic hypotension.</p>

            <p>1.14.5.4 Investigate a person with unexplained bladder-emptying problems for the possibility of autonomic neuropathy affecting the bladder.</p>

            <p>1.14.5.5 Include in the management of autonomic neuropathy symptoms the specific interventions indicated by the manifestations (for example, for abnormal sweating or nocturnal diarrhoea).</p>

          </div>

        </div>

        <div class="footnotes">

          <br />

          <hr width="100" align="left" />

          <div class="footnote">

            <p>

              <sup>[<a id="ftn.footnote_2" href="#footnote_2" class="para">2</a>] </sup> The recommendations in this section replace 'Guidance on the use of patient-education models for diabetes' (NICE technology appraisal guidance 60).</p>

          </div>

          <div class="footnote">

            <p>

              <sup>[<a id="ftn.footnote_3" href="#footnote_3" class="para">3</a>] </sup> Structured patient education in diabetes: report from the patient education working group. Available from: <a class="link" href="http://www.dh.gov.uk/" target="_top">www.dh.gov.uk</a></p>

          </div>

          <div class="footnote">

            <p>

              <sup>[<a id="ftn.footnote_4" href="#footnote_4" class="para">4</a>] </sup> Little RR, Rohlfing CL, Wiedmeyer HM, et al (2001) The National Glycohemoglobin Standardization Program (NGSP): a five-year progress report. Clinical Chemistry 47: 1985–1992</p>

          </div>

          <div class="footnote">

            <p>

              <sup>[<a id="ftn.footnote_5" href="#footnote_5" class="para">5</a>] </sup> See 'Obesity: the prevention, identification, assessment and management of overweight and obesity in adults and children' (NICE clinical guideline 43) (<a class="link" href="http://www.nice.org.uk/CG43" target="_top">www.nice.org.uk/CG43</a>).  </p>

          </div>

          <div class="footnote">

            <p>

              <sup>[<a id="ftn.footnote_6" href="#footnote_6" class="para">6</a>] </sup> At the time of publication, sitagliptin was the only DPP-4 inhibitor with UK marketing authorisation for use in this combination.</p>

          </div>

          <div class="footnote">

            <p>

              <sup>[<a id="ftn.footnote_7" href="#footnote_7" class="para">7</a>] </sup> Because of employment, social or recreational issues related to putative hypoglycaemia, injection anxieties, other personal issues or obesity.</p>

          </div>

          <div class="footnote">

            <p>

              <sup>[<a id="ftn.footnote_8" href="#footnote_8" class="para">8</a>] </sup> The recommendations in this section replace 'Guidance on the use of glitazones for the treatment of type 2 diabetes' (NICE technology appraisal guidance 63).</p>

          </div>

          <div class="footnote">

            <p>

              <sup>[<a id="ftn.footnote_9" href="#footnote_9" class="para">9</a>] </sup> Because of employment, social or recreational issues related to putative hypoglycaemia, injection anxieties, other personal issues or obesity.</p>

          </div>

          <div class="footnote">

            <p>

              <sup>[<a id="ftn.footnote_10" href="#footnote_10" class="para">10</a>] </sup> At the time of publication pioglitazone was the only thiazolidinedione with UK marketing authorisation for use with insulin.</p>

          </div>

          <div class="footnote">

            <p>

              <sup>[<a id="ftn.footnote_11" href="#footnote_11" class="para">11</a>] </sup> Because of employment, social or recreational issues related to putative hypoglycaemia, injection anxieties, other personal issues or obesity.</p>

          </div>

          <div class="footnote">

            <p>

              <sup>[<a id="ftn.footnote_12" href="#footnote_12" class="para">12</a>] </sup> See 'Obesity: the prevention, identification, assessment and management of overweight and obesity in adults and children (NICE clinical guideline 43). (<a class="link" href="http://www.nice.org.uk/CG043" target="_top">www.nice.org.uk/CG043</a>)</p>

          </div>

          <div class="footnote">

            <p>

              <sup>[<a id="ftn.footnote_13" href="#footnote_13" class="para">13</a>] </sup> 'Statins for the prevention of cardiovascular events' (NICE technology appraisal guidance 94); 'Ezetimibe for the treatment of primary (heterozygous-familial and non-familial) hypercholesterolaemia' (NICE technology appraisal guidance 132).</p>

          </div>

        </div>

      </div>



	

	<div class="chapter-controls">

		

            <div>

				<a href="/type-2-diabetes-cg87/key-priorities-for-implementation" title="Go to previous chapter" class="previous-img">

					<img src='/media/2/Viewer-2.6/images/previous-chapter-button.png' alt="Navigate to Previous chapter icon"/>

                </a>

                <a href="/type-2-diabetes-cg87/key-priorities-for-implementation" title="Go to previous chapter" class="previous">   

                    Previous

			    </a>

            </div>

            <div>

			    <a href="/type-2-diabetes-cg87/notes-on-the-scope-of-the-guidance" title="Go to next chapter" class="next">

				    Next

			    </a>

                <a href="/type-2-diabetes-cg87/notes-on-the-scope-of-the-guidance" title="Go to next chapter" class="next-img">

                    <img src='/media/2/Viewer-2.6/images/next-chapter-button.png' alt="Navigate to Next chapter icon"/>

                </a>

            </div>

        

	</div>





	</div>











		</div>





		<div style="clear:both"/>

		

  </div>





                </div>

            </div>

            <div id="footerWrap" class="clearfix"><div id="footer" class="grid_16 clearfix">

  <p id="siteCopyright" class="prefix_2">

    Copyright © NICE 2011. All rights reserved.

  </p>

</div>



            </div>

        </div></body><style type="text/css" style="display: none !important; ">/*This block of style rules is inserted by AdBlock*/#FFN_Banner_Holder,#FFN_imBox_Container,#RadAd_Skyscraper,#ab_pointer,#adxLeaderboard,#bbccom_leaderboard,#center_banner,#dir_ads_site,#flashad,#footer_adcode,#hbBHeaderSpon,#hiddenHeaderSpon,#navbar_adcode,#p360-format-box,#rightAds,#rightcolumn_adcode,#rm_container,#tads table[align="center"][width="100%"],#tooltipbox[class^="itxt"],#top-advertising,#topMPU,#tracker_advertorial,#ve_threesixty_swf[name="ve_threesixty_swf"],.ad-now,.ad_marquee,.dfpad,.kLink span[id^="preLoadWrap"].preLoadWrap,.prWrap,[id^="ad_block"],[id^="adbrite"],[id^="dclkAds"],[id^="ew"][id$="_bannerDiv"],[id^="konaLayer"],[src*="sixsigmatraffic.com"],a[href^="http://ad."][href*=".doubleclick.net/"],a[href^="http://adserver.adpredictive.com"],div[class^="dms_ad_IDS"],div[id^="adKontekst_"],div[id^="google_ads_div"],div[id^="kona_"][id$="_wrapper"],div[id^="sponsorads"],div[id^="y5_direct"],embed[flashvars*="AdID"],iframe[id^="dapIfM"],iframe[id^="etarget"][id$="banner"],iframe[name^="AdBrite"],iframe[name^="google_ads_"],img[src^="http://cdn.adnxs.com"],script[src="//pagead2.googleadservices.com/pagead/show_ads.js"] + ins > ins > iframe,script[src="http://pagead2.googlesyndication.com/pagead/show_ads.js"] + ins > ins > iframe,table[cellpadding="0"][width="100%"] > * > * > * > div[id^="tpa"],#A9AdsMiddleBoxTop,#A9AdsOutOfStockWidgetTop,#A9AdsServicesWidgetTop,#ADNETwallBanner1,#ADNETwallBanner2,#ADSLOT_1,#ADSLOT_2,#ADSLOT_3,#ADSLOT_4,#ADSLOT_SKYSCRAPER,#ADVERTISE_HERE_ROW,#AD_CONTROL_22,#AD_CONTROL_28,#AD_CONTROL_29,#AD_CONTROL_8,#AD_ROW,#AD_Top,#AD_newsblock,#ADgoogle_newsblock,#ADsmallWrapper,#Ad160x600,#Ad300x250,#Ad3Left,#Ad3Right,#Ad3TextAd,#AdArea,#AdBanner_F1,#AdBar,#AdBar1,#AdBox2,#AdContainer,#AdContainerTop,#AdContentModule_F,#AdDetails_GoogleLinksBottom,#AdDetails_InsureWith,#AdFrame4,#AdHeader,#AdLeaderboardBottom,#AdLeaderboardTop,#AdMiddle,#AdMobileLink,#AdPopUp,#AdRectangle,#AdSenseDiv,#AdSenseResults1_adSenseSponsorDiv,#AdServer,#AdShowcase_F1,#AdSky23,#AdSkyscraper,#AdSpacing,#AdSponsor_SF,#AdSubsectionShowcase_F1,#AdTargetControl1_iframe,#AdTop,#AdTopLeader,#Ad_BelowContent,#Ad_Block,#Ad_Center1,#Ad_Right1,#Ad_RightBottom,#Ad_RightTop,#Ad_Top,#Adbanner,#Adrectangle,#AdsContent,#AdsRight,#AdsWrap,#Ads_BA_CAD,#Ads_BA_CAD2,#Ads_BA_CAD_box,#Ads_BA_SKY,#Ads_CAD,#Ads_OV_BS,#Ads_Special,#AdvertMPU23b,#AdvertPanel,#AdvertiseFrame,#Advertisement,#Advertisements,#Advertorial,#Advertorials,#AdvertsBottom,#AdvertsBottomR,#BANNER_160x600,#BANNER_300x250,#BANNER_728x90,#BannerAd,#BannerAdvert,#BigBoxAd,#BodyAd,#BotAd,#Bottom468x60AD,#ButtonAd,#ClickPop_LayerPop_Container,#CompanyDetailsNarrowGoogleAdsPresentationControl,#CompanyDetailsWideGoogleAdsPresentationControl,#ContentAd,#ContentAd1,#ContentAd2,#ContentAdPlaceHolder1,#ContentAdPlaceHolder2,#ContentAdXXL,#ContentPolepositionAds_Result,#CornerAd,#DartAd300x250,#DivAdEggHeadCafeTopBanner,#FIN_videoplayer_300x250ad,#FooterAd,#FooterAdContainer,#GOOGLE_ADS_47,#GoogleAd1,#GoogleAd2,#GoogleAd3,#GoogleAdsPlaceHolder,#GoogleAdsPresentationControl,#GoogleAdsense,#Google_Adsense_Main,#HEADERAD,#HOME_TOP_RIGHT_BOXAD,#HeaderAD,#HeaderAdsBlock,#HeaderAdsBlockFront,#HeaderBannerAdSpacer,#HeaderTextAd,#HeroAd,#HomeAd1,#HouseAd,#ID_Ad_Sky,#JobsearchResultsAds,#Journal_Ad_125,#Journal_Ad_300,#JuxtapozAds,#KH-contentAd,#LargeRectangleAd,#LeftAd,#LeftAd1,#LeftAdF1,#LeftAdF2,#LftAd,#LoungeAdsDiv,#LowerContentAd,#MPUAdSpace,#MainSponsoredLinks,#Meebo\:AdElement\.Root,#Nightly_adContainer,#NormalAdModule,#OpenXAds,#OverrideAdArea,#PREFOOTER_LEFT_BOXAD,#PREFOOTER_RIGHT_BOXAD,#PageLeaderAd,#PreRollAd,#RelevantAds,#RgtAd1,#RightAd,#RightBottom300x250AD,#RightNavTopAdSpot,#RightSponsoredAd,#SectionAd300-250,#SectionSponsorAd,#SideAdMpu,#SidebarAdContainer,#SkyAd,#SpecialAds,#SponsoredAd,#SponsoredLinks,#TL_footer_advertisement,#TOP_ADROW,#TOP_RIGHT_BOXAD,#Tadspacefoot,#Tadspacehead,#Tadspacemrec,#TextLinkAds,#ThreadAd,#Top468x60AD,#TopAd,#TopAdBox,#TopAdContainer,#TopAdDiv,#TopAdPos,#TopBannerAd,#VM-MPU-adspace,#VM-footer-adspace,#VM-header-adspace,#VM-header-adwrap,#XEadLeaderboard,#XEadSkyscraper,#YahooAdParentContainer,#_ads,#abHeaderAdStreamer,#about_adsbottom,#abovepostads,#ad-1000x90-1,#ad-120x600-sidebar,#ad-120x60Div,#ad-160x600,#ad-160x600-sidebar,#ad-250,#ad-250x300,#ad-300,#ad-300x250,#ad-300x250-1,#ad-300x250-sidebar,#ad-300x250Div,#ad-300x60-1,#ad-376x280,#ad-728,#ad-728x90,#ad-728x90-1,#ad-728x90-leaderboard-top,#ad-728x90-top0,#ad-ads,#ad-article,#ad-banner,#ad-banner-1,#ad-bigbox,#ad-billboard-bottom,#ad-block-125,#ad-bottom,#ad-bottom-wrapper,#ad-box,#ad-box-first,#ad-box-second,#ad-boxes,#ad-bs,#ad-buttons,#ad-colB-1,#ad-column,#ad-container,#ad-content,#ad-contentad,#ad-first-post,#ad-flex-first,#ad-footer,#ad-footprint-160x600,#ad-frame,#ad-front-footer,#ad-front-sponsoredlinks,#ad-fullbanner2,#ad-globalleaderboard,#ad-halfpage,#ad-header,#ad-header-728x90,#ad-horizontal-header,#ad-img,#ad-inner,#ad-label,#ad-leaderboard,#ad-leaderboard-1-container,#ad-leaderboard-bottom,#ad-leaderboard-container,#ad-leaderboard-spot,#ad-leaderboard-top,#ad-left,#ad-left-sidebar-ad-1,#ad-left-sidebar-ad-2,#ad-left-sidebar-ad-3,#ad-links-content,#ad-list-row,#ad-lrec,#ad-medium,#ad-medium-rectangle,#ad-medrec,#ad-middlethree,#ad-middletwo,#ad-module,#ad-mpu,#ad-mpu1-spot,#ad-mpu2,#ad-mpu2-spot,#ad-north,#ad-one,#ad-placard,#ad-placeholder,#ad-rectangle,#ad-right,#ad-right-sidebar-ad-1,#ad-right-sidebar-ad-2,#ad-righttop,#ad-row,#ad-side,#ad-side-text,#ad-sidebar,#ad-sky,#ad-skyscraper,#ad-slug-wrapper,#ad-small-banner,#ad-space,#ad-special,#ad-splash,#ad-sponsors,#ad-spot,#ad-squares,#ad-story-bottom-out,#ad-story-right,#ad-target,#ad-target-Leaderbord,#ad-teaser,#ad-text,#ad-top,#ad-top-banner,#ad-top-text-low,#ad-top-wrap,#ad-tower,#ad-trailerboard-spot,#ad-two,#ad-typ1,#ad-unit,#ad-wrap,#ad-wrap-right,#ad-wrapper,#ad-wrapper1,#ad-yahoo-simple,#ad-zone-1,#ad-zone-2,#ad-zone-inline,#ad01,#ad02,#ad1006,#ad11,#ad125BL,#ad125BR,#ad125TL,#ad125TR,#ad125x125,#ad160x600,#ad160x600right,#ad1Sp,#ad2Sp,#ad300,#ad300-250,#ad300X250,#ad300_x_250,#ad300x100Middle,#ad300x150,#ad300x250,#ad300x250Module,#ad300x60,#ad300x600,#ad300x600_callout,#ad336,#ad336x280,#ad375x85,#ad468,#ad468x60,#ad468x60_top,#ad526x250,#ad600,#ad728,#ad728Mid,#ad728Top,#ad728Wrapper,#ad728top,#ad728x90,#ad728x90_1,#ad90,#adBadges,#adBanner,#adBanner10,#adBanner120x600,#adBanner160x600,#adBanner2,#adBanner3,#adBanner336x280,#adBanner4,#adBanner728,#adBanner9,#adBannerTable,#adBannerTop,#adBar,#adBelt,#adBlock125,#adBlockTop,#adBlocks,#adBottbanner,#adBox,#adBox11,#adBox16,#adBox350,#adBox390,#adCirc300X200,#adCirc_620_100,#adCol,#adColumn,#adCompanionSubstitute,#adComponentWrapper,#adContainer,#adContainer_1,#adContainer_2,#adContainer_3,#adDiv,#adDiv300,#adDiv728,#adFiller,#adFps,#adFtofrs,#adGallery,#adGoogleText,#adGroup1,#adHeader,#adHeaderTop,#adIsland,#adLB,#adLabel,#adLayer,#adLeader,#adLeaderTop,#adLeaderboard,#adMPU,#adMediumRectangle,#adMiddle0Frontpage,#adMiniPremiere,#adMonster1,#adOuter,#adPlaceHolderRight,#adPlacer,#adPosOne,#adRight,#adRight2,#adSPLITCOLUMNTOPRIGHT,#adSenseModule,#adSenseWrapper,#adServer_marginal,#adShortTower,#adSidebar,#adSidebarSq,#adSky,#adSkyscraper,#adSlider,#adSpace,#adSpace0,#adSpace1,#adSpace10,#adSpace11,#adSpace12,#adSpace13,#adSpace14,#adSpace15,#adSpace16,#adSpace17,#adSpace18,#adSpace19,#adSpace2,#adSpace20,#adSpace21,#adSpace22,#adSpace23,#adSpace24,#adSpace25,#adSpace3,#adSpace300_ifrMain,#adSpace4,#adSpace5,#adSpace6,#adSpace7,#adSpace8,#adSpace9,#adSpace_footer,#adSpace_right,#adSpace_top,#adSpacer,#adSpecial,#adSplotlightEm,#adSpot-Leader,#adSpot-banner,#adSpot-island,#adSpot-mrec1,#adSpot-sponsoredlinks,#adSpot-textbox1,#adSpot-widestrip,#adSpotAdvertorial,#adSpotIsland,#adSpotSponsoredLinks,#adSquare,#adStaticA,#adStrip,#adSuperAd,#adSuperPremiere,#adSuperSkyscraper,#adSuperbanner,#adTableCell,#adTag1,#adTag2,#adText,#adTextCustom,#adTextLink,#adText_container,#adTile,#adTop,#adTopContent,#adTopbanner,#adTopboxright,#adTower,#adUnit,#adWrapper,#adZoneTop,#ad_1,#ad_130x250_inhouse,#ad_160x160,#ad_160x600,#ad_190x90,#ad_2,#ad_3,#ad_300,#ad_300_250,#ad_300_250_1,#ad_300a,#ad_300b,#ad_300c,#ad_300x100_m_c,#ad_300x250,#ad_300x250_content_column,#ad_300x250_m_c,#ad_300x250m,#ad_300x90,#ad_4,#ad_468_60,#ad_468x60,#ad_5,#ad_728_foot,#ad_728x90,#ad_728x90_container,#ad_940,#ad_984,#ad_A,#ad_B,#ad_Banner,#ad_C,#ad_C2,#ad_D,#ad_E,#ad_F,#ad_G,#ad_H,#ad_I,#ad_J,#ad_K,#ad_L,#ad_M,#ad_N,#ad_O,#ad_P,#ad_YieldManager-300x250,#ad_YieldManager-728x90,#ad_adsense,#ad_after_navbar,#ad_anchor,#ad_area,#ad_banner,#ad_bannerManage_1,#ad_banner_top,#ad_banners,#ad_bar,#ad_bellow_post,#ad_bigsize_wrapper,#ad_block_1,#ad_block_2,#ad_bottom,#ad_box,#ad_box_colspan,#ad_box_top,#ad_branding,#ad_bs_area,#ad_buttons,#ad_center_monster,#ad_circ300x250,#ad_cna2,#ad_cont,#ad_container,#ad_container_0,#ad_container_marginal,#ad_container_side,#ad_container_sidebar,#ad_container_top,#ad_content_top,#ad_content_wrap,#ad_feature,#ad_firstpost,#ad_footer,#ad_frame,#ad_front_three,#ad_fullbanner,#ad_gallery,#ad_global_header,#ad_h3,#ad_haha_1,#ad_haha_4,#ad_halfpage,#ad_head,#ad_header,#ad_holder,#ad_horizontal,#ad_horseshoe_left,#ad_horseshoe_right,#ad_horseshoe_spacer,#ad_horseshoe_top,#ad_hotpots,#ad_in_arti,#ad_island,#ad_label,#ad_large_rectangular,#ad_lastpost,#ad_layer2,#ad_leader,#ad_leaderBoard,#ad_leaderboard,#ad_leaderboard728x90,#ad_leaderboard_top,#ad_left,#ad_lnk,#ad_lrec,#ad_lwr_square,#ad_main,#ad_medium_rectangle,#ad_medium_rectangular,#ad_mediumrectangle,#ad_menu_header,#ad_message,#ad_middle,#ad_most_pop_234x60_req_wrapper,#ad_mpu,#ad_mpu300x250,#ad_mpuav,#ad_mrcontent,#ad_newsletter,#ad_overlay,#ad_place,#ad_play_300,#ad_rect,#ad_rect_body,#ad_rect_bottom,#ad_rectangle,#ad_rectangle_medium,#ad_related_links_div,#ad_related_links_div_program,#ad_replace_div_0,#ad_replace_div_1,#ad_report_leaderboard,#ad_report_rectangle,#ad_results,#ad_right,#ad_right_main,#ad_ros_tower,#ad_rr_1,#ad_script_head,#ad_sec,#ad_sec_div,#ad_sgd,#ad_sidebar,#ad_sidebar1,#ad_sidebar2,#ad_sidebar3,#ad_sky,#ad_skyscraper,#ad_skyscraper160x600,#ad_skyscraper_text,#ad_slot_leaderboard,#ad_slot_livesky,#ad_slot_sky_top,#ad_space,#ad_square,#ad_ss,#ad_table,#ad_term_bottom_place,#ad_text:not(textarea),#ad_thread_first_post_content,#ad_top,#ad_top_holder,#ad_tp_banner_1,#ad_tp_banner_2,#ad_txt,#ad_unit,#ad_vertical,#ad_wide,#ad_wide_box,#ad_widget,#ad_window,#ad_wrap,#ad_wrapper,#adaptvcompanion,#adbForum,#adbanner,#adbar,#adbig,#adbnr,#adboard,#adbody,#adbottom,#adbox,#adbox1,#adbox2,#adbutton,#adclear,#adcode,#adcode1,#adcode2,#adcode3,#adcode4,#adcolumnwrapper,#adcontainer,#adcontainer1,#adcontainerRight,#adcontainsm,#adcontent,#adcontent1,#adcontrolPushSite,#add_ciao2,#addbottomleft,#addiv-bottom,#addiv-top,#adfooter,#adfooter_728x90,#adframe:not(frameset),#adhead,#adhead_g,#adheader,#adhome,#adiframe1_iframe,#adiframe2_iframe,#adiframe3_iframe,#adimg,#adition_content_ad,#adlabel,#adlabelFooter,#adlayer,#adlayerContainer,#adlayer_back,#adlayerad,#adleaderboard,#adleaderboard_flex,#adleaderboardb,#adleaderboardb_flex,#adleft,#adlinks,#adlinkws,#adlrec,#admanager_leaderboard,#admid,#admiddle3center,#admiddle3left,#adposition,#adposition-C,#adposition-FPMM,#adposition1,#adposition2,#adposition3,#adposition4,#adrectangle,#adrectanglea,#adrectanglea_flex,#adrectangleb,#adrectangleb_flex,#adrig,#adright,#adright2,#adrighthome,#ads-250,#ads-468,#ads-area,#ads-block,#ads-bot,#ads-bottom,#ads-col,#ads-dell,#ads-footer,#ads-footer-inner,#ads-horizontal,#ads-indextext,#ads-leaderboard1,#ads-lrec,#ads-main,#ads-menu,#ads-middle,#ads-prices,#ads-rhs,#ads-right,#ads-sponsored-boxes,#ads-top,#ads-vers7,#ads-wrapper,#ads120,#ads125,#ads160left,#ads300,#ads300-250,#ads300Bottom,#ads300Top,#ads315,#ads336x280,#ads728,#ads728bottom,#ads728top,#ads790,#adsBox-460_left,#adsBox-dynamic-right,#adsBoxResultsPage,#adsContent,#adsDisplay,#adsDiv1,#adsDiv2,#adsDiv3,#adsDiv4,#adsDiv5,#adsDiv6,#adsDiv7,#adsHeader,#adsID,#ads_160,#ads_300,#ads_728,#ads_banner,#ads_belowforumlist,#ads_belownav,#ads_bottom,#ads_bottom_inner,#ads_bottom_outer,#ads_box,#ads_button,#ads_catDiv,#ads_container,#ads_footer,#ads_fullsize,#ads_halfsize,#ads_header,#ads_html1,#ads_html2,#ads_inner,#ads_lb,#ads_medrect,#ads_notice,#ads_right,#ads_right_sidebar,#ads_sidebar_roadblock,#ads_space,#ads_text,#ads_top,#ads_topbanner,#ads_watch_top_square,#ads_zone27,#adsbottom,#adsbox,#adsbox-left,#adsbox-right,#adscolumn,#adsd_contentad_r1,#adsd_contentad_r2,#adsd_contentad_r3,#adsd_topbanner,#adsd_txt_sky,#adsdiv,#adsection,#adsense,#adsense-2,#adsense-header,#adsense-new,#adsense-tag,#adsense-text,#adsense03,#adsense04,#adsense05,#adsense1,#adsenseLeft,#adsenseOne,#adsenseWrap,#adsense_article_left,#adsense_block,#adsense_box,#adsense_box_video,#adsense_inline,#adsense_leaderboard,#adsense_overlay,#adsense_placeholder_2,#adsenseheader,#adsensetopplay,#adsensewidget-3,#adserv,#adshometop,#adsimage,#adskinlink,#adsky,#adskyscraper,#adslider,#adslot,#adsmiddle,#adsonar,#adspace,#adspace-1,#adspace-300x250,#adspace-leaderboard-top,#adspace300x250,#adspaceBox,#adspaceBox300,#adspace_header,#adspace_leaderboard,#adspacer,#adsponsorImg,#adspot,#adspot-1,#adspot-149x170,#adspot-1x4,#adspot-2,#adspot-295x60,#adspot-2a,#adspot-2b,#adspot-300x110-pos-1,#adspot-300x125,#adspot-300x250-pos-1,#adspot-300x250-pos-2,#adspot-468x60-pos-2,#adspot-a,#adspot300x250,#adspot_220x90,#adspot_300x250,#adspot_468x60,#adspot_728x90,#adsquare,#adsright,#adstop,#adtab,#adtag_right_side,#adtagfooter,#adtagheader,#adtagrightcol,#adtaily-widget-light,#adtech_0,#adtech_1,#adtech_2,#adtech_3,#adtech_googleslot_03c,#adtech_takeover,#adtext,#adtop,#adtophp,#adtxt,#adv-300,#adv-leaderboard,#adv-left,#adv-masthead,#adv-middle,#adv-mpux,#adv-x36,#adv-x37,#adv-x38,#adv-x39,#adv-x40,#adv1,#adv300bottom,#adv300top,#adv728 { display:none !important; } #adv_300,#adv_728,#adv_border,#adv_google_300,#adv_google_728,#adv_halfpage,#adv_halfpage_title,#adv_leaderboard,#adv_sky,#adv_top_banner_wrapper,#adver1,#adver2,#adver3,#adver4,#adver5,#adver6,#adver7,#advert-1,#advert-120,#advert-boomer,#advert-display,#advert-header,#advert-leaderboard,#advert-links-bottom,#advert-skyscraper,#advert-top,#advert1,#advertBanner,#advertContainer,#advertDB,#advertRight,#advertSection,#advert_125x125,#advert_250x250,#advert_box,#advert_home01,#advert_leaderboard,#advert_lrec_format,#advert_mid,#advert_mpu,#advert_mpu_1,#advert_right_skyscraper,#advert_sky,#advertbox,#advertbox2,#advertbox3,#advertbox4,#adverthome,#advertise,#advertise-here,#advertise-here-sidebar,#advertise-now,#advertise1,#advertiseHere,#advertisement1,#advertisement160x600,#advertisement3,#advertisement728x90,#advertisementHorizontal,#advertisementLigatus,#advertisementPrio2,#advertisementRight,#advertisementRightcolumn0,#advertisementRightcolumn1,#advertisementsarticle,#advertiser-container,#advertiserLinks,#advertisers,#advertising,#advertising-banner,#advertising-caption,#advertising-container,#advertising-control,#advertising-skyscraper,#advertising-top,#advertising2,#advertisingModule160x600,#advertisingModule728x90,#advertisingTopWrapper,#advertising_btm,#advertising_contentad,#advertising_horiz_cont,#advertisment,#advertismentElementInUniversalbox,#advertorial,#advertorial_red_listblock,#adverts,#adverts-top-container,#adverts-top-left,#adverts-top-middle,#adverts-top-right,#advertsingle,#advertspace,#advheader,#advsingle,#advt,#advtext,#advtop,#adwhitepaperwidget,#adwin_rec,#adwith,#adwords-4-container,#adwrapper,#adxBigAd,#adxMiddle5,#adxSponLink,#adxSponLinkA,#adxtop,#adxtop2,#adzbanner,#adzerk,#adzerk1,#adzerk2,#adzone,#adzoneBANNER,#adzoneheader,#afc-container,#affinityBannerAd,#after-content-ads,#after-header-ad-left,#after-header-ad-right,#after-header-ads,#agi-ad300x250,#agi-ad300x250overlay,#agi-sponsored,#alert_ads,#anchorAd,#annoying_ad,#ap_adframe,#ap_cu_overlay,#ap_cu_wrapper,#apiBackgroundAd,#apiTopAdWrap,#apmNADiv,#apolload,#araHealthSponsorAd,#area-adcenter,#area1ads,#article-ad,#article-ad-container,#article-box-ad,#articleAdReplacement,#articleLeftAdColumn,#articleSideAd,#article_ad,#article_ad_container,#article_box_ad,#articlead1,#articlead2,#asideads,#asinglead,#atlasAdDivGame,#awds-nt1-ad,#babAdTop,#banner-300x250,#banner-ad,#banner-ad-container,#banner-ads,#banner250x250,#banner300x250,#banner468x60,#banner728x90,#bannerAd,#bannerAdTop,#bannerAdWrapper,#bannerAd_ctr,#bannerAd_rdr,#banner_160x600,#banner_300_250,#banner_ad,#banner_ad_footer,#banner_ad_module,#banner_admicro,#banner_ads,#banner_advertisement,#banner_content_ad,#banner_topad,#bannerad,#bannerad2,#baseAdvertising,#basket-adContainer,#bbccom_mpu,#bbo_ad1,#bg-footer-ads,#bg-footer-ads2,#bg_YieldManager-160x600,#bg_YieldManager-300x250,#bg_YieldManager-728x90,#bigAd,#bigBoxAd,#bigad300outer,#bigadbox,#bigadframe,#bigadspot,#billboard_ad,#block-ad_cube-1,#block-openads-0,#block-openads-1,#block-openads-2,#block-openads-3,#block-openads-4,#block-openads-5,#block-spti_ga-spti_ga_adwords,#block-thewrap_ads_250x300-0,#block_advert,#block_advertisement,#blog-ad,#blog_ad_content,#blog_ad_opa,#blog_ad_right,#blog_ad_top,#blox-big-ad,#blox-big-ad-bottom,#blox-big-ad-top,#blox-halfpage-ad,#blox-tile-ad,#blox-tower-ad,#body_728_ad,#book-ad,#botad,#bott_ad2,#bott_ad2_300,#bottom-ad,#bottom-ad-container,#bottom-ad-tray,#bottom-ad-wrapper,#bottom-ads,#bottomAd,#bottomAdCCBucket,#bottomAdContainer,#bottomAdSense,#bottomAdSenseDiv,#bottomAds,#bottomAdvBox,#bottomContentAd,#bottomRightAd,#bottomRightAdSpace,#bottom_ad,#bottom_ad_area,#bottom_ad_unit,#bottom_ads,#bottom_banner_ad,#bottom_overture,#bottom_sponsor_ads,#bottom_sponsored_links,#bottom_text_ad,#bottomad,#bottomads,#bottomadsense,#bottomadwrapper,#bottomleaderboardad,#box-ad-section,#box-ads-small-1,#box-ads-small-2,#box-content-ad,#box-googleadsense-1,#box-googleadsense-r,#box1ad,#boxAd300,#boxAdContainer,#boxAdvert,#box_ad,#box_advertisment,#box_mod_googleadsense,#boxad1,#boxad2,#boxad3,#boxad4,#boxad5,#boxads,#bpAd,#bps-header-ad-container,#btnAds,#btnads,#btr_horiz_ad,#burn_header_ad,#button-ads-horizontal,#button-ads-vertical,#buttonAdWrapper1,#buttonAdWrapper2,#buttonAds,#buttonAdsContainer,#button_ad_container,#button_ad_wrap,#button_ads,#buttonad,#buy-sell-ads,#c4ad-Middle1,#c_ad_sb,#c_ad_sky,#caAdLarger,#catad,#category-ad,#cellAd,#channel_ad,#channel_ads,#ciHomeRHSAdslot,#circ_ad,#closeable-ad,#cmn_ad_box,#cmn_toolbar_ad,#cnnAboveFoldBelowAd,#cnnRR336ad,#cnnSponsoredPods,#cnnTopAd,#cnnVPAd,#col3_advertising,#colAd,#colRightAd,#collapseobj_adsection,#column4-google-ads,#comments-ad-container,#commercial_ads,#common_right_ad_wrapper,#common_right_lower_ad_wrapper,#common_right_lower_adspace,#common_right_lower_player_ad_wrapper,#common_right_lower_player_adspace,#common_right_player_ad_wrapper,#common_right_player_adspace,#common_right_right_adspace,#common_top_adspace,#comp_AdsLeaderboardTop,#companion-ad,#companionAd,#companionAdDiv,#companionad,#container-righttopads,#container-topleftads,#containerLocalAds,#containerLocalAdsInner,#containerMrecAd,#containerSqAd,#content-ad-header,#content-header-ad,#content-left-ad,#content-right-ad,#contentAd,#contentBoxad,#contentTopAds2,#content_ad,#content_ad_square,#content_ad_top,#content_ads_content,#content_box_300body_sponsoredoffers,#content_box_adright300_google,#content_lower_center_right_ad,#content_mpu,#contentad,#contentad_imtext,#contentad_right,#contentads,#contentinlineAd,#contents_post_ad,#contextad,#contextual-ads,#contextual-ads-block,#contextualad,#coverADS,#coverads,#ctl00_Adspace_Top_Height,#ctl00_BottomAd,#ctl00_ContentMain_BanManAd468_BanManAd,#ctl00_ContentPlaceHolder1_blockAdd_divAdvert,#ctl00_ContentRightColumn_RightColumn_Ad1_BanManAd,#ctl00_ContentRightColumn_RightColumn_Ad2_BanManAd,#ctl00_ContentRightColumn_RightColumn_PremiumAd1_ucBanMan_BanManAd,#ctl00_LHTowerAd,#ctl00_LeftHandAd,#ctl00_MasterHolder_IBanner_adHolder,#ctl00_TopAd,#ctl00_TowerAd,#ctl00_VBanner_adHolder,#ctl00__Content__RepeaterReplies_ctl03__AdReply,#ctl00_abot_bb,#ctl00_adFooter,#ctl00_advert_LargeMPU_div_AdPlaceHolder,#ctl00_atop_bt,#ctl00_cphMain_hlAd1,#ctl00_cphMain_hlAd2,#ctl00_cphMain_hlAd3,#ctl00_ctl00_MainPlaceHolder_itvAdSkyscraper,#ctl00_ctl00_ctl00_Main_Main_PlaceHolderGoogleTopBanner_MPTopBannerAd,#ctl00_ctl00_ctl00_Main_Main_SideBar_MPSideAd,#ctl00_dlTilesAds,#ctl00_m_skinTracker_m_adLBL,#ctl00_phCrackerMain_ucAffiliateAdvertDisplayMiddle_pnlAffiliateAdvert,#ctl00_phCrackerMain_ucAffiliateAdvertDisplayRight_pnlAffiliateAdvert,#ctl00_topAd,#ctrlsponsored,#cubeAd,#cube_ads,#cube_ads_inner,#cubead,#cubead-2,#currencies-sponsored-by,#custom-advert-leadboard-spacer,#dAdverts,#dItemBox_ads,#dart_160x600,#dc-display-right-ad-1,#dcadSpot-Leader,#dcadSpot-LeaderFooter,#dcol-sponsored,#defer-adright,#detail_page_vid_topads,#div-gpt-ad-1,#div-gpt-ad-2,#div-gpt-ad-3,#div-gpt-ad-4,#divAd,#divAdBox,#divAdWrapper,#divAdvertisement,#divBottomad1,#divBottomad2,#divDoubleAd,#divLeftAd12,#divLeftRecAd,#divMenuAds,#divWNAdHeader,#divWrapper_Ad,#div_ad_leaderboard,#div_video_ads,#dlads,#dni-header-ad,#dnn_adLeaderBoard2008,#dnn_ad_banner,#download_ads,#dp_ads1,#ds-mpu,#ds_ad_north_leaderboard,#editorsmpu,#em_ad_superbanner,#embedded-ad,#evotopTen_advert,#ex-ligatus,#exads,#extra-search-ads,#fb_adbox,#fb_rightadpanel,#featAds,#featuread,#featured-advertisements,#featuredAdContainer2,#featuredAds,#featured_ad_links,#feed_links_ad_container,#file_sponsored_link,#first-300-ad,#first-adlayer,#first_ad_unit,#firstad,#flAdData6,#fl_hdrAd,#flash_ads_1,#flexiad,#floatingAd,#floating_ad_container,#foot-ad-1,#footad,#footer-ad,#footer-ads,#footer-advert,#footer-adverts,#footer-sponsored,#footerAd,#footerAdDiv,#footerAds,#footerAdvertisement,#footerAdverts,#footer_ad,#footer_ad_01,#footer_ad_block,#footer_ad_container,#footer_ad_modules,#footer_ads,#footer_adspace,#footer_text_ad,#footerad,#footerads,#footeradsbox,#forum_top_ad,#four_ads,#fpad1,#fpad2,#fpv_companionad,#fr_ad_center,#frame_admain,#frnAdSky,#frnBannerAd,#frnContentAd,#front_ad728,#front_advert,#front_mpu,#ft-ad,#ft-ad-1,#ft-ad-container,#ft_mpu,#fullsizebanner_468x60,#fusionad,#fw-advertisement,#g_ad,#g_adsense,#ga_300x250,#galleries-tower-ad,#gallery-ad,#gallery-ad-m0,#gallery-random-ad,#gallery_ads,#game-info-ad,#gamead,#gameads,#gasense,#gglads,#global_header_ad_area,#gm-ad-lrec,#gmi-ResourcePageAd,#gmi-ResourcePageLowerAd,#goad1,#goads,#gooadtop,#google-ad,#google-ad-art,#google-ad-table-right,#google-ad-tower,#google-ads,#google-ads-bottom,#google-ads-header,#google-ads-left-side,#google-adsense-mpusize,#googleAd,#googleAdArea,#googleAds,#googleAdsSml,#googleAdsense,#googleAdsenseBanner,#googleAdsenseBannerBlog,#googleAdwordsModule,#googleAfcContainer,#googleSearchAds,#googleShoppingAdsRight,#googleShoppingAdsTop,#googleSubAds,#google_ad,#google_ad_container,#google_ad_inline,#google_ad_test,#google_ads,#google_ads_aCol,#google_ads_frame1,#google_ads_frame1_anchor,#google_ads_frame2,#google_ads_frame2_anchor,#google_ads_frame3,#google_ads_frame3_anchor,#google_ads_test,#google_ads_top,#google_adsense_home_468x60_1,#googlead,#googlead-sidebar-middle,#googlead-sidebar-top,#googlead2,#googleadbox,#googleads,#googleads_mpu_injection,#googleadsense,#googlesponsor,#gpt-ad-halfpage,#gpt-ad-rectangle1,#gpt-ad-rectangle2,#gpt-ad-skyscraper,#gpt-ad-story_rectangle3,#grid_ad,#gsyadrectangleload,#gsyadrightload,#gsyadtop,#gsyadtopload,#gtopadvts,#half-page-ad,#halfPageAd,#halfe-page-ad-box,#hd-ads,#hd-banner-ad,#hdtv_ad_ss,#head-ad,#head-ad-1,#head-banner468,#headAd,#head_ad,#head_advert,#headad,#header-ad,#header-ad-left,#header-ad-rectangle-container,#header-ad-right,#header-ad2010,#header-ads,#header-adspace,#header-advert,#header-advertisement,#header-advertising,#header-adverts,#header-banner-ad,#headerAd,#headerAdBackground,#headerAdContainer,#headerAdWrap,#headerAds,#headerAdsWrapper,#headerTopAd,#header_ad,#header_ad_728_90,#header_ad_container,#header_adcode,#header_ads,#header_advertisement_top,#header_flag_ad,#header_leaderboard_ad_container,#header_publicidad,#headerad,#headeradbox,#headerads,#headeradsbox,#headeradvertholder,#headeradwrap,#headline_ad,#headlinesAdBlock,#hiddenadAC,#hideads,#hl-sponsored-results,#hly_ad_side_bar_tower_left,#hly_inner_page_google_ad,#home-advert-module,#home-rectangle-ad,#home-top-ads,#homeMPU,#homeTopRightAd,#home_ad,#home_bottom_ad,#home_contentad,#home_feature_ad,#home_lower_center_right_ad,#home_mpu,#home_spensoredlinks,#homead,#homepage-ad,#homepageAdsTop,#homepageFooterAd,#homepage_right_ad,#homepage_right_ad_container,#homepage_top_ads,#hometop_234x60ad,#hor_ad,#horizad,#horizontal-banner-ad,#horizontal_ad,#horizontal_ad_top,#horizontalads,#hot-deals-ad,#houseAd,#hp-header-ad,#hp-mpu,#hp-right-ad,#hp-store-ad,#hpV2_300x250Ad,#hpV2_googAds,#hp_ad300x250,#ibt_local_ad728,#icePage_SearchLinks_AdRightDiv,#icePage_SearchLinks_DownloadToolbarAdRightDiv,#icePage_SearchResults_ads0_SponsoredLink,#icePage_SearchResults_ads1_SponsoredLink,#icePage_SearchResults_ads2_SponsoredLink,#icePage_SearchResults_ads3_SponsoredLink,#icePage_SearchResults_ads4_SponsoredLink,#idSponsoredresultend,#idSponsoredresultstart,#iframeRightAd,#iframeTopAd,#imu_ad_module,#in_serp_ad,#inadspace,#indexad,#inline-story-ad,#inlineAd,#inlinead,#inlinegoogleads,#inlist-ad-block,#inner-advert-row,#inner-top-ads,#innerpage-ad,#inside-page-ad,#insider_ad_wrapper,#instoryad,#instoryadtext,#instoryadwrap,#int-ad,#interstitial_ad_wrapper,#iqadtile8,#islandAd,#j_ad,#ji_medShowAdBox,#jmp-ad-buttons,#joead,#joead2,#js_adsense,#ka_adRightSkyscraperWide,#ka_samplead,#kaufDA-widget,#kdz_ad1,#kdz_ad2,#keyadvertcontainer,#landing-adserver,#lapho-top-ad-1,#largead,#lateAd,#layerAds_layerDiv,#layerTLDADSERV,#layer_ad_content,#layer_ad_main,#layerad,#leader-board-ad,#leaderAd,#leaderAdContainer,#leader_ad,#leader_board_ad,#leaderad,#leaderad_section,#leaderboard-ad,#leaderboard-bottom-ad,#leaderboardAd,#leaderboard_ad,#leaderboard_ad_gam,#left-ad-1,#left-ad-2,#left-ad-col,#left-ad-skin,#left-bottom-ad,#left-lower-adverts,#left-lower-adverts-container,#leftAdContainer,#leftAd_rdr,#leftAdvert,#leftSectionAd300-100,#left_ad,#left_adspace,#leftad,#leftads,#leftcolAd,#lg-banner-ad,#ligatus,#linkAds,#linkads,#live-ad,#localAds,#logoAd,#longAdSpace,#long_advertisement,#lowerAdvertisementImg,#lower_ad,#lowerads,#lowerthirdad,#lowertop-adverts,#lowertop-adverts-container,#lpAdPanel,#lrecad,#lsadvert-left_menu_1,#lsadvert-left_menu_2,#lsadvert-top,#mBannerAd,#main-ad,#main-ad160x600,#main-ad160x600-img,#main-ad728x90,#main-advert1,#main-advert2,#main-advert3,#main-bottom-ad,#main-tj-ad,#mainAd,#mainAdUnit,#mainAdvert,#mainAdvertismentP,#mainHeaderAdvertisment,#main_ad,#main_rec_ad,#main_top_ad_container,#marketing-promo,#mastAd,#mastAdvert,#mastad,#mastercardAd,#masthead_ad,#masthead_topad,#medRecAd,#media_ad,#mediaplayer_adburner,#mediumAdvertisement,#medrectad,#menuAds,#menubanner-ad-content,#mi_story_assets_ad,#mid-ad300x250,#mid-table-ad,#midRightTextAds,#mid_ad_div,#mid_ad_title,#mid_mpu,#midadd,#midadspace,#middle-ad,#middle_ad,#middle_body_advertising,#middlead,#middleads,#midrect_ad,#midstrip_ad,#mini-ad,#mochila-column-right-ad-300x250,#mochila-column-right-ad-300x250-1,#module-google_ads,#module_ad,#module_box_ad,#module_sky_scraper,#monsterAd,#moogleAd,#moreads,#most_popular_ad,#motionAd,#mpu-advert,#mpu-cont,#mpu300250,#mpuAd,#mpuDiv,#mpuSlot,#mpuWrapper,#mpuWrapperAd,#mpu_banner,#mpu_firstpost,#mpu_holder,#mpu_text_ad,#mpuad,#mpubox,#mr_banner_topad,#mrecAdContainer,#msAds,#ms_ad,#msad,#multiLinkAdContainer,#multi_ad,#my-ads,#myads_HeaderButton,#n_sponsor_ads,#namecom_ad_hosting_main,#narrow-ad,#narrow_ad_unit,#natadad300x250,#national_microlink_ads,#nationalad,#navi_banner_ad_780,#nba160PromoAd,#nba300Ad,#nbaGI300ad,#nbaHouseAnd600Ad,#nbaLeft600Ad,#nbaMidAds,#nbaVid300Ad,#nbcAd300x250,#new_topad,#newads,#news_advertorial_content,#news_advertorial_top,#ng_rtcol_ad,#noresults_ad_container,#noresultsads,#northad,#northbanner-advert,#northbanner-advert-container,#ns_ad1,#ns_ad2,#ns_ad3,#oanda_ads,#onespot-ads,#online_ad,#ovadsense,#p-googleadsense,#page-header-ad,#page-top-ad,#pageAds,#pageAdsDiv,#pageBannerAd,#page_ad,#page_content_top_ad,#pagelet_adbox,#pagelet_netego_ads,#pagelet_search_ads2,#panelAd,#pb_report_ad,#pcworldAdBottom,#pcworldAdTop,#pinball_ad,#player-below-advert,#player_ad,#player_ads,#pmad-in1,#pod-ad-video-page,#populate_ad_bottom,#populate_ad_left,#popup_domination_lightbox_wrapper,#portlet-advertisement-left,#portlet-advertisement-right,#post-promo-ad,#post5_adbox,#post_ad,#premium_ad,#priceGrabberAd,#prime-ad-space,#print-header-ad,#print_ads,#printads,#product-adsense,#promo-ad,#promoAds,#ps-vertical-ads,#pub468x60,#publicidad,#pushdown_ad,#qm-ad-big-box,#qm-ad-sky,#qm-dvdad,#quigo_ad,#r1SoftAd,#rail_ad1,#rail_ad2,#realEstateAds,#rectAd,#rect_ad,#rectangle-ad,#rectangleAd,#rectangle_ad,#refine-300-ad,#region-node-advert,#region-top-ad,#relocation_ad_container,#rh-ad-container,#rh_tower_ad,#rhapsodyAd,#rhs_ads,#rhsadvert,#right-ad,#right-ad-col,#right-ad-skin,#right-ad-title,#right-ad1,#right-ads-3,#right-advert,#right-bar-ad,#right-box-ad,#right-featured-ad,#right-mpu-1-ad-container,#right-uppder-adverts,#right-uppder-adverts-container,#rightAd,#rightAd300x250,#rightAd300x250Lower,#rightAdBar,#rightAdColumn,#rightAd_rdr,#rightAdsDiv,#rightColAd,#rightColumnMpuAd,#rightColumnSkyAd,#right_ad,#right_ad_wrapper,#right_ads,#right_advert,#right_advertisement,#right_advertising,#right_column_ad_container,#right_column_ads,#right_column_adverts,#right_column_internal_ad_container,#right_column_top_ad_unit,#rightad,#rightadContainer,#rightads,#rightadvertbar-doubleclickads,#rightbar-ad,#rightcolhouseads,#rightcolumn_300x250ad,#rightgoogleads,#rightinfoad,#rightside-ads,#rightside_ad,#righttop-adverts,#righttop-adverts-container,#rm_ad_text,#ros_ad,#rotatingads { display:none !important; } #row2AdContainer,#rprightHeaderAd,#rr_MSads,#rt-ad,#rt-ad-top,#rt-ad468,#rtMod_ad,#rtmod_ad,#sAdsBox,#sb-ad-sq,#sb_ad_links,#sb_advert,#search-google-ads,#search-sponsored-links,#search-sponsored-links-top,#searchAdSenseBox,#searchAdSenseBoxAd,#searchAdSkyscraperBox,#search_ads,#search_result_ad,#sec_adspace,#second-adlayer,#secondBoxAdContainer,#secondrowads,#sect-ad-300x100,#sect-ad-300x250-2,#section-ad-1-728,#section-ad-300-250,#section-ad-4-160,#section-blog-ad,#section-container-ddc_ads,#section_advertisements,#section_advertorial_feature,#servfail-ads,#sew-ad1,#shoppingads,#shortads,#show-ad,#showAd,#showad,#side-ad,#side-ad-container,#side-ads,#sideAd,#sideAd1,#sideAd2,#sideAdSub,#sideAds,#sideBarAd,#side_ad,#side_ad_wrapper,#side_ads_by_google,#side_sky_ad,#sidead,#sideads,#sideadtop-to,#sidebar-125x125-ads,#sidebar-125x125-ads-below-index,#sidebar-ad,#sidebar-ad-boxes,#sidebar-ad-space,#sidebar-ad-wrap,#sidebar-ad3,#sidebar-ads,#sidebar-adv,#sidebar-sponsor-link,#sidebar2ads,#sidebar_ad,#sidebar_ad_widget,#sidebar_ads,#sidebar_ads_180,#sidebar_sponsoredresult_body,#sidebar_txt_ad_links,#sidebarad,#sidebaradpane,#sidebarads,#sidebaradver_advertistxt,#sideline-ad,#single-mpu,#singlead,#site-ad-container,#site-leaderboard-ads,#site_top_ad,#sitead,#sky-ad,#skyAd,#skyAdContainer,#skyScrapperAd,#skyWrapperAds,#sky_ad,#sky_advert,#skyads,#skyadwrap,#skyline_ad,#skyscrapeAd,#skyscraper-ad,#skyscraperAd,#skyscraperAdContainer,#skyscraper_ad,#skyscraper_advert,#skyscraperad,#slide_ad,#sliderAdHolder,#slideshow_ad_300x250,#sm-banner-ad,#small_ad,#small_ad_banners_vertical,#small_ads,#smallerAd,#some-ads,#some-more-ads,#specialAd_one,#specialAd_two,#specialadvertisingreport_container,#specials_ads,#speeds_ads,#speeds_ads_fstitem,#speedtest_mrec_ad,#sphereAd,#spnAds,#sponlink,#sponlinks,#sponsAds,#sponsLinks,#sponseredlinks,#sponsorAd1,#sponsorAd2,#sponsorAdDiv,#sponsorLinks,#sponsorTextLink,#sponsor_banderole,#sponsor_deals,#sponsored,#sponsored-ads,#sponsored-features,#sponsored-links,#sponsored-listings,#sponsored-resources,#sponsored1,#sponsoredBox1,#sponsoredBox2,#sponsoredLinks,#sponsoredList,#sponsoredResults,#sponsoredResultsWide,#sponsoredSiteMainline,#sponsoredSiteSidebar,#sponsored_ads_v4,#sponsored_container,#sponsored_content,#sponsored_game_row_listing,#sponsored_head,#sponsored_link,#sponsored_link_bottom,#sponsored_links,#sponsored_v12,#sponsoredads,#sponsoredlinks,#sponsoredlinks_cntr,#sponsoredlinkslabel,#sponsoredresults_top,#sponsoredwellcontainerbottom,#sponsoredwellcontainertop,#sponsorlink,#spotlightAds,#spotlightad,#sqAd,#squareAd,#squareAdSpace,#squareAds,#square_ad,#start_middle_container_advertisment,#sticky-ad,#stickyBottomAd,#story-90-728-area,#story-ad-a,#story-ad-b,#story-leaderboard-ad,#story-sponsoredlinks,#storyAd,#storyAdWrap,#storyad2,#submenu-ads,#subpage-ad-right,#subpage-ad-top,#swads,#synch-ad,#systemad_background,#tabAdvertising,#takeoverad,#tblAd,#tbl_googlead,#tcwAd,#td-GblHdrAds,#template_ad_leaderboard,#tertiary_advertising,#test_adunit_160_article,#text-ad,#text-ads,#text-link-ads,#textAd,#textAds,#text_ad,#text_ads,#text_advert,#textad,#textad3,#textad_block,#the-last-ad-standing,#thefooterad,#themis-ads,#tile-ad,#tmglBannerAd,#tmp2_promo_ad,#toolbarSlideUpAd,#top-ad,#top-ad-container,#top-ad-menu,#top-ads,#top-ads-tabs,#top-advertisement,#top-banner-ad,#top-search-ad-wrapper,#topAd,#topAd728x90,#topAdBanner,#topAdBox,#topAdContainer,#topAdSenseDiv,#topAdcontainer,#topAds,#topAdsContainer,#topAdvBox,#topAdvert,#topAdvert-09,#topBannerAd,#topBannerAdContainer,#topContentAdTeaser,#topNavLeaderboardAdHolder,#topOverallAdArea,#topRightBlockAdSense,#topSponsoredLinks,#top_ad,#top_ad-sense,#top_ad_area,#top_ad_banner,#top_ad_game,#top_ad_unit,#top_ad_wrapper,#top_ad_zone,#top_ads,#top_ads_wrap,#top_advertise,#top_advertising,#top_rectangle_ad,#top_right_ad,#top_wide_ad,#topad1,#topad2,#topad_left,#topad_right,#topadbar,#topadblock,#topaddwide,#topads,#topadsense,#topadspace,#topadwrap,#topadzone,#topbanner_ad,#topbannerad,#topbar-ad,#topcustomad,#topleaderboardad,#topnav-ad-shell,#topnavad,#toprightAdvert,#toprightad,#topsponsored,#toptextad,#tour300Ad,#tour728Ad,#tourSponsoredLinksContainer,#towerad,#ts-ad_module,#ttp_ad_slot1,#ttp_ad_slot2,#twogamesAd,#txfPageMediaAdvertVideo,#txt_link_ads,#txtads,#undergameAd,#upper-ads,#upperAdvertisementImg,#upperMpu,#upper_small_ad,#upperad,#urban_contentad_1,#urban_contentad_2,#urban_contentad_article,#v_ad,#vert-ads,#vert_ad,#vert_ad_placeholder,#vertical_ad,#vertical_ads,#videoAd,#videoAdvert,#video_ads_overdiv,#video_advert2,#video_advert3,#video_cnv_ad,#video_overlay_ad,#videoadlogo,#view_ads,#view_ads_advertisements,#viewads,#viewportAds,#viewvid_ad300x250,#wXcds12-ad,#wall_advert,#wallpaper-ad-link,#wallpaperAd_left,#wallpaperAd_right,#walltopad,#weblink_ads_container,#welcomeAdsContainer,#welcome_ad_mrec,#welcome_advertisement,#wf_ContentAd,#wf_FrontSingleAd,#wf_SingleAd,#wf_bottomContentAd,#wgtAd,#whatsnews_top_ad,#whitepaper-ad,#whoisRightAdContainer,#wide_ad_unit_top,#wideskyscraper_160x600_left,#wideskyscraper_160x600_right,#widget_Adverts,#widget_advertisement,#widgetwidget_adserve2,#wrapAdRight,#wrapAdTop,#wrapperAdsTopLeft,#wrapperAdsTopRight,#xColAds,#y-ad-units,#y708-ad-expedia,#y708-ad-lrec,#y708-ad-partners,#y708-ad-ysm,#y708-advertorial-marketplace,#yahoo-ads,#yahoo-sponsors,#yahooSponsored,#yahoo_ads,#yahoo_ads_2010,#yahoo_text_ad,#yahooad-tbl,#yan-sponsored,#yatadsky,#ybf-ads,#yfi_fp_ad_mort,#yfi_fp_ad_nns,#yfi_pf_ad_mort,#ygrp-sponsored-links,#ymap_adbanner,#yn-gmy-ad-lrec,#yreSponsoredLinks,#ysm_ad_iframe,#zoneAdserverMrec,#zoneAdserverSuper,.ADBAR,.ADPod,.AD_ALBUM_ITEMLIST,.AD_MOVIE_ITEM,.AD_MOVIE_ITEMLIST,.AD_MOVIE_ITEMROW,.ADbox,.Ad-300x100,.Ad-Container-976x166,.Ad-Header,.Ad-MPU,.Ad-Wrapper-300x100,.Ad120x600,.Ad160x600,.Ad160x600left,.Ad160x600right,.Ad247x90,.Ad300x,.Ad300x250,.Ad300x250L,.Ad728x90,.AdBorder,.AdBox,.AdBox7,.AdContainerBox308,.AdContainerModule,.AdHeader,.AdHere,.AdInfo,.AdInline,.AdMedium,.AdPlaceHolder,.AdProS728x90Container,.AdProduct,.AdRingtone,.AdSense,.AdSenseLeft,.AdSlot,.AdSpace,.AdTextSmallFont,.AdTitle,.AdUnit,.AdUnit300,.Ad_C,.Ad_D_Wrapper,.Ad_E_Wrapper,.Ad_Right,.AdsBottom,.AdsBoxBottom,.AdsBoxSection,.AdsBoxTop,.AdsLinks1,.AdsLinks2,.AdsRec,.AdvBoxSidebar,.Advert,.Advert300x250,.AdvertMidPage,.AdvertiseWithUs,.Advertisement,.AdvertisementTextTag,.Advman_Widget,.ArticleAd,.ArticleInlineAd,.BCA_Advertisement,.Banner300x250,.BannerAd,.BigBoxAd,.BlockAd,.BlueTxtAdvert,.BottomAdContainer,.BottomAffiliate,.BoxAd,.CG_adkit_leaderboard,.CG_details_ad_dropzone,.CWReviewsProdInfoAd,.ComAread,.CommentAd,.ContentAd,.ContentAds,.DAWRadvertisement,.DeptAd,.DisplayAd,.FT_Ad,.FeaturedAdIndexAd,.FlatAds,.FooterAds,.GOOGLE_AD,.GoogleAd,.GoogleAdSenseBottomModule,.GoogleAdSenseRightModule,.HPG_Ad_B,.HPNewAdsBannerDiv,.HPRoundedAd,.HeaderAds,.HomeContentAd,.IABAdSpace,.InArticleAd,.IndexRightAd,.LazyLoadAd,.LeftAd,.LeftButtonAdSlot,.LeftTowerAd,.M2Advertisement,.MD_adZone,.MOS-ad-hack,.MPUHolder,.MPUTitleWrapperClass,.MREC_ads,.MiddleAd,.MiddleAdContainer,.MiddleAdvert,.NewsAds,.OpaqueAdBanner,.OpenXad,.PU_DoubleClickAdsContent,.Post5ad,.Post8ad,.Post9ad,.RBboxAd,.RW_ad300,.RectangleAd,.RelatedAds,.Right300x250AD,.RightAd1,.RightAdvertiseArea,.RightAdvertisement,.RightGoogleAFC,.RightRailAd,.RightRailTop300x250Ad,.RightSponsoredAdTitle,.RightTowerAd,.STR_AdBlock,.SectionSponsor,.SideAdCol,.SidebarAd,.SidebarAdvert,.SitesGoogleAdsModule,.SkyAdContainer,.SponsoredAdTitle,.SponsoredContent,.SponsoredLinkItemTD,.SponsoredLinks,.SponsoredLinksGrayBox,.SponsoredLinksModule,.SponsoredLinksPadding,.SponsoredLinksPanel,.Sponsored_link,.SquareAd,.StandardAdLeft,.StandardAdRight,.TRU-onsite-ads-leaderboard,.TextAd,.TheEagleGoogleAdSense300x250,.TopAd,.TopAdContainer,.TopAdL,.TopAdR,.TopBannerAd,.UIWashFrame_SidebarAds,.UnderAd,.VerticalAd,.Video-Ad,.VideoAd,.WidgetAdvertiser,.a160x600,.a728x90,.ad-120x60,.ad-120x600,.ad-160,.ad-160x600,.ad-160x600x1,.ad-160x600x2,.ad-160x600x3,.ad-250,.ad-300,.ad-300-block,.ad-300-blog,.ad-300x100,.ad-300x250,.ad-300x250-first,.ad-300x250-right0,.ad-300x600,.ad-350,.ad-355x75,.ad-600,.ad-635x40,.ad-728,.ad-728x90,.ad-728x90-1,.ad-728x90-top0,.ad-728x90_forum,.ad-90x600,.ad-above-header,.ad-adlink-bottom,.ad-adlink-side,.ad-area,.ad-background,.ad-banner,.ad-banner-smaller,.ad-bigsize,.ad-block,.ad-block-square,.ad-blog2biz,.ad-body,.ad-bottom,.ad-box,.ad-break,.ad-btn,.ad-btn-heading,.ad-button,.ad-cell,.ad-column,.ad-container,.ad-container-300x250,.ad-container-728x90,.ad-container-994x282,.ad-context,.ad-disclaimer,.ad-display,.ad-div,.ad-enabled,.ad-feedback,.ad-filler,.ad-flex,.ad-footer,.ad-footer-leaderboard,.ad-forum,.ad-google,.ad-graphic-large,.ad-gray,.ad-grey,.ad-hdr,.ad-head,.ad-header,.ad-heading,.ad-holder,.ad-homeleaderboard,.ad-img,.ad-in-post,.ad-index-main,.ad-inline,.ad-island,.ad-item,.ad-label,.ad-leaderboard,.ad-left,.ad-link,.ad-links,.ad-lrec,.ad-medium,.ad-medium-two,.ad-mpl,.ad-mpu,.ad-msn,.ad-note,.ad-notice,.ad-other,.ad-permalink,.ad-place-active,.ad-placeholder,.ad-postText,.ad-poster,.ad-priority,.ad-rect,.ad-rectangle,.ad-rectangle-text,.ad-related,.ad-rh,.ad-ri,.ad-right,.ad-right-header,.ad-right-txt,.ad-row,.ad-section,.ad-show-label,.ad-side,.ad-sidebar,.ad-sidebar-outer,.ad-sidebar300,.ad-sky,.ad-skyscr,.ad-skyscraper,.ad-slot,.ad-slot-234-60,.ad-slot-300-250,.ad-slot-728-90,.ad-source,.ad-space,.ad-space-mpu-box,.ad-space-topbanner,.ad-spot,.ad-square,.ad-square300,.ad-squares,.ad-statement,.ad-story-inject,.ad-tabs,.ad-text,.ad-text-links,.ad-tile,.ad-title,.ad-top,.ad-top-left,.ad-unit,.ad-unit-300,.ad-unit-300-wrapper,.ad-unit-anchor,.ad-unit-top,.ad-vert,.ad-vertical-container,.ad-vtu,.ad-widget-list,.ad-with-us,.ad-wrap,.ad-wrapper,.ad-zone,.ad-zone-s-q-l,.ad.super,.ad08sky,.ad100,.ad120,.ad120x240backgroundGray,.ad120x600,.ad125,.ad140,.ad160,.ad160600,.ad160x600,.ad160x600GrayBorder,.ad200x60,.ad230,.ad250,.ad250c,.ad300,.ad300250,.ad300_250,.ad300x100,.ad300x250,.ad300x250-hp-features,.ad300x250Module,.ad300x250Top,.ad300x250_container,.ad300x250box,.ad300x50-right,.ad300x600,.ad310,.ad315,.ad336x280,.ad343x290,.ad400right,.ad450,.ad468,.ad468_60,.ad468x60,.ad540x90,.ad600,.ad620x70,.ad626X35,.ad644,.ad728,.ad728_90,.ad728x90,.ad728x90_container,.ad90x780,.adAgate,.adArea674x60,.adBanner,.adBanner300x250,.adBanner728x90,.adBannerTyp1,.adBannerTypSortableList,.adBannerTypW300,.adBar,.adBgBottom,.adBgMId,.adBgTop,.adBlock,.adBottomLink,.adBottomboxright,.adBox,.adBox1,.adBox230X96,.adBox728X90,.adBoxBody,.adBoxBorder,.adBoxContainer,.adBoxContent,.adBoxInBignews,.adBoxSidebar,.adBoxSingle,.adBwrap,.adCMRight,.adCell,.adColumn,.adCont,.adContTop,.adContainer,.adContentAd,.adContour,.adCreative,.adCube,.adDiv,.adElement,.adFender3,.adFrame,.adFtr,.adFullWidthMiddle,.adGoogle,.adHeader,.adHeadline,.adHolder,.adHome300x250,.adHorisontal,.adInNews,.adIsland,.adLabel,.adLeader,.adLeaderForum,.adLeaderboard,.adLeft,.adLoaded,.adLocal,.adMPU,.adMarker,.adMastheadLeft,.adMastheadRight,.adMegaBoard,.adMinisLR,.adMkt2Colw,.adModule,.adModuleAd,.adMpu,.adNewsChannel,.adNoOutline,.adNotice,.adNoticeOut,.adObj,.adPageBorderL,.adPageBorderR,.adPanel,.adPod,.adRect,.adResult,.adSKY,.adSelfServiceAdvertiseLink,.adServer,.adSky,.adSky600,.adSkyscaper,.adSkyscraperHolder,.adSlot,.adSpBelow,.adSpace,.adSpacer,.adSplash,.adSponsor,.adSpot,.adSpot-brought,.adSpot-searchAd,.adSpot-textBox,.adSpot-twin,.adSpotIsland,.adSquare,.adSubColPod,.adSummary,.adSuperboard,.adSupertower,.adTD,.adTab,.adTag,.adText,.adTileWrap,.adTiler,.adTitle,.adTopLink,.adTopboxright,.adTout,.adTxt,.adUnit,.adUnitHorz,.adUnitVert,.adUnitVert_noImage,.adWebBoard,.adWidget,.adWithTab,.adWord,.adWrap,.adWrapper,.ad_0,.ad_1,.ad_120x90,.ad_125,.ad_130x90,.ad_160,.ad_160x600,.ad_2,.ad_200,.ad_200x200,.ad_250x250,.ad_250x250_w,.ad_3,.ad_300,.ad_300_250,.ad_300x250,.ad_300x250_box_right,.ad_336,.ad_336x280,.ad_350x100,.ad_350x250,.ad_400x200,.ad_468,.ad_468x60,.ad_600,.ad_680x15,.ad_728,.ad_728_90b,.ad_728x90,.ad_925x90,.ad_Left,.ad_Right,.ad_ad_300,.ad_amazon,.ad_banner,.ad_banner_border,.ad_bar,.ad_bg,.ad_bigbox,.ad_biz,.ad_block,.ad_block_338,.ad_body,.ad_border,.ad_botbanner,.ad_bottom,.ad_bottom_leaderboard,.ad_bottom_left,.ad_box,.ad_box2,.ad_box_ad,.ad_box_div,.ad_callout,.ad_caption,.ad_column,.ad_column_box,.ad_column_hl,.ad_contain,.ad_container,.ad_content,.ad_content_wide,.ad_contents,.ad_descriptor,.ad_disclaimer,.ad_eyebrow,.ad_footer,.ad_frame,.ad_framed,.ad_front_promo,.ad_gutter_top,.ad_head,.ad_header,.ad_heading,.ad_headline,.ad_holder,.ad_hpm,.ad_info_block,.ad_inline,.ad_island,.ad_jnaught,.ad_label,.ad_launchpad,.ad_leader,.ad_leaderboard,.ad_left,.ad_line,.ad_link,.ad_links,.ad_linkunit,.ad_loc,.ad_lrec,.ad_main,.ad_medrec,.ad_medrect,.ad_middle,.ad_mod,.ad_mp,.ad_mpu,.ad_mr,.ad_mrec,.ad_mrec_title_article,.ad_mrect,.ad_news,.ad_note,.ad_notice,.ad_one,.ad_p360,.ad_partner,.ad_partners,.ad_plus,.ad_post,.ad_power,.ad_primary,.ad_promo,.ad_rec,.ad_rectangle,.ad_right,.ad_right_col,.ad_row,.ad_row_bottom_item,.ad_side,.ad_sidebar,.ad_skyscraper,.ad_slug,.ad_slug_table,.ad_space,.ad_space_300_250,.ad_spacer,.ad_sponsor,.ad_sponsoredsection,.ad_spot_b,.ad_spot_c,.ad_square_r,.ad_square_top,.ad_sub,.ad_tag_middle,.ad_text { display:none !important; } .ad_text_w,.ad_title,.ad_top,.ad_top_leaderboard,.ad_top_left,.ad_topright,.ad_tower,.ad_unit,.ad_unit_rail,.ad_url,.ad_warning,.ad_wid300,.ad_wide,.ad_wrap,.ad_wrapper,.ad_wrapper_fixed,.ad_wrapper_top,.ad_wrp,.ad_zone,.adarea,.adarea-long,.adbanner,.adbannerbox,.adbannerright,.adbar,.adboard,.adborder,.adbot,.adbottom,.adbottomright,.adbox-outer,.adbox-wrapper,.adbox_300x600,.adbox_366x280,.adbox_468X60,.adbox_bottom,.adbox_br,.adbox_left,.adboxclass,.adboxesrow,.adbreak,.adbug,.adbutton,.adbuttons,.adcode,.adcol1,.adcol2,.adcolumn,.adcolumn_wrapper,.adcont,.adcopy,.add_300x250,.addiv,.adenquire,.adfieldbg,.adfoot,.adfootbox,.adframe,.adhead,.adhead_h,.adhead_h_wide,.adheader,.adheader100,.adheader416,.adhi,.adhint,.adholder,.adhoriz,.adiframe,.adinfo,.adinside,.adintro,.adits,.adjlink,.adkicker,.adkit,.adkit-advert,.adkit-lb-footer,.adlabel-horz,.adlabel-vert,.adlabelleft,.adleader,.adleaderboard,.adleft1,.adline,.adlink,.adlinks,.adlist,.adlnklst,.admarker,.admediumred,.admedrec,.admessage,.admodule,.admpu,.admpu-small,.adnation-banner,.adnotice,.adops,.adp-AdPrefix,.adpadding,.adpane,.adpic,.adprice,.adproxy,.adrec,.adright,.adroot,.adrotate_widget,.adrow,.adrow-post,.adrow1box1,.adrow1box3,.adrow1box4,.adrule,.ads-125,.ads-300,.ads-300x250,.ads-728x90-wrap,.ads-ads-top,.ads-banner,.ads-below-content,.ads-categories-bsa,.ads-custom,.ads-favicon,.ads-item,.ads-links-general,.ads-mpu,.ads-outer,.ads-profile,.ads-right,.ads-section,.ads-sidebar,.ads-sky,.ads-small,.ads-sponsors,.ads-stripe,.ads-text,.ads-top,.ads-wide,.ads-widget,.ads-widget-partner-gallery,.ads03,.ads160,.ads1_250,.ads24Block,.ads300,.ads460,.ads460_home,.ads468,.ads728,.ads728x90,.adsArea,.adsBelowHeadingNormal,.adsBlock,.adsBottom,.adsBox,.adsCell,.adsCont,.adsDiv,.adsFull,.adsImages,.adsInsideResults_v3,.adsMPU,.adsMiddle,.adsRight,.adsRow,.adsTextHouse,.adsTop,.adsTower2,.adsTowerWrap,.adsWithUs,.ads_125_square,.ads_180,.ads_300,.ads_300x100,.ads_300x250,.ads_320,.ads_337x280,.ads_728x90,.ads_big,.ads_big-half,.ads_box,.ads_box_headline,.ads_brace,.ads_catDiv,.ads_container,.ads_disc_anchor,.ads_disc_leader,.ads_disc_lwr_square,.ads_disc_skyscraper,.ads_disc_square,.ads_div,.ads_footer,.ads_header,.ads_holder,.ads_horizontal,.ads_leaderboard,.ads_lr_wrapper,.ads_medrect,.ads_mpu,.ads_outer,.ads_post_end,.ads_post_end_code,.ads_post_start,.ads_post_start_code,.ads_rectangle,.ads_remove,.ads_right,.ads_rightbar_top,.ads_sc_bl_i,.ads_sc_tb,.ads_sc_tl_i,.ads_show_if,.ads_side,.ads_sidebar,.ads_singlepost,.ads_spacer,.ads_takeover,.ads_title,.ads_top,.ads_top_promo,.ads_tr,.ads_verticalSpace,.ads_vtlLink,.ads_widesky,.ads_wrapperads_top,.adsafp,.adsbg300,.adsblockvert,.adsborder,.adsbottom,.adsbox,.adsboxitem,.adsbttmpg,.adsbyyahoo,.adscaleAdvert,.adscaleP6_canvas,.adsclick,.adscontainer,.adscreen,.adsd_shift100,.adsection_a2,.adsection_c2,.adsense-468,.adsense-ad,.adsense-category,.adsense-category-bottom,.adsense-googleAds,.adsense-heading,.adsense-overlay,.adsense-post,.adsense-right,.adsense-title,.adsense3,.adsense300,.adsenseAds,.adsenseBlock,.adsenseContainer,.adsenseGreenBox,.adsenseInPost,.adsenseList,.adsense_bdc_v2,.adsense_mpu,.adsensebig,.adsenseblock,.adsenseblock_bottom,.adsenseblock_top,.adsenselr,.adsensem_widget,.adsensesq,.adsenvelope,.adserver_zone,.adset,.adsforums,.adsghori,.adsgvert,.adshome,.adside,.adsidebox,.adsider,.adsingle,.adsleft,.adsleftblock,.adslink,.adslogan,.adslotleft,.adslotright,.adsmalltext,.adsmessage,.adsnippet_widget,.adspace,.adspace-MR,.adspace-widget,.adspace180,.adspace_bottom,.adspace_buysell,.adspace_rotate,.adspace_skyscraper,.adspacer,.adspot,.adspot728x90,.adstext,.adstextpad,.adstitle,.adstop,.adstory,.adstrip,.adtab,.adtable,.adtag,.adtech,.adtext,.adtext_gray,.adtext_horizontal,.adtext_onwhite,.adtext_vertical,.adtile,.adtips,.adtips1,.adtitle,.adtop,.adtravel,.adtxt,.adtxtlinks,.adunit,.adv-mpu,.adv-sidebar,.adv300,.advBox,.advSquare,.advVideobox,.adv_120x600,.adv_300x250,.adv_728x90,.adv_banner_hor,.adv_medium_rectangle,.adver,.adverTag,.adverTxt,.adver_cont_below,.advert-300-side,.advert-300x100-side,.advert-728x90,.advert-article-bottom,.advert-bannerad,.advert-bg-250,.advert-bloggrey,.advert-box,.advert-btm,.advert-head,.advert-horizontal,.advert-iab-300-250,.advert-iab-468-60,.advert-mpu,.advert-skyscraper,.advert-text,.advert-title,.advert-txt,.advert120,.advert300,.advert300x250,.advert300x300,.advert300x440,.advert350ih,.advert4,.advert5,.advert728x90,.advert8,.advertColumn,.advertCont,.advertContainer,.advertContent,.advertHeadline,.advertIslandWrapper,.advertRight,.advertSuperBanner,.advertText,.advertTitleSky,.advert_336,.advert_468x60,.advert_box,.advert_cont,.advert_container,.advert_djad,.advert_google_content,.advert_google_title,.advert_home_300,.advert_label,.advert_leaderboard,.advert_list,.advert_note,.advert_surr,.advert_top,.advertheader-red,.advertise,.advertise-here,.advertise-homestrip,.advertise-horz,.advertise-inquiry,.advertise-leaderboard,.advertise-list,.advertise-top,.advertise-vert,.advertiseContainer,.advertiseText,.advertise_ads,.advertise_here,.advertise_link,.advertise_link_sidebar,.advertisement,.advertisement-728x90,.advertisement-block,.advertisement-sidebar,.advertisement-space,.advertisement-sponsor,.advertisement-swimlane,.advertisement-text,.advertisement-top,.advertisement300x250,.advertisement468,.advertisementBox,.advertisementColumnGroup,.advertisementContainer,.advertisementHeader,.advertisementLabel,.advertisementPanel,.advertisementText,.advertisement_300x250,.advertisement_btm,.advertisement_caption,.advertisement_g,.advertisement_header,.advertisement_horizontal,.advertisement_top,.advertisementsOutterDiv,.advertiser,.advertiser-links,.advertisespace_div,.advertising-banner,.advertising-header,.advertising-leaderboard,.advertising-local-links,.advertising2,.advertisingTable,.advertising_block,.advertising_images,.advertisment,.advertisment_bar,.advertisment_caption,.advertisment_two,.advertize,.advertize_here,.advertorial,.advertorial-2,.advertorial-promo-box,.advertorial_red,.advertorialtitle,.adverts,.adverts-125,.adverts_RHS,.advt,.advt-banner-3,.advt-block,.advt-sec,.advt300,.advt720,.advtitle,.adwhitespace,.adwordListings,.adwords,.adwordsHeader,.adwrap,.adwrapper-lrec,.adwrapper948,.adzone-footer,.adzone-sidebar,.affiliate-link,.affiliate-sidebar,.affiliateAdvertText,.affiliates-sidebar,.affinityAdHeader,.afsAdvertising,.after_ad,.agi-adsaleslinks,.alb-content-ad,.alignads,.alt_ad,.anchorAd,.another_text_ad,.answer_ad_content,.aolSponsoredLinks,.aopsadvert,.apiAdMarkerAbove,.apiAds,.app_advertising_skyscraper,.archive-ads,.art_ads,.article-ad-box,.article-ads,.article-content-adwrap,.articleAd,.articleAd300x250,.articleAds,.articleAdsL,.articleEmbeddedAdBox,.article_ad,.article_adbox,.article_mpu_box,.article_page_ads_bottom,.articleads,.aseadn,.aux-ad-widget-1,.aux-ad-widget-2,.b-astro-sponsored-links_horizontal,.b-astro-sponsored-links_vertical,.b_ads_cont,.b_ads_top,.banmanad,.banner-468-60,.banner-468x60,.banner-ad,.banner-ads,.banner-adv,.banner-advert,.banner-adverts,.banner-buysellads,.banner160x600,.banner300by250,.banner300x100,.banner300x250,.banner468,.banner468by60,.banner728x90,.bannerADV,.bannerAd,.bannerAdWrapper300x250,.bannerAdWrapper730x86,.bannerAds,.bannerAdvert,.bannerRightAd,.banner_160x600,.banner_300x250,.banner_728x90,.banner_ad,.banner_ad_footer,.banner_ad_leaderboard,.bannerad,.bannerad-125tower,.bannerad-468x60,.barkerAd,.base-ad-mpu,.base_ad,.base_printer_widgets_AdBreak,.bg-ad-link,.bgnavad,.big-ads,.bigAd,.big_ad,.big_ads,.bigad,.bigad2,.bigbox_ad,.bigboxad,.billboard300x250,.billboard_ad,.biz-ad,.biz-ads,.biz-adtext,.blk_advert,.block-ad,.block-ad300,.block-admanager,.block-ads-bottom,.block-ads-top,.block-adsense,.block-adsense-managed,.block-adspace-full,.block-bg-advertisement-region-1,.block-deca_advertising,.block-google-admanager,.block-google_admanager,.block-openads,.block-openadstream,.block-openx,.block-thirdage-ads,.block-wtg_adtech,.blockAd,.blockAds,.block_ad,.block_ad_floating_bar,.block_ad_sb_text,.block_ad_sb_text2,.block_ad_sponsored_links,.block_ad_sponsored_links-wrapper,.block_ad_sponsored_links_localized,.blockad,.blocked-ads,.blog-ad-leader-inner,.blog-ads-container,.blogAd,.blogAdvertisement,.blogArtAd,.blogBigAd,.blog_ad,.blogads,.blox3featuredAd,.bn_textads,.body_ad,.body_sponsoredresults_bottom,.body_sponsoredresults_middle,.body_sponsoredresults_top,.bodyads,.bodyads2,.bookseller-header-advt,.bottom-ad,.bottom-ad-fr,.bottom-ads,.bottomAd,.bottomAds,.bottom_ad,.bottom_ad_block,.bottom_ads,.bottom_adsense,.bottom_right_ad,.bottomad,.bottomads,.bottomadvert,.bottombarad,.bottomrightrailAd,.bottomvidad,.box-ad,.box-ad-grey,.box-ads,.box-ads-small,.box-adsense,.box-adverts,.boxAd,.boxAds,.boxAdsInclude,.box_ad,.box_ad_container,.box_ad_content,.box_ad_spacer,.box_ad_wrap,.box_ads,.box_adv,.box_adv_new,.box_advertising,.box_advertisment_62_border,.box_content_ad,.box_content_ads,.box_textads,.boxad,.boxads,.boxyads,.bps-ad-wrapper,.bps-advertisement,.bps-advertisement-inline-ads,.br-ad,.breakad_container,.brokerad,.bsa_ads,.btm_ad,.btm_ad_container,.btn-ad,.bullet-sponsored-links,.bullet-sponsored-links-gray,.burstContentAdIndex,.busrep_poll_and_ad_container,.buttonAd,.buttonAds,.button_ads,.button_advert,.buttonadbox,.buttonads,.bx_ad,.bx_ad_right,.cA-adStrap,.cColumn-TextAdsBox,.cLeftTextAdUnit,.c_ligatus_nxn,.calendarAd,.calloutAd,.carbonad,.carbonad-tag,.care2_adspace,.catalog_ads,.category-ad,.categorySponsorAd,.category__big_game_container_body_games_advertising,.cb-ad-banner,.cb-ad-container,.cb_ads,.cb_navigation_ad,.cbstv_ad_label,.cbzadvert,.cbzadvert_block,.cdAdTitle,.cdmainlineSearchAdParent,.cdsidebarSearchAdParent,.centerAd,.center_ad,.centerad,.centered-ad,.chitikaAdCopy,.cinemabotad,.classifiedAdThree,.clearerad,.cmAdContainer,.cmAdFind,.cmAdSponsoredLinksBox,.cm_ads,.cms-Advert,.cnbc_badge_banner_ad_area,.cnbc_banner_ad_area,.cnbc_leaderboard_ad,.cnn160AdFooter,.cnnAd,.cnnMosaic160Container,.cnnStoreAd,.cnnStoryElementBoxAd,.cnnWCAdBox,.cnnWireAdLtgBox,.cnn_728adbin,.cnn_adcntr300x100,.cnn_adcntr728x90,.cnn_adspc336cntr,.cnn_adtitle,.cntrad,.column2-ad,.columnBoxAd,.columnRightAdvert,.com-ad-server,.comment-ad,.comment-ad-wrap,.comment-advertisement,.comment_ad_box,.common_advertisement_title,.communityAd,.conTSponsored,.conductor_ad,.confirm_ad_left,.confirm_ad_right,.confirm_leader_ad,.consoleAd,.container-adwords,.containerSqAd,.container_serendipity_plugin_google_adsense,.content-ad,.content-ads,.content-advert,.contentAd,.contentAdContainer,.contentAdFoot,.contentAdsWrapper,.content_ad,.content_ad_728,.content_adsense,.content_adsq,.content_tagsAdTech,.contentad,.contentad-home,.contentad300x250,.contentad_right_col,.contentadcontainer,.contentadfloatl,.contentadleft,.contentads,.contentadstartpage,.contents-ads-bottom-left,.contenttextad,.contest_ad,.cp_ad,.cpmstarHeadline,.cpmstarText,.create_ad,.cs-mpu,.cscTextAd,.cse_ads,.cspAd,.ct_ad,.ctnAdSkyscraper,.ctnAdSquare300,.cube-ad,.cubeAd,.cube_ads,.currency_ad,.custom_ads,.cwAdvert,.cxAdvertisement,.darla_ad,.dart-ad,.dartAdImage,.dart_ad,.dart_tag,.dartadvert,.dartiframe,.dc-ad,.dcAdvertHeader,.deckAd,.deckads,.detail-ads,.detailMpu,.detail_ad,.detail_top_advert,.dfrads,.displayAdSlot,.divAd,.divAdright,.div_adv300,.div_advstrip,.divad1,.divad2,.divad3,.divads,.divider_ad,.dlSponsoredLinks,.dmco_advert_iabrighttitle,.downloadAds,.download_ad,.downloadad,.dsq_ad,.dualAds,.dynamic-ads,.dynamic_ad,.e-ad,.ec-ads,.ec-ads-remove-if-empty,.em-ad,.em_ads_box_dynamic_remove,.embed-ad,.embeddedAd,.entry-body-ad,.entry-injected-ad,.entry_sidebar_ads,.entryad,.ez-clientAd,.f_Ads,.feature_ad,.featuredAds,.featured_ad,.featuredadvertising,.fireplaceadleft,.fireplaceadright,.fireplaceadtop,.firstpost_advert_container,.flagads,.flash-advertisement,.flash_ad,.flash_advert,.flashad,.flexiad,.flipbook_v2_sponsor_ad,.floatad,.floated_right_ad,.floatingAds,.fm-badge-ad,.fns_td_wrap,.fold-ads,.footad,.footer-ad,.footer-advert,.footerAd,.footerAdModule,.footerAds,.footerAdslot,.footerAdverts,.footerTextAd,.footer_ad,.footer_ad336,.footer_ads,.footer_block_ad,.footer_bottomad,.footer_line_ad,.footer_text_ad,.footerad,.forumtopad,.freedownload_ads,.frn_adbox,.frn_cont_adbox,.frontads,.frontpage-google-ad,.ft-ad,.ftdAdBar,.ftdContentAd,.full_ad_box,.full_width_ad,.fullbannerad,.g3rtn-ad-site,.gAdRows,.gAdSky,.gAdvertising,.g_ggl_ad,.ga-ads,.ga-textads-bottom,.ga-textads-top,.gaTeaserAds,.gaTeaserAdsBox,.gads_cb,.gads_container,.gallery_ad,.gam_ad_slot,.gameAd,.gamesPage_ad_content,.gbl_advertisement,.gen_side_ad,.gglAds,.global_banner_ad,.googad,.googads,.google-ad,.google-ad-container,.google-ads,.google-ads-boxout,.google-ads-slim,.google-adsense,.google-right-ad,.google-sponsored-ads,.google-sponsored-link,.google468,.google468_60,.googleAd,.googleAd-content,.googleAd-list,.googleAd300x250_wrapper,.googleAdBox,.googleAdSense,.googleAdSenseModule,.googleAd_body,.googleAds,.googleAds_article_page_above_comments,.googleAdsense,.googleContentAds,.googleProfileAd,.googleSearchAd_content,.googleSearchAd_sidebar,.google_ad,.google_ad_wide,.google_add_container,.google_ads,.google_ads_bom_title,.google_ads_content,.google_adsense_footer,.googlead,.googleaddiv,.googleaddiv2,.googleads,.googleads_300x250,.googleads_title,.googleadsense,.googleafc,.googley_ads,.gpAdBox,.gpAds,.gradientAd,.grey-ad-line,.group_ad,.gsAd,.gsfAd,.gt_ad,.gt_ad_300x250,.gt_ad_728x90,.gt_adlabel,.gutter-ad-left,.gutter-ad-right,.gx_ad,.h-ad-728x90-bottom,.h_Ads,.h_ad,.half-ad,.half_ad_box,.hcf-ad,.hcf-ad-rectangle,.hcf-cms-ad,.hd_advert,.hdr-ads,.head_ad,.header-ad,.header-advert,.header-google-ads,.header-taxonomy-image-sponsor,.headerAd,.headerAdCode,.headerAds,.headerAdvert,.headerTextAd,.header_ad,.header_ad_center,.header_ad_div,.header_ads,.header_advertisement,.header_advertisment,.headerad,.headerad-720,.hi5-ad,.highlightsAd,.hm_advertisment,.hn-ads,.home-ad-links { display:none !important; } .homeAd,.homeAd1,.homeAd2,.homeAdBoxA,.homeAdBoxBetweenBlocks,.homeAdBoxInBignews,.homeAdSection,.homeMediumAdGroup,.home_ad_bottom,.home_advertisement,.home_advertorial,.home_mrec_ad,.homead,.homepage-ad,.homepage300ad,.homepageFlexAdOuter,.homepageMPU,.homepage_middle_right_ad,.homepageinline_adverts,.hor_ad,.horiz_adspace,.horizontalAd,.horizontal_ad,.horizontal_ads,.horizontaltextadbox,.horizsponsoredlinks,.hortad,.houseAd1,.houseAdsStyle,.housead,.hoverad,.hp-col4-ads,.hp2-adtag,.hp_ad_cont,.hp_ad_text,.hp_t_ad,.hp_w_ad,.hpa-ad1,.html-advertisement,.ic-ads,.ico-adv,.idMultiAd,.iframe-ad,.image-advertisement,.imageAd,.imageads,.imgad,.in-page-ad,.in-story-ads,.in-story-text-ad,.inStoryAd-news2,.indEntrySquareAd,.indie-sidead,.indy_googleads,.infoBoxThreadPageRankAds,.inhousead,.inline-ad,.inline-mpu,.inline-mpu-left,.inlineSideAd,.inline_ad,.inline_ad_title,.inlinead,.inlineadsense,.inlineadtitle,.inlist-ad,.inlistAd,.inner-advt-banner-3,.innerAds,.innerad,.inpostad,.insert_advertisement,.insertad,.insideStoryAd,.inteliusAd_image,.interest-based-ad,.internalAdsContainer,.iprom-ad,.is24-adplace,.isAd,.islandAd,.islandAdvert,.islandad,.itemAdvertise,.jimdoAdDisclaimer,.jp-advertisment-promotional,.js-advert,.kdads-empty,.kdads-link,.kw_advert,.kw_advert_pair,.l_ad_sub,.label-ad,.labelads,.largeRecAdNewsContainerRight,.largeRectangleAd,.largeUnitAd,.large_ad,.lastRowAd,.lazyload_ad,.lcontentbox_ad,.leadAd,.leaderAdSlot,.leaderAdTop,.leaderAdvert,.leaderBoardAdHolder,.leaderOverallAdArea,.leader_ad,.leaderboardAd,.leaderboardAdContainer,.leaderboardAdContainerInner,.leaderboard_ad,.leaderboardad,.leaderboardadtop,.left-ad,.left-advert,.leftAd,.leftAdColumn,.leftAds,.left_ad,.left_ad_box,.left_adlink,.left_ads,.left_adsense,.leftad,.leftadtag,.leftbar_ad_160_600,.leftbarads,.leftbottomads,.leftnavad,.lgRecAd,.lg_ad,.ligatus,.linead,.link_adslider,.link_advertise,.live-search-list-ad-container,.livingsocial-ad,.ljad,.local-ads,.log_ads,.logoAds,.logoad,.logoutAd,.longAd,.longAdBox,.lowerAds,.lr-ad,.m-ad-tvguide-box,.m4-adsbygoogle,.m_banner_ads,.macAd,.macad,.main-ad,.main-advert,.main-tabs-ad-block,.mainAd,.mainLeftAd,.mainLinkAd,.mainRightAd,.main_ad,.main_ad_bg_div,.main_adbox,.main_ads,.main_intro_ad,.map_media_banner_ad,.marginadsthin,.marketing-ad,.masthead_topad,.matador_sidebar_ad_600,.mdl-ad,.media-advert,.mediaAd,.mediaAdContainer,.mediaResult_sponsoredSearch,.medium-rectangle-ad,.mediumRectangleAdvert,.medium_ad,.medrect_ad,.member-ads,.menuItemBannerAd,.menueadimg,.messageBoardAd,.mf-ad300-container,.micro_ad,.mid_ad,.mid_page_ad,.midad,.middle-ad,.middleAds,.middlead,.middleads,.min_navi_ad,.mini-ad,.miniad,.miscAd,.mmc-ad,.mmcAd_Iframe,.mod-ad-lrec,.mod-ad-n,.mod-adopenx,.mod-vertical-ad,.mod_admodule,.module-ad,.module-ad-small,.module-ads,.module-advertisement,.module-sponsored-ads,.moduleAd,.moduleAdvertContent,.module_ad,.module_box_ad,.modulegad,.moduletable-advert,.moduletable-googleads,.moduletablesquaread,.mos-ad,.mpu-ad,.mpu-ad-con,.mpu-advert,.mpu-footer,.mpu-fp,.mpu-title,.mpu-top-left,.mpu-top-left-banner,.mpu-top-right,.mpu01,.mpuAd,.mpuAdSlot,.mpuAdvert,.mpuArea,.mpuBox,.mpuContainer,.mpuHolder,.mpuTextAd,.mpu_ad,.mpu_advert,.mpu_container,.mpu_gold,.mpu_holder,.mpu_platinum,.mpu_side,.mpu_text_ad,.mpuad,.mpuholderportalpage,.mrec_advert,.ms-ads-link,.msfg-shopping-mpu,.mvw_onPageAd1,.mwaads,.my-ad250x300,.nSponsoredLcContent,.nSponsoredLcTopic,.nadvt300,.narrow_ad_unit,.narrow_ads,.navAdsBanner,.navBads,.nav_ad,.navadbox,.navcommercial,.navi_ad300,.naviad,.nba300Ad,.nbaT3Ad160,.nbaTVPodAd,.nbaTwo130Ads,.nbc_ad_carousel_wrp,.newPex_forumads,.newTopAdContainer,.newad,.newsAd,.news_article_ad_google,.newsviewAdBoxInNews,.newsvinemsn_adtype,.nexusad,.nf-adbox,.nn-mpu,.noAdForLead,.normalAds,.nrAds,.nsAdRow,.nu2ad,.oas-ad,.oas-bottom-ads,.oas_ad,.oas_advertisement,.offer_sponsoredlinks,.oio-banner-zone,.oio-link-sidebar,.oio-zone-position,.on_single_ad_box,.onethirdadholder,.openads,.openadstext_after,.openx,.openx-ad,.openx_ad,.osan-ads,.other_adv2,.outermainadtd1,.ovAdPromo,.ovAdSky,.ovAdartikel,.ov_spns,.ovadsenselabel,.pageAds,.pageBottomGoogleAd,.pageGoogleAd,.pageGoogleAdFlat,.pageGoogleAdSubcontent,.pageGoogleAds,.pageGoogleAdsContainer,.pageLeaderAd,.page_content_right_ad,.pagead,.pageads,.pagenavindexcontentad,.paneladvert,.partner-ad,.partner-ads-container,.partnerAd,.partnersTextLinks,.pencil_ad,.player_ad_box,.player_hover_ad,.player_page_ad_box,.plista_inimg_box,.pm-ad,.pmad-in2,.pnp_ad,.pod-ad-300,.podRelatedAdLinksWidget,.podSponsoredLink,.portalCenterContentAdBottom,.portalCenterContentAdMiddle,.portalCenterContentAdTop,.portal_searchresultssponsoredlist,.portalcontentad,.post-ad,.postAd,.post_ad,.post_ads,.post_sponsor_unit,.postbit_adbit_register,.postbit_adcode,.postgroup-ads,.postgroup-ads-middle,.prebodyads,.premium_ad_container,.promoAd,.promoAds,.promo_ad,.promoboxAd,.promotionTextAd,.ps-ligatus_placeholder,.pub_300x250,.pub_300x250m,.pub_728x90,.publication-ad,.publicidad,.puff-advertorials,.qa_ad_left,.qm-ad-content,.qm-ad-content-news,.quigo-ad,.qzvAdDiv,.r_ad_1,.r_ad_box,.r_ads,.rad_container,.rect_ad_module,.rectad,.rectangle-ad,.rectangleAd,.rectanglead,.redads_cont,.referrerDetailAd,.regular_728_ad,.regularad,.relatedAds,.related_post_google_ad,.relatesearchad,.remads,.resourceImagetAd,.result_ad,.reviewMidAdvertAlign,.rght300x250,.rhads,.rhs-ad,.rhs-ads-panel,.rhs-advert-container,.rhs-advert-link,.rhs-advert-title,.right-ad,.right-ad-holder,.right-ad2,.right-ads,.right-ads2,.right-sidebar-box-ad,.rightAd,.rightAdBox,.rightAdverts,.rightColAd,.rightColumnRectAd,.rightRailAd,.right_ad,.right_ad_160,.right_ad_box,.right_ad_common_block,.right_ad_text,.right_ad_top,.right_ads,.right_ads_column,.right_box_ad_rotating_container,.right_col_ad,.right_hand_advert_column,.right_side-partyad,.rightad,.rightad_1,.rightad_2,.rightadbox1,.rightads,.rightadunit,.rightbigcolumn_ads,.rightbigcolumn_ads_nobackground,.rightcol_boxad,.rightcoladvert,.rightcoltowerad,.rightmenu_ad,.rnav_ad,.rngtAd,.rot_ads,.round_box_advert,.roundedCornersAd,.roundingrayboxads,.rt_ad1_300x90,.rt_ad_300x250,.rt_ad_call,.s2k_ad,.savvyad_unit,.sb-ad-sq-bg,.sbAd,.sbAdUnitContainer,.sb_ad_holder,.sb_adsN,.sb_adsNv2,.sb_adsW,.sb_adsWv2,.scanAd,.scc_advert,.sci-ad-main,.sci-ad-sub,.search-ad,.search-results-ad,.search-sponsor,.search-sponsored,.searchAd,.searchAdTop,.searchAds,.searchSponsoredResultsBox,.searchSponsoredResultsList,.search_column_results_sponsored,.search_results_sponsored_top,.section-ad2,.section_mpu_wrapper,.section_mpu_wrapper_wrapper,.selfServeAds,.sepContentAd,.serp_sponsored,.servsponserLinks,.shoppingGoogleAdSense,.showAd_No,.showAd_Yes,.showcaseAd,.sidbaread,.side-ad,.side-ads,.side-sky-banner-160,.sideAd,.sideBoxAd,.side_ad,.side_ad2,.side_ad_1,.side_ad_2,.side_ad_3,.sidead,.sideads,.sideadsbox,.sideadvert,.sidebar-ad,.sidebar-ads,.sidebar-content-ad,.sidebar-text-ad,.sidebarAd,.sidebarAdUnit,.sidebarAdvert,.sidebar_ad,.sidebar_ad_300_250,.sidebar_ads,.sidebar_ads_336,.sidebar_adsense,.sidebar_box_ad,.sidebarad,.sidebarad_bottom,.sidebaradbox,.sidebarads,.sidebarboxad,.sideheadnarrowad,.sideheadsponsorsad,.simple_ads_manager_widget,.single-google-ad,.singleAd,.singleAdsContainer,.single_ad,.singlead,.singleadstopcstm2,.site_ad_120_600,.site_ad_300x250,.sitesponsor,.skinAd,.skin_ad_638,.sky-ad,.skyAd,.skyAdd,.skyAdvert,.skyAdvert2,.sky_ad,.sky_scraper_ad,.skyad,.skyjobsadtext,.skyscraper-ad,.skyscraper_ad,.skyscraper_bannerAdHome,.sleekadbubble,.slideshow-ad,.slpBigSlimAdUnit,.slpSquareAdUnit,.sm_ad,.smallSkyAd1,.smallSkyAd2,.small_ad,.small_ads,.smallad-left,.smallads,.smallsponsorad,.smart_ads_bom_title,.spLinks,.specialAd175x90,.speedyads,.sphereAdContainer,.spl-ads,.spl_ad,.spl_ad2,.spl_ad_plus,.splitAd,.splitAdResultsPane,.sponlinkbox,.spons-link,.spons_links,.sponslink,.sponsor-ad,.sponsor-link,.sponsor-links,.sponsor-services,.sponsorPanel,.sponsorPost,.sponsorPostWrap,.sponsorStrip,.sponsor_ad_area,.sponsor_area,.sponsor_bar,.sponsor_columns,.sponsor_footer,.sponsor_line,.sponsor_links,.sponsor_logo,.sponsoradtitle,.sponsored-ads,.sponsored-chunk,.sponsored-editorial,.sponsored-features,.sponsored-links,.sponsored-links-alt-b,.sponsored-links-holder,.sponsored-links-right,.sponsored-post,.sponsored-post_ad,.sponsored-results,.sponsored-right-border,.sponsored-text,.sponsoredBox,.sponsoredInfo,.sponsoredInner,.sponsoredLabel,.sponsoredLink,.sponsoredLinks,.sponsoredLinks2,.sponsoredLinksHeader,.sponsoredProduct,.sponsoredResults,.sponsoredSideInner,.sponsored_ads,.sponsored_box,.sponsored_box_search,.sponsored_by,.sponsored_link,.sponsored_links,.sponsored_links_title_container,.sponsored_links_title_container_top,.sponsored_links_top,.sponsored_result,.sponsored_results,.sponsored_ss,.sponsored_well,.sponsoredibbox,.sponsoredlink,.sponsoredlinks,.sponsoredlinkscontainer,.sponsoredresults,.sponsoredtextlink_container_ovt,.sponsoring_link,.sponsorlink,.sponsorlink2,.sponsormsg,.sport-mpu-box,.spotlightAd,.squareAd,.square_ad,.square_banner_ad,.squared_ad,.ss-ad-banner,.ss-ad-mpu,.standard-ad,.start__newest__big_game_container_body_games_advertising,.staticAd,.stickyAdLink,.stock-ticker-ad-tag,.stocks-ad-tag,.store-ads,.story_AD,.story_ad_div,.story_right_adv,.storyad,.subad,.subadimg,.subcontent-ad,.subtitle-ad-container,.sugarad,.super-ad,.supercommentad_left,.supercommentad_right,.supp-ads,.supportAdItem,.surveyad,.t10ad,.tab_ad,.tab_ad_area,.tablebordersponsor,.tadsanzeige,.tadsbanner,.tadselement,.tallad,.tblTopAds,.tbl_ad,.tbox_ad,.td-Adholder,.td-TrafficWeatherWidgetAdGreyBrd,.teaser-sponsor,.teaserAdContainer,.teaser_adtiles,.teaser_advert_content,.text-ad,.text-ad-links,.text-ads,.text-advertisement,.text-g-advertisement,.text-g-group-short-rec-ad,.text-g-net-grp-google-ads-article-page,.textAd,.textAdBox,.textAds,.text_ad,.text_ads,.textad,.textadContainer,.textad_headline,.textadbox,.textadheadline,.textadlink,.textads,.textads_left,.textads_right,.textadsds,.textadsfoot,.textadtext,.textadtxt,.textadtxt2,.textlink-ads,.textlinkads,.tf_page_ad_search,.thirdage_ads_300x250,.thirdage_ads_728x90,.thisIsAd,.thisIsAnAd,.ticket-ad,.tileAds,.tips_advertisement,.title-ad,.title_adbig,.tncms-region-ads,.toolad,.toolbar-ad,.top-ad,.top-ad-space,.top-ads,.top-banner-ad,.top-left-nav-ad,.top-menu-ads,.topAd,.topAdWrap,.topAds,.topAdvertisement,.topAdverts,.topBannerAd,.topLeaderboardAd,.top_Ad,.top_ad,.top_ad1,.top_ad_728,.top_ad_728_90,.top_ad_disclaimer,.top_ad_div,.top_ad_post,.top_ad_wrapper,.top_ads,.top_advert,.top_advertisement,.top_advertising_lb,.top_bar_ad,.top_container_ad,.topad,.topad-bar,.topadbox,.topads,.topadspot,.topadvertisementsegment,.topboardads,.topcontentadvertisement,.topic_inad,.topstoriesad,.toptenAdBoxA,.tourFeatureAd,.tower-ad,.towerAd,.towerAdLeft,.towerAds,.tower_ad,.tower_ad_disclaimer,.towerad,.tr-ad-adtech-placement,.tribal-ad,.ts-ad_unit_bigbox,.ts-banner_ad,.ttlAdsensel,.tto-sponsored-element,.tucadtext,.tvs-mpu,.twoColumnAd,.twoadcoll,.twoadcolr,.tx_smartadserver_pi1,.txt-ads,.txtAd,.txtAds,.txt_ads,.txtadvertise,.type_adscontainer,.type_miniad,.type_promoads,.ukAds,.ukn-banner-ads,.under_ads,.undertimyads,.unit-ad,.universalboxADVBOX01,.universalboxADVBOX03,.universalboxADVBOX04a,.usenext,.v5rc_336x280ad,.vert-ads,.vert-adsBlock,.vertad,.vertical-adsense,.vidadtext,.videoAd,.videoBoxAd,.video_ad,.view-promo-mpu-right,.view_rig_ad,.virgin-mpu,.wa_adsbottom,.wantads,.weather_ad,.webads336x280,.wide-ad,.wide-advert,.wide-skyscraper-ad,.wideAd,.wideAdTable,.wide_ad,.wide_ad_unit_top,.wide_ads,.wide_google_ads,.widget-ad,.widget-ad-codes,.widget-ad300x250,.widget-entry-ads-160,.widgetYahooAds,.widget_ad,.widget_ad_boxes_widget,.widget_ad_rotator,.widget_adrotate_widgets,.widget_advert_widget,.widget_econaabachoadswidget,.widget_island_ad,.widget_maxbannerads,.widget_sdac_bottom_ad_widget,.widget_sdac_footer_ads_widget,.widget_sdac_skyscraper_ad_widget,.wikia-ad,.wikia_ad_placeholder,.wingadblock,.withAds,.wl-ad,.wnMultiAd,.wp125_write_ads_widget,.wp125ad,.wp125ad_2,.wpn_ad_content,.wrap-ads,.wrapper-ad,.wrapper-ad-sidecol,.wsSponsoredLinksRight,.wsTopSposoredLinks,.x03-adunit,.x04-adunit,.x81_ad_detail,.xads-blk-top-hld,.xads-blk2,.xads-ojedn,.y-ads,.y-ads-wide,.y7-advertisement,.yahoo-sponsored,.yahoo-sponsored-links,.yahooAd,.yahooAds,.yahoo_ads,.yahooad,.yahooad-image,.yahooad-urlline,.yan-sponsored,.ygrp-ad,.yom-ad,.youradhere,.yrail_ad_wrap,.yrail_ads,.ysmsponsor,.ysponsor,.yw-ad,.zRightAdNote,a[href*="/adrotate/adrotate-out.php?"],a[href^="http://ad-apac.doubleclick.net/"],a[href^="http://ad-emea.doubleclick.net/"],a[href^="http://ad.doubleclick.net/"],a[href^="http://ads.pheedo.com/"],a[href^="http://adserving.liveuniversenetwork.com/"],a[href^="http://api.ringtonematcher.com/"],a[href^="http://galleries.pinballpublishernetwork.com/"],a[href^="http://galleries.securewebsiteaccess.com/"],a[href^="http://install.securewebsiteaccess.com/"],a[href^="http://latestdownloads.net/download.php?"],a[href^="http://secure.signup-page.com/"],a[href^="http://secure.signup-way.com/"],a[href^="http://www.FriendlyDuck.com/AF_"],a[href^="http://www.adbrite.com/mb/commerce/purchase_form.php?"],a[href^="http://www.firstload.de/affiliate/"],a[href^="http://www.friendlyduck.com/AF_"],a[href^="http://www.google.com/aclk?"],a[href^="http://www.liutilities.com/aff"],a[href^="http://www.liutilities.com/products/campaigns/adv/"],a[href^="http://www.my-dirty-hobby.com/?sub="],a[href^="http://www.ringtonematcher.com/"],#mbEnd[cellspacing="0"][cellpadding="0"],#mclip_container:last-child,#ssmiwdiv[jsdisplay],#tads.c,#tadsb.c,#tadsto.c,.ch[onclick="ga(this,event)"],.ra[align="left"][width="30%"],.ra[align="right"][width="30%"],#ad-slot-right,#ad_layer,#bottomadholder,#sponsoredLinks_Top,#srp_adsense-top,#topad,#vap_adsense-top,.adRight,.ad_image,.adlayer,.adv-p,.cdo-ad-section,.flexbanneritemad,.mobile_featuredad,.txt_ad,#center_col > div[style="background:#fbf0fa;margin:0 0 14px;min-height:0;padding-top:2px;padding-bottom:1px;padding-right:8px;padding-left:7px"] { display:none !important; }</style></html>